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Preface – How this thesis is structured 
This thesis is presented in the form of a publication-based thesis.  
 
Chapter 1, the introduction, gives an overview of hypertensive disorders of 
pregnancy, multiple pregnancy as well as current understanding and use of 
placental growth factor. It introduces the gaps in current knowledge relating to 
placental growth factor and the challenges to conducting research in a 
pregnant population. I believe it is important for the reader of this thesis to 
have a thorough understanding of the background to the content of this thesis 
and the day today challenges faced by clinicians caring for women with 
disorders of placental dysfunction.  
 
Chapter 2 focuses on hypertensive disorders and twin pregnancy and is made 
up of one manuscript (Paper 1). This paper was published in Acta 
Obstetricia et Gynecologica Scandinavica January 2020. It was a 
retrospective review of a large cohort of women delivering a twin pregnancy in 
a single large tertiary unit, evaluating the implications of hypertensive 
disorders of pregnancy on both maternal outcomes and perinatal outcomes.  
 
Chapter 3 highlights the origin, structure and function of placental growth 
factor and its receptors. It also comprises of one manuscript (Paper 2) which 
was published in Pregnancy Hypertension March 2018. This literature 
review, discusses how the pro-angiogenic/anti-angiogenic synergism of these  




PlGF may be utilised as a diagnostic marker of disease or a potential 
therapeutic target for adverse pregnancy outcomes. 
 
Chapter 4 focuses on expanding knowledge of placental growth factor in twin 
pregnancy and is comprised of two papers. The first manuscript (Paper 3) is a 
comparative study of two immunoassays of maternal placental growth factor, 
conducted in a twin pregnancy cohort. It highlights the requirements for 
translating a lab-based test into one appropriate for clinical utility and is 
currently under review in the Irish Journal of Medical Science. The 
second manuscript (Paper 4) is a prospective study of placental growth factor 
in twin pregnancy.  It compares gestational specific PlGF levels in twin 
pregnancies complicated by pre-eclampsia/HDP/IUGR to controls and 
presents a dichorionic twin pregnancy specific reference range for placental 
growth factor. This manuscript is currently submitted to BJOG: an 
international journal of obstetrics and gynaecology.  
 
Chapter 5 presents the PARROT Ireland randomised controlled trial and is 
comprised of two papers. The first manuscript (Paper 5) details the 
methodology of the multi-site stepped wedge randomised controlled trial and 
is published in the British Medical Journal Online Open Access March 
2019. The second paper outlines the interim results of the trial and is 
presented in confidence for the purpose of this thesis.  
 
Chapter 6 identifies barriers and facilitators to pregnant women’s participation 




published in Health Expectations August 2019. This qualitative study 
examines pregnant women’s willingness to participate in research while 
pregnant and explores women’s experience about being involved in a clinical 
trial, specifically a randomised controlled trial, while pregnant.  
 
Chapter 7 is the discussion of this thesis and is presented by themes as 
follows;  
Theme 1; (Chapters 2 and 4) The impact of HDP in the setting of twin 
pregnancy and the potential of using PlGF as a potential biomarker of 
HDP/placental dysfunction in twin pregnancy.   
Theme 2; (Chapter 3 and 5) An overview of PlGF knowledge and use to date 
and investigate the impact of adding PlGF to routine clinical investigations of 
women with suspected preterm pre-eclampsia and a singleton pregnancy. 
Theme 3; (Chapter 6) the facilitators and barriers to conducting clinical 










Hypertensive Disorders of Pregnancy are common and may result in 
increased maternal and neonatal morbidity and mortality. Twin pregnancies 
confer an increased risk of development of a hypertensive disorder of 
pregnancy.  
Placental growth factor is an angiogenic protein highly expressed during 
pregnancy. The pro-angiogenic/anti-angiogenic synergism of PlGF and its 
receptors is critical for successful placentation in early pregnancy.  Circulating 
maternal levels of placental growth factor correlate well with placental function.  
Women presenting with suspected pre-eclampsia are currently triaged based 
on hypertension and dipstick proteinuria.  Numerous studies advocate a role 
for placental growth factor testing as a useful adjunct in the management of 
women presenting with preterm pre-eclampsia.  
Several automated immunoassay platforms to quantify placental growth factor 
are currently available. Comparative studies of these immunoassays are 
limited. Current reference values and clinical cut-offs for PlGF were 
constructed from singleton pregnancy cohorts. Given the larger placental 
volume present in a twin pregnancy, separate reference ranges are likely 
required.  
Pregnant women are seldom included in randomised controlled trials and their 
attitudes and experiences of this are not often investigated. Gathering 





In this thesis, I reviewed nine years of clinical data in twin pregnancies from a 
single maternity unit to understand the impact of hypertensive disorders on 
maternal and neonatal outcomes. I examined cross sectional values from 
uncomplicated twin pregnancies to assess the potential for using PlGF in this 
population. I compared the PlGF results obtained from an ELISA to an 
automated immunoassay, to determine if clinical cut-offs developed for one 
platform were transferrable to another. I conducted a national multi-site 
randomised control trial; PARROT Ireland, to evaluate the impact of 
incorporation of PlGF testing into routine clinical care. Lastly, through one on 
one interviews with trial participants, I investigated the barriers and facilitators 
to pregnant women taking part in clinical research.  
The data from these studies revealed that maternal age >40 years, nulliparity, 
conception through use of a donor oocyte, and presence of obstetric 
cholestasis are all important risk factors for the development of a hypertensive 
disorder in a twin pregnancy. The incidence of iatrogenic late prematurity and 
neonatal hypoglycaemia are increased when a hypertensive disorder 
complicates a twin pregnancy. PlGF levels in twin pregnancy differ significantly 
between those women with a pregnancy that will later be complicated by pre-
eclampsia and those that will not. The difference is present many weeks before 
clinical signs or symptoms are present, indicating that PlGF has potential to 
aid diagnosis of pre-eclampsia in twin pregnancies. A dichorionic twin 
pregnancy specific reference range for PlGF has been developed, which may 




The findings also indicate that PlGF biomarker levels vary significantly 
between different immunoassay platforms, highlighting the importance of 
developing validated clinical cut-offs for any automated immunoassay before 
they can be clinically applied.  
The result of the interim analysis from the PARROT Ireland trial is of no 
significant reduction in either maternal or neonatal morbidity with the 
integration of point of care PlGF based testing. These are interim results only 
however and the final results may differ. Should the final trial results 
demonstrate a positive impact on maternal morbidity, without a negative 
impact on neonatal morbidity, it would indicate that PlGF testing should be 
incorporated into routine clinical investigations for women presenting with 
suspected pre-eclampsia before 37 weeks’ gestation. 
The final study of the thesis highlights that pregnant women are interested and 
willing to participate in research. Identifying the correct timepoint and location 
to approach women, as well as the manner and language used to 
communicate with them, are key elements in ensuring their participation. 
The findings from this thesis, though supportive of the current literature in 





























1.1 Hypertensive Disorders of Pregnancy 
 Definition of Hypertension 
Hypertension constitutes raised blood pressure measurements. In the setting 
of pregnancy; a systolic blood pressure ≥ 140mmHg and/or a diastolic blood 
pressure ≥ 90mmHg are considered elevated. In order to ensure accuracy and 
reproducibility, it is important that blood pressure measurements are taken 
with a woman resting in a sitting position with the arm at the level of the heart 
using a calibrated aneroid device or an automated machine that has been 
validated for use in pregnancy (1, 2).   
Hypertension in pregnancy can further be defined as mild, moderate or severe 
dependent on the degree of elevation of blood pressure readings. Most 
international guidelines on hypertension in pregnancy agree on the following 
definition of severity (1, 3, 4); 
• Mild Hypertension; Diastolic blood pressure 90–99mmHg or systolic 
blood pressure 140–149mmHg  
• Moderate Hypertension: Diastolic blood pressure 100–109mmHg, 
systolic blood pressure 150–159mmHg. 
• Severe Hypertension: Diastolic blood pressure 110mmHg or 





 Classification of Hypertension 
There are two Irish national guidelines on hypertensive disorders in pregnancy 
(2012 & 2016) (1, 2) as well a NICE guideline (2010)(3).  In order to harmonise 
these guidelines and provide a standardised approach to the classification of 
the hypertensive disorders of pregnancy (HDP), the International Society for 
the study of Hypertension in Pregnancy (ISSHP) published updated 
recommendations in 2018 (4). Essentially all guidelines agree that HDP can 
be broken down into the following classification groups; chronic hypertension, 
gestational hypertension and pre-eclampsia. The exact definition for each of 















Table 1. 1: Classification of hypertensive disorders of pregnancy. From Irish (1, 2), NICE (3) and ISSHP (4) guidelines.  
 ISSHP Irish Guidelines NICE Guidelines 
Chronic 
Hypertension 
Hypertension pre dating 
pregnancy or in first 
trimester 
Hypertension pre dating the 
pregnancy or appears before 
20 weeks’ gestation 
Hypertension that is present at the 
booking visit or before 20 weeks or 
if the woman is already taking 
antihypertensive medication when 




New onset hypertension 
after 20 weeks gestation 
New onset hypertension after 
20 weeks gestation without 
any maternal or fetal features 
of pre-eclampsia that resolves 
by 3/12 postpartum 
New hypertension presenting after 20 






Pre-eclampsia New onset hypertension 
after 20 weeks gestation 
with one/more of the 
following new onset 
• Proteinuria 




New onset hypertension after 
20 weeks gestation with 
one/more of the following new 
onset 
• Proteinuria 
• Maternal organ dysfunction 
• Fetal growth restriction 
 
New hypertension presenting after 20 




  Pre-eclampsia with severe hypertension 
and/or with symptoms, and/or biochemical 
and/or haematological impairment. 
Superimposed Pre-
eclampsia 
1. Patients with underlying 
hypertension who develop 
one/more of the following 
When a woman with chronic 
hypertension or pre-existing 
proteinuria develops one or 











2. Patients with underlying 
renal disease +/-
proteinuria who develop 
new onset 
• Maternal organ 
dysfunction 








Chronic Hypertension  
All guidelines agree on the criteria for diagnosing chronic hypertension; when 
elevated blood pressure predates the pregnancy or is found to be present prior 
to 20 weeks’ gestation. It’s estimated that between 0.2% to 5% of pregnancies 
are complicated by chronic hypertension and with the rising tide of obesity and 
the advancing age of the prospective mother at conception this prevalence is 
likely to increase further in years to come. A number of subtypes of chronic 
hypertension exist; 
Essential Hypertension 
Essential hypertension is the commonest form of chronic hypertension, 
accounting for approximately 90-95% of cases. It is defined as confirmed 
raised blood pressure either before pregnancy or before 20 completed weeks’ 
gestation without a known cause and hence is considered a diagnosis of 
exclusion. Normally in pregnancy, generalised vasodilation causes a decrease 
in peripheral vascular resistance resulting in a physiological drop in blood 
pressure during the second trimester. Occasionally this drop in blood pressure 
can obscure pre-existing hypertension, making diagnosis difficult in women 
whose blood pressure before pregnancy or early in the first trimester is 
unknown. Essential hypertension can only be diagnosed once a thorough 







Secondary hypertension is defined as chronic hypertension occurring 
secondary to an underlying medical cause. If a woman is identified as having 
high blood pressure in the first half of pregnancy, it is important she is promptly 
evaluated for underlying medical causes, as many of these causes have their 
own implications for pregnancy. Dependent on the cause or medical condition 
suspected however, complete evaluation may need to be deferred until after 
delivery if the necessary investigation is not appropriate to conduct during 
pregnancy. 
The commonest underlying medical causes of hypertension are; chronic 
kidney disease (glomerulonephritis, reflux nephropathy & adult polycystic 
kidney disease) renal artery stenosis, systemic disease with renal involvement 
(diabetes mellitus, systemic lupus erythaematosus), endocrine disorders 
(phaeochromocytoma, Cushing’s syndrome & primary hyperaldosteronism) 
and coarctation of the aorta. In the absence of any of the above conditions, it 
is likely that a woman with high blood pressure in the first half of pregnancy 









White Coat Hypertension or Transient Hypertensive Effect 
Some women with apparent essential hypertension may actually have white-
coat hypertension. This is defined as a raised blood pressure in the presence 
of a clinical attendant but normal blood pressure otherwise. White-coat effect 
in early pregnancy is fairly common, partly due to heightened anxiety when 
attending for medical appointments.  Delineation from essential hypertension 
may be achieved by performing ambulatory or home blood pressure 
monitoring using a calibrated device, validated for use in pregnancy. 
Occasionally elevated blood pressure may be due to environmental stimuli 
such as the pain of labour or. Such a transient hypertensive effect is 
distinguishable by performing serial blood pressure assessment.  
 
Gestational Hypertension 
All guidelines agree on the criteria for diagnosis of gestational hypertension. It 
is characterised by the new onset of hypertension after 20 weeks’ gestation 
without any maternal or fetal features of pre-eclampsia, followed by return of 
blood pressure to normal within 3 months post-partum. It is estimated to 
complicate up to 10% of pregnancies. Some women (up to 25%) initially 
diagnosed with gestational hypertension will progress to develop pre-
eclampsia, hence increased vigilance in this group is good clinical practice. 
Also, some women diagnosed with gestational hypertension will have 
persistent blood pressure elevation beyond 12 weeks post-partum and 





Pre-eclampsia is a multi-system disorder of pregnancy characterised by 
hypertension and involvement of one or more other organ systems and/or the 
foetus that occurs after 20 weeks gestation. Raised blood pressure is 
commonly, but not always, the first clinical sign of pre-eclampsia. Traditionally 
the presence of significant proteinuria (spot urine protein/creatinine >30 mg/ 
mmol (0.3mg/mg) or >300mg/day or at least 1g/L (‘2 +’) on dipstick testing) 
with elevated blood pressure amounted to diagnosis of pre-eclampsia.  
Although proteinuria is the most commonly recognised additional feature of 
pre-eclampsia after hypertension, both ISSHP and Irish guidelines advocate 
that it is no longer considered mandatory to make the diagnosis. In the 
absence of proteinuria, the presence of maternal organ dysfunction or fetal 
growth restriction should be considered sufficient criteria for a diagnosis of pre-
eclampsia.  
Examples of maternal organ dysfunction that may arise with pre-eclampsia 
include;  
• Renal Insufficiency; serum or plasma creatinine >90μmol/L 
• Haematological Involvement; thrombocytopenia <100,000/μL, 
haemolysis or disseminated intravascular coagulation (DIC) 
• Liver Involvement; raised serum transaminases, severe epigastric 




• Neurological Involvement; eclampsia, hypereflexia with sustained 
clonus, persistent new headache, persistent visual disturbances 
(photopsia, scotomata, cortical blindness, posterior reversible 
encephalopathy syndrome, retinal vasospasm), Stroke 
• Pulmonary Oedema. 
 
ISSHP does not advocate for any clinical distinction between mild and severe 
pre-eclampsia in usual clinical practice. Instead, it advises all cases of pre-
eclampsia should be treated in the knowledge that the condition can change 




It is well documented that women with pre-existing hypertension or renal 
disease are at increased risk of developing pre-eclampsia in their pregnancies. 
In recent years the term “superimposed pre-eclampsia” has been coined to 
describe this particular subset of women. The diagnosis of superimposed pre-
eclampsia is often difficult. In women with chronic hypertension after 20 weeks 
gestation, worsening or accelerated hypertension should increase surveillance 
for pre-eclampsia but it is not diagnostic. Proteinuria normally increases in 
pregnancy, so in women with chronic renal disease worsening proteinuria is 
not diagnostic of pre-eclampsia but warrants close observation. In order to 




development of other maternal systemic features of pre-eclampsia or the 
presence of fetal growth restriction in the setting of chronic hypertension or 
chronic renal disease. ISSHP includes superimposed pre-eclampsia as a 
subtype of pre-eclampsia whereas the Irish guidelines categorise it separately.  
The NICE guideline does not comment on superimposed pre-eclampsia. 
 
 Reducing the risk for development of HDP 
A large number of randomised controlled trials have shown that the antiplatelet 
agent aspirin may reduce or prevent pre-eclampsia among women at 
moderate or high risk of developing it (5-7). Meta-analyses have shown a 53% 
(95% confidence interval 35% to 66%) reduction in relative risk for pre-
eclampsia among high risk women when aspirin is commenced prior to 16 
weeks’ gestation (8, 9). Internationally published clinical practice guidelines 
strongly recommend that physicians and midwives risk assess in early 
pregnancy with consideration of administration of aspirin to women at high risk 
of pre-eclampsia (1, 3, 4). Risk factors that are easily identifiable in early 
pregnancy increase a womans risk for the subsequent development of pre-
eclampsia exist. These include; hypertensive disease during a previous 
pregnancy, chronic kidney disease, autoimmune disease such as systemic 
lupus erythematosis or antiphospholipid syndrome, type 1 or type 2 diabetes, 
chronic hypertension, nulliparity, maternal age 40 years or older, maternal 




eclampsia and a twin pregnancy (1, 3, 4). A recent systematic review and 
meta-analysis of 92 cohort studies has validated these risk factors (10). 
Determination of whom is at increased risk is critical not just for the 
commencement of aspirin prophylaxis but also for appropriate planning of 
subsequent antenatal care (11, 12). 
 
 Potential Adverse Outcomes of HDP 
Hypertensive disorders of pregnancy account for nearly 18% of all maternal 
deaths world-wide, with an estimated 62 000–77 000 deaths per year (13). 
Women with a pregnancy complicated by hypertension require frequent 
surveillance by an experienced clinician and potentially multidisciplinary care 
(3, 4, 14). Chronic hypertension, whether essential or secondary, poses 
increased risk of pregnancy complications and adverse pregnancy outcomes 
compared to gestational hypertension (3, 14, 15). There is some evidence that 
in women with chronic hypertension and end organ damage, tighter blood 
pressure control is beneficial and therapy should be used to keep systolic 
blood pressure below 140 mmHg and diastolic blood pressure at 80-90 mmHg 
(1, 16).  
Pre-eclampsia, especially if undiagnosed and left untreated, may progress to 
a myriad of maternal complications including eclampsia, cerebrovascular 
accidents, liver rupture, disseminated intravascular coagulation and death (3, 




complicate 0.28% of pregnancies in low resource settings with maternal near-
miss incidents up to 60 times more frequent in women with eclampsia (18). In 
developed countries, the incidence of eclampsia and its complications have 
decreased significantly following the introduction of management guidelines 
for eclampsia and pre‐eclampsia in the last number of years (19, 20). While 
the latest MBRRACE report shows the maternal death rate from pre-eclampsia 
and eclampsia continues to be low (0.26 per 100,000 maternities 2014-2016) 
there is however no evidence of an ongoing decrease in the mortality rate, 
highlighting this remains an on-going area of concern (21). 
Infants of women with a hypertensive disorder of pregnancy, especially chronic 
hypertension or pre-eclampsia, are at increased risk for complications such as 
intrauterine growth restriction and stillbirth due to deteriorating placental 
dysfunction, which often necessitates iatrogenic preterm delivery (1, 4, 16, 17, 
19). Preterm birth (<37wks gestation) is one of the leading causes of perinatal 
morbidity and mortality worldwide, accounting for 75% of cases of perinatal 
mortality and more than half the cases of long-term morbidity (22, 23).  Each 
year in Ireland, approximately 6.5% of infants are born prematurely (5% for 
singleton births and 55% for twin births) (24). The 2017 NPEC report identified 
345 perinatal deaths, of which 235 were stillbirths (>500g and/or ≥24wks 
gestation) and 110 were deaths of liveborn infants within the first 7 days of life. 
Of the 110 early neonatal deaths in normally formed infants, 36 (32.7%) cases 
were directly attributable to preterm birth (24). Prematurity related perinatal 




hospitals have limited access to neonatal intensive care and necessary 
facilities (25-27). 
 
 Long Term Health Implications 
Pregnancy is a physiological stress test and as such is an effective indicator 
of potential long-term health issues. Women who develop pre-eclampsia are 
known to have a 4-7 fold increased risk of long term hypertension, 2-3 fold 
increased risk of coronary artery disease and 4-7 fold increased risk of chronic 
renal failure (28, 29). Hypertensive disorders of pregnancy may be considered 
a natural screening tool for cardiovascular events, enabling cardiovascular risk 
prevention. It is an ideal opportunity for health care professionals to intervene 
and counsel women in relation to reducing risk factors such as obesity, 
cholesterol and smoking (3). All women with previous hypertensive disorders 
in pregnancy should be encouraged to undergo an annual blood pressure 
check after pregnancy and regular assessment of other cardiovascular risk 
factors including serum lipids and blood glucose (1, 28, 29).  
Advances in medical care have resulted in improved survival rates for preterm 
infants over recent decades, however longitudinal studies with follow-up into 
adulthood are needed to determine if these improvements in neonatal 
medicine have translated into improved outcomes. These infants have a high 
prevalence of intellectual disabilities, behavioural, social and emotional 




into adult life (30). The “developmental origins of adult disease” hypothesis, 
often called “the Barker hypothesis” has provided clear evidence that pace and 
pathway of growth, including intrauterine and early neonatal growth, increases 
a person’s susceptibility to obesity, diabetes, insulin insensitivity, 
hypertension, and hyperlipidaemia and thereby increases the incidence of 
later adult complications  such as coronary heart disease and stroke (31, 32). 
1.2 Twin Pregnancy 
1.2.1 Epidemiology 
A twin pregnancy, also known as a multiple pregnancy, arises by one of two 
means. The first type of twinning, known as dizygotic twinning, accounts for 
approximately 70% of cases of twins. It occurs when superovulation due to 
increased levels of follicle stimulating hormone results in the release of two 
oocytes during a single cycle. These separate oocytes are then fertilised by 
separate sperm. The resultant zygotes are essentially siblings and share no 
more genetic identity than any other siblings share. Each will have their own 
placenta and amniotic sac known as a dichorionic, diamniotic twin pregnancy 
(33-36).  
The remaining 30% of cases of twins are monozygotic. These occur when a 
single oocyte is fertilised by a single sperm and the resultant blastocyst splits 
in the early days following fertilisation into two separate but genetically 




separation before 72 hours results in separate placenta and separate amniotic 
sacs; a dichorionic diamniotic pregnancy (DCDA). Separation from day 4-7 
results in separate sacs but a shared placenta; a monochorionic diamniotic 
(MCDA) pregnancy. Separation between day 7-14 is rarer and results a single 
shared sac as well as a shared placenta; monochorionic monoamniotic 
(MCMA) (Figure 1) (38, 39).  
Occasionally pregnancies with more than two or three fetuses, known as 
higher order multiple pregnancies, (HOMP) occur. Rarely these may result 
spontaneously from a blastocyst splitting into more than three parts, resulting 
in monozygotic quadruplet pregnancy (40, 41). Alternatively, the practice of 
multiple embryo transfers in assisted reproductive technology (ART) may 
result in HOMP of differing zygosity (42). Due to the increased maternal and 
neonatal morbidity risk associated with a HOMP, fetal reduction may be 
employed in some such cases, resulting in an ongoing twin pregnancy, in 






Figure 1. 1: Monozygotic twin pregnancy showing three types of monozygotic 
placenta and membranes. A=dichorionic diamniotic pregnancy. 
B=monochorionic pregnancy. C=monochorionic monoamniotic pregnancy. 
From The Lancet, J. Hall (33). 
 
1.2.2 Incidence 
Although geographic variation exists, the incidence of twin pregnancy has 
been consistent throughout the centuries, arising spontaneously 
approximately one in every 80 pregnancies (33, 45, 46). Over the last four 
decades, the incidence of twin pregnancy has been steadily rising, with a more 
pronounced increase in dizygotic twins (37, 47). A shift toward older maternal 




and increased use of ART, which is more likely to result in a multifetal gestation 
are most likely behind these rising rates (48-50). According to Irish data, the 
number of twins born here has increased from 10.5 per 1,000 live births in 
1985, to 19.0 per 1,000 in 2016, with an increase of 22.5% over the last decade 
alone (51). In the UK, a concerted effort has been made to reduce the high 
multiple birth rate following IVF. Campaigns such as the “One at a time; better 
outcomes from fertility treatment” have resulted in a reduction in the multiple 
birth rate following IVF treatment from 24% in 2008 to 10% in 2017 (52). 
Currently in the UK, multiple births account for approximately 3% of live births 
(53) and similar trends are reported in other developed countries (54-56).  
Currently no regulations of the Irish ART sector exist; hence no monitoring or 
audits are in place for the practice of multiple embryo transfer or use of 
ovulation induction agents (50, 57). Unlike the UK, Irish fertility clinics are not 
obliged to officially publish their success rates therefore figures on the 
incidence of multiple births following IVF in Ireland are difficult to ascertain, but 
estimated to be in the region of 10-20% (51, 58). The Irish ART sector is 
predominantly privately funded, hence providers may be pressured to perform 
multiple embryo transfers in order to maximise chances of achieving a 
pregnancy for their clients (59). A number of European countries that have 
introduced state funding for ART services have shown a significant reduction 





1.2.3 Potential Adverse Outcomes of Twin Pregnancy 
The specific risks of a twin pregnancy correlate well with the underlying 
chorionicity (53, 62), hence why it is important to identify a twin pregnancy at 
an early gestation,  ideally <14 weeks gestation, when chorionicity can be 
accurately determined by ultrasound (63).  Twin pregnancies overall have a 
higher risk of adverse perinatal outcomes such as mortality, preterm birth, 
congenital abnormalities and fetal growth restriction with monozygotic more 
vulnerable than dizygotic (49, 56, 64-66).  
Specifically to monochorionic pregnancies, conditions such as twin-twin 
transfusion (TTTS)  or twin reversed arterial perfusion sequence (TRAP) may 
arise, while in monoamniotic pregnancies cord entanglement is a significant 
concern (56, 67). The widespread use of ultrasound in obstetrics has enabled 
better surveillance and earlier detection of some of these complications (67). 
Clinical advances such as fetoscophic laser surgery have allowed therapeutic 
intervention in cases who previously would have had a dismal prognosis (68). 
A retrospective study in 2016 from three tertiary maternity hospitals in Ireland, 
reported a reduction in perinatal mortality in twin pregnancies between 1996-
2012 owing to reduction in mortality from TTTS during the time period 
examined (69). Figures from the 2017 NPEC perinatal mortality report highlight 
an association between perinatal death and twin pregnancies. Twin births 
accounted for 3.8% of all births in 2017, yet accounted for 12.4% of all 
perinatal deaths (24). Of the 43 perinatal deaths in twin births, the vast majority 




were stillbirths, with aetiology ranging from specific placental conditions (n=8, 
38.1%), specific fetal conditions (n=5, 23.8%), major congenital anomalies 
(n=2, 9.5%) associated obstetric factors (n=1, 4.8%) and unexplained (n=5, 
23.8%). The remaining perinatal deaths (n=22) were early neonatal deaths, 
with the majority (n=12, 54.5%) due to respiratory disorders, most often severe 
pulmonary immaturity. The remaining early neonatal deaths were due to major 
congenital anomalies (n=8, 36.4%) and neurological disorders (n=2, 9.1%) 
(24).  
As well as adverse neonatal outcomes, adverse maternal outcomes are also 
more frequently observed with a twin pregnancy (67, 70). Obstetric 
complications such as such as anaemia, post-partum haemorrhage, 
gestational diabetes mellitus (GDM) and obstetric cholestasis (OC) arise more 
often in a twin pregnancy (56, 71). Despite our knowledge of increased 
maternal risks, active surveillance for same and dedicated multiple pregnancy 
clinics led by consultant obstetricians with expertise in management of twin 
pregnancy, maternal morbidity remains a problem. Figures from the 2017 
NPEC severe maternal morbidity report highlight the increased incidence of 
severe maternal morbidity with a multiple pregnancy, with a rate of 5.76 per 





1.2.4 Hypertensive Disorders of Pregnancy in Twin Pregnancy 
Multiple pregnancy confers a 2-3 fold-increased risk for the development of 
hypertensive disorders of pregnancy (HDP) compared to singletons (73, 74). 
The incidence of HDP in twin pregnancy varies in the literature from 13-37% 
(73-77) with some recent studies, focused on comparison of gestationally 
matched singletons to twins, reporting a nine fold increased risk of pre-
eclampsia with twin pregnancy (78). The reason for this increased risk of HDP 
in twin pregnancy is not fully understood, but is likely due to a combination of 
maternal risk factors and the presence of a larger placental mass (56, 73).  
Maternal age >40 years, nulliparity and conception through use of a donor 
oocyte are independent risk factors for adverse perinatal outcomes (79-81). 
They are also well established risk factors for the development of HDP in a 
pregnancy (3, 53).  These risk factors are more likely to be present in women 
with a twin pregnancy as in developed countries women are now commonly 
deferring pregnancy to focus on education and career advancement (82). Due 
to reduced fertility with advancing maternal age, older women often require 
assistance by ART, and commonly also oocyte donation, in order to achieve 
a pregnancy (81, 83, 84).  The use of oocyte donation confers increased risk 
of adverse outcomes, in particular in relation to the development of 
hypertensive disorders of pregnancy (3, 85, 86).  
With any type of twin pregnancy, a larger placenta mass is present and hence 




these angiogenic factors have been shown to correlate with the clinical onset 
of pre-eclampsia (88, 89) with each two fold elevation in sFlt-1 increasing the 
risk of development of pre-eclampsia (90). In section 3 of this Introduction, I 
will expand further on these angiogenic growth factors and their respective 
receptors while in section 4, I will discuss them in relation to twin pregnancy.  
 
1.2.5 Potential Adverse Outcomes from a Hypertensive Disorder in Twin 
Pregnancy 
When a multiple pregnancy is complicated by a HDP, national and 
international guidelines and research report a higher risk of adverse 
pregnancy outcomes compared either to an uncomplicated twin pregnancy or 
to a singleton pregnancy complicated by a HDP (14, 53, 72, 74, 77). HDP 
commonly arises due to impaired placentation, hence small for gestational age 
infants and placental abruption due to placental dysfunction are both more 
likely to occur (91). Owing to maternal and /or fetal concerns iatrogenic 
preterm delivery is also more likely and consequently an increased incidence 
of caesarean delivery is also reported (24, 72, 74, 92). Further driving perinatal 
morbidity, these complications usually arise earlier in the setting of twin 
pregnancy with HDP compared to singletons with HDP or to uncomplicated 





1.3 Placental Growth Factor 
1.3.1 Background 
Placental growth factor (PlGF) is a member of the vascular endothelial growth 
factor (VEGF) family of proteins (95). All VEGF proteins share a similar 
structure with a distinctive cystine knot (96, 97) characterised by eight spatially 
conserved cysteines stabilised by a hydrophobic core region (96, 98-100). 
VEGF-A was discovered in 1989 and two years later PlGF was the second 
member of the family identified (101-103). This pro-inflammatory factor is 
produced by trophoblast cells of the placenta and was discovered by an Italian 
scientist while she was investigating the angiogenic potential of human 
placental tissue (95).  
PlGF can exist in multiple isoforms with four isoforms of human PlGF currently 
known to exist (104, 105). PlGF-1 and PlGF-2 are thought to be the 
predominate isoforms and they share almost 88% sequence identity (106). 
The isoforms differ in terms of their size, number of amino acids, binding and 
secretion properties (107). VEGF-A and PlGF can also exist as homodimers 
and heterodimers (PlGF:PlGF, PlGF:VEGF-A, VEGF-A:VEGF-A), with 
PlGF:VEGF heterodimers displaying fair less mitogenic activity than VEGF 






Figure 1. 2: Depiction of the hetero and homodimer structures in which PlGF 
and VEGF-A may exist. From Pregnancy Hypertension, D. Hayes-Ryan et al  
(110). 
 
All VEGF proteins, including PlGF, must bind and activate a tyrosine kinase 
receptor in order to be able to function. There are three known homologous 
receptors they may bind to; Flt-1, Flk-1 or VEGFR3 (111-113). PlGF has been 
shown to only bind to Flt-1 (114). Flt-1 is non mobile, anchored to the cell wall 
membrane (115). A very similar receptor known as sFlt-1 also exists, however 











Figure 1. 3: Depiction of the binding that may occur between PlGF/ VEGF-A 
proteins and the membrane bound receptors Flt-1 ad Flk-1 and the freely 
circulating receptor sFlt-1. From Pregnancy Hypertension, D. Hayes-Ryan et 
al  (110). 
 
Placental growth factor (PlGF) is highly involved in the regulation of 
angiogenesis under pathological conditions (95). Early studies in mice, bred 
to be deficient in PlGF, demonstrated they had reduced angiogenic ability 
when subjected to ischaemia, inflammation or cancer (18). PlGF exerts this 
angiogenic effect by binding to the anchored membrane receptor Flt-1. This 
binding activates endothelial cells, macrophages and haematopoietic 
progenitor cells and displaces VEGF-A from Flt-1, allowing VEGF-A to bind 
instead to the more potent FDK (109, 117-121). In contrast, sFlt-1 has an anti-




effects by reducing the amount of PlGF available to the cell membrane bound 
Flt-1 (122, 123). The net result of this is vasoconstriction and endothelial 
dysfunction (124) with levels of sFlt-1 rising under hypoxic conditions in an 
effort to compensate for impaired oxygenation (125).  
 
1.3.2 Hypertensive Disorders of Pregnancy & Placental Growth Factor 
Studies have shown a distinct gestational pattern of PlGF in normal pregnancy 
corresponding to placenta development (87). PlGF levels rise alongside 
gestational age, peaking at 32 weeks’ gestation when the placenta is 
developed fully and then decline until term (126, 127). In women whose 
pregnancies are complicated by pre-eclampsia, the rise and fall of PlGF shows 
the same pattern but the exact levels of PlGF are much lower throughout all 
their pregnancy, and extremely low at the time point when pre-eclampsia 
exists clinically (87-89). Also in women who develop pre-eclampsia there are 
increased levels of sFlt-1 present, particularly in the early onset form of the 
disease, weeks prior to the clinical existence of pre-eclampsia (88, 89, 128-
132). It is thought that the substantial increase in sFlt-1 levels arise from the 
endothelial dysfunction that occurs in pre-eclampsia (133, 134). Support for 
this theory comes from ex vivo studies that show significant damage occurs to 
endothelial cells when they are exposed to serum from pregnant women with 




A three-stage model for the development of pre-eclampsia is now generally 
accepted; should impaired placentation occur in early pregnancy, it results in 
a deficiency of PlGF and consequently impaired angiogenesis. This leads to 
hypoxia and oxidative damage from 20 weeks gestation with low PlGF levels 
likely to be a good marker of an oxidatively damaged placenta. The hypoxic 
placenta then releases sFlt-1 in a self-defence bid to induce vasoconstriction 
and increase oxygen supply. The net result of this is systemic endothelial cell 
dysfunction and end-organ ischemia, which leads to the classical clinical signs 
and symptoms of pre-eclampsia (138-140).  
In 2016 the UK National Institute for Clinical Excellence (NICE) issued 
guidance advocating that PlGF testing, combined with routine clinical care, 
could be used to help rule out pre-eclampsia in singleton pregnancies in 
women presenting with suspected pre-eclampsia between 20 weeks and 34 
weeks plus 6 days of gestation. NICE also recommended that these tests 
should not yet be used to diagnose pre-eclampsia until further research was 
available, specifically on how an abnormal PlGF result would affect 
management decisions regarding timing and gestation of delivery and the 
outcomes associated with this (141). 
 
1.3.3 Placental Growth Factor Immunoassay platforms 
A number of different immunoassay platforms for quantification of PlGF alone 




Initial laboratory work on the biomarker was conducted using laboratory based 
immunoassay platforms such as an enzyme-linked immunosorbent assay 
(ELISA) (87, 142-146). Commercial interest in the biomarker has resulted in a 
number of companies developing automated tests that allow rapid and easy 
quantification of PlGF, most of which require significant infrastructure and 
financial investment for initial set up (147-151). Although ELISAs continue to 
be available they are predominantly now used for research purposes rather 
than clinical application.  
 
The Quantikine® Human PlGF Immunoassay (R&D systems) 
This plate ELISA has a measureable range of 15.6-1000 pg/ml of PlGF and 
an assay completion time of 3.5 to 4.5 hours. The pre-coated 96 well 
polystyrene microplate uses a monoclonal antibody specific for human PlGF. 
The manufacturers report the ELISA detects PIGF-2 and PIGF-3 isoforms in 
addition to PlGF-1. The procedure for performing analysis with this platform is 
in line with any ELISA and is generally performed in duplicate with the average 
measurement obtained, to aid precision and to minimise the potential for error 
(152). 
ELISA procedure; 
I. Standards and samples are loaded onto the plate and any PlGF present 




II. After washing away any unbound substances, an enzyme-linked 
polyclonal antibody specific for human PlGF is added to the wells 
III. Following a wash to remove any unbound antibody-enzyme reagent, a 
substrate solution is added to the wells and colour develops in 
proportion to the amount of PlGF bound in the initial step 
IV. The colour development is stopped and the intensity of the colour is 
measured using an automated microplate reader 
 
Triage® PlGF test (Quidel, San Diego)   
The Triage® PlGF test (Quidel, San Diego) is currently the only point of care 
test on the market for measuring PlGF. The CE marked platform involves a 
single use, point of care, fluorescence immunoassay device. The test 
procedure involves the addition of several drops of plasma to the sample port 
on the single use cartridge device. The plasma reacts with the fluorescent 
antibody conjugates and flows through the test cartridge by capillary action. 
The presence of a target analyte causes the corresponding fluorescent 
antibody conjugates to bind to the discrete zone specific to that analyte. The 
test cartridge is inserted into the meter which is programmed to automatically 
perform an analysis after the specimen has reacted with the reagents within 
the cartridge. The analysis is based on the amount of fluorescence the meter 
detects within a measurement zone on the test device. The results are 
displayed on the meter screen in approximately 15 minutes and have a 




uses antibodies against PlGF isoform-1, with some cross-reactivity for 
isoform-2.  Developed initially by Alere Inc. (San Diego, USA) the intellectual 
property rights were acquired by Quidel Inc. (San Diego, USA) in 2018 and the 
product is now commercially available again (153). 
 
Elecsys® Immunoassay sFlt-1/PlGF ratio (Roche Diagnostics, Germany) 
This immunoassay ratio test quantifies levels of both PlGF and sFlt-1. The 
ratio is formed by combining the results from two CE-marked sandwich 
electrochemiluminescence immunoassays (Elecsys® PlGF and Elecsys® 
sFlt-1 assays), which are compatible with both the Roche Elecsys® and the 
Cobas e automated analysers. The laboratory information system calculates 
and reports the sFlt-1/PlGF ratio and the individual assay values. The 
Elecsys® sFlt-1 immunoassay has a measuring range 10 to 85,000 pg/ml 
while the Elecsys® PlGF immunoassay has a measuring range 3 to 10,000 
pg/ml. The Elecsys® PlGF immunoassay detects free PlGF isoforms as well 
as that part of PlGF isoforms complexed with sFlt-1. It has a limit of quantitation 
of 10 pg/ml and manufacturer quoted cross-reactivity with PlGF-2 of< 8%. The 
turnaround time of  test is about 18 minutes (149).  
 
The DELFIA® Xpress PlGF 1-2-3 test (Perkin Elmer, Finland) 
This CE-marked fluoroimmunometric sandwich assay is designed to measure 




Xpress random access analyser, has a measureable range from 1.9 to 4,000 
pg/ml, a limit of quantitation of 3.3 pg/ml and a test turnaround time of about 
30 minutes. The manufacturers quote PlGF-2 and PlGF-3 isoforms cross-
reactivity of 28% and 20% (non-glycosylated) respectively (150).  
 
BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio (Thermo-
Fisher Scientific) 
This assay is formed by combining the results from 2 automated 
immunofluorescent sandwich assays, the BRAHMS sFlt-1 Kryptor assay 
(measuring range 22 to 90,000 pg/ml) and the BRAHMS PlGF plus Kryptor 
assay (measuring range 3.6 to 7,000 pg/ml).  The BRAHMS PlGF plus assay 
is designed to measure the free PlGF-1 isoform with a manufacturer quoted 
cross-reactivity with PlGF-2 and PlGF-3 isoforms of 13% and 4% respectively. 
Serum samples are required for use as well as the BRAHMS Kryptor compact 
plus analyser. The turnaround time for the BRAHMS sFlt-1 Kryptor assay is 9 
minutes and the turnaround time for the BRAHMS PlGF plus Kryptor assay is 
29 minutes (151) 
 
1.3.4 Inter-immunoassay performance  
The Triage® and Elecsys® platforms have been utilised in a number of clinical 




154-156). The manufactures of both the DELFIA®  and the BRAHMS®  assays 
provide reference ranges for each assay in the product instructions, however 
the companies recommend that individual laboratories should validate these 
ranges or establish their own reference ranges before clinical use (150, 151). 
Importantly to note, PlGF values obtained with one automated platform are 
likely not interchangeable with those from another. Differences in actual PlGF 
and sFlt-1 values between test platforms, owing to inter-manufacturer 
immunoassay analytical differences and isoform cross reactivity, may exist, a 
fact highlighted in a recent comparative study including the Delfia®, Elecsys® 
and Brahms® platforms (157).  
A dearth of information currently exists on comparative performance of 
commercially available PlGF immunoassay platforms (147, 157, 158). The 
recently published COMPARE study was the first head-to head comparison of 
three such platforms; Delfia®, Elecsys® and Triage®. It reported a 
performance of each, with high negative predictive values, in prediction of 
delivery within 14 days from testing in women with a singleton pregnancy and 
suspected preterm pre-eclampsia before 35 weeks' gestation (158). NICE 
have advocated that at present should PlGF testing be conducted in a clinical 
setting, either the Triage® or the Elecsys® should be the platforms 
preferentially used owing to the lack of available information as yet on the 
DELFIA® and the BRAHMS® platforms. NICE also recommends that further 
validation studies, head-to-head comparative studies, and cost effective 




1.4 Placental Growth Factor and Twin Pregnacy 
1.4.1 Background  
Owing to a larger placental mass and use of assisted reproductive therapy 
(ART), especially  use of non-autologous gametes, women with a twin 
pregnancy are at a two to three fold increased risk of developing pre-eclampsia 
(159-161). As knowledge on the aetiology of pre-eclampsia expands, the 
importance of the balance of placental angiogenic factors in its development 
becomes more apparent (131, 137, 162). As previously described, placental 
growth factor (PlGF) has shown great promise as a predictor of subsequent 
preterm pre-eclampsia and overall placental dysfunction in a singleton cohort, 
with lowered levels of angiogenic PlGF and increased levels of anti-angiogenic 
sFlt-1 in maternal plasma, weeks prior to the clinical onset of disease (87, 89, 
95).  
Few studies have examined these angiogenic factors in twin pregnancy, 
unsurprising given that research in a twin pregnancy cohort is more 
challenging given that both zygosity and chorionicity need to be considered.  
Also, given the inherently higher incidence of adverse outcomes in this 
population, larger numbers of recruits are required in order to obtain a normal 
sample of the population (163, 164). Prior studies of angiogenic factors in twin 
pregnancy vary hugely on a wide variety of factors, limiting comparison of 
results.  Numbers of participants, gestational age at time of sampling, 




each study, not to mention studies often involve pooled results from a number 
of sites or countries across a variety of time periods (73, 160, 164-173) 
 
1.4.2 Normal Range of Angiogenic Factors in Twin Pregnancy 
Initially it was assumed that given the doubling of placental size in a twin 
pregnancy, that all biomarkers would be present in double the concentration 
in maternal serum in a twin pregnancy compared to a singleton (174). A 2012 
paper by Sanchez et al, demonstrated increased levels of PlGF and its soluble 
anti-angiogenic receptor sFlt-1 in 61 twin pregnancies compared to 50 
matched singletons, using an ELISA immunoassay for quantification of the 
angiogenic factors  (165). The following year a paper by Cowans et al 
assessing first trimester PlGF concentrations using the DELFIA platform, 
demonstrated that PlGF levels were 41% higher in 440 dichorionic compared 
to 116 monochorionic twin pregnancies and 16% higher in monochorionic 
compared to 116 matched singleton pregnancies (175). A Spanish 2016 study 
demonstrated a similarity in median PlGF/sFlt-1 ratios, quantified using the 
ELECYS platform in twins and singletons up until 29 weeks gestation, however 
a significant lower median PlGF value in twins thereafter (176).  
These results highlight that normal reference ranges for singletons cannot 
simply be doubled for use in the twin population. Individual chorionicity-




receptors, to enable further research on the clinical utility of these angiogenic 
factors in the twin population.   
 
1.4.3 Potential benefit of PlGF use in screening in twin pregnancy  
A number of studies have demonstrated the potential use of PlGF in the twin 
population. A 2011 study, performed using an ELISA immunoassay, examined 
first trimester levels of circulating angiogenic factors in 61 women with a twin 
pregnancy. They noted maternal serum sFlt-1 levels to be significantly higher 
in the pregnancies conceived through assisted reproductive techniques (ART) 
compared to spontaneous conceptions (165). It is well documented that ART 
assisted pregnancies are at increased risk of pre-eclampsia development, 
hence the potential for using these angiogenic factors as a combined first 
trimester screening tool for pre-eclampsia (177). Indeed a 2012 study by a 
Canadian group showed PlGF to be a useful predictor of subsequent pre-
eclampsia as early as 12 to 18 weeks in twin pregnancies, but not clinically 
useful enough to be used as a single marker (178). 
 
1.4.4 Potential benefit of PlGF in diagnostics in twin pregnancy  
In singletons, PlGF is currently being utilised and evaluated as an adjunct to 
aid the diagnosis of preterm pre-eclampsia (141, 179). Studies in twins have 




Powers et al published in 2010 on a series of 234 women with a twin 
pregnancy that had quantification of circulating PlGF and sFlt-1 samples 
across their pregnancy using an ELISA immunoassay. The authors reported 
increased risk for the development of pre-eclampsia with each two fold 
increase in sFlt-1 (OR 2.18, 95% CI 1.46-3.32) and reduced risk for pre-
eclampsia development with each two fold increase in PlGF (OR 0.50 95% CI 
0.30-0.82) (90).  A study by Droge et al reported on a cohort of 49 women with 
a twin pregnancy, 18 of whom developed pre-eclampsia. Maternal serum PlGF 
levels were decreased and sFlt-1 levels increased in the pre-eclampsia cases 
at time of their presentation compared to the controls with quantification of 
angiogenic factors performed using the Elecsys platform (166). Another study 
by Rana et al, again utilising the Elecsys platform, described serum PlGF and 
sFlt-1 in 79 women with a twin pregnancy presenting with suspected pre-
eclampsia in the third trimester (180). Using a clinical outcome of an adverse 
clinical event in the subsequent fortnight, the angiogenic factors were 
compared between the two groups. An adverse maternal outcome was 
defined as the presence of hypertension plus at least one of the following; 
elevated aspartate aminotransferase or alanine aminotransferase (≥80 U/L),  
platelet count ≤100 × 109/L, disseminated intravascular coagulation (DIC), 
abruption (clinical and/or pathological), pulmonary oedema, cerebral 
haemorrhage, eclampsia, abnormal renal function (creatinine >132.6 µmol/L), 
or maternal death. An adverse fetal/neonatal outcome included iatrogenic 
delivery for hypertensive complications of pregnancy, small-for-gestational 




artery Doppler (absent or reverse flow), fetal death, and neonatal death (in 
either twin). Median PlGF was noted to be significantly reduced, while median 
sFlt-1 was elevated in those that developed an adverse event (n=52). 
Together, these studies highlight the potential that exists for use of PlGF +/- 
sFlt-1 as a diagnostic aid for pre-eclampsia in twin pregnancy and as 
prognostic indicator for its subsequent adverse outcomes.  
 
1.4.5 Cut-offs for clinical utility of angiogenic factors in twin pregnancy  
To allow these biomarkers to be utilised clinically in the twin population, it is 
imperative that relevant cut-offs are developed and validated specifically for 
this group. This was highlighted in a 2018 study by Saleh et al. The Dutch 
group compared PlGF and sFlt-1 levels in normotensive and pre-eclamptic 
singleton and twin pregnancies using the Elecsys platform (181). Previously, 
a sFlt-1/PlGF ratio cut-off of ≤38, using the Elecsys, has been identified as 
useful in predicting the one week absence of pre-eclampsia in women with 
clinical signs/symptoms with a high negative predictive value (88).  Twenty-
one twins along with 21 matched singletons were included and analysed. All 
pre-eclamptic singleton pregnancies had a ratio of >38 however only 5 of the 
13 women with a pre-eclamptic twin pregnancy had a ratio of >38. Importantly 
this demonstrates that clinical cut-offs for PlGF +/- sFlt-1 identified for use in 





1.4.6 PlGF in Growth Discordant Twin Pregnancy 
Birth weight discordance in a twin pregnancy may represent either a 
physiological variation or a pathological event (67). Significant birth weight 
discordance (>greater than 25% difference) that arises after the mid trimester 
is generally the result of uterine inability to equally nurture both placentae 
(163). Published in 2008, a paper by Nevo et al evaluated the similarity in 
angiogenic imbalance between IUGR and pre-eclamptic pregnancies by 
examining placental angiogenic factors from IUGR, SGA, pre-eclamptic and 
control pregnancies in both singletons and twins. The main findings were a 
similarity in the angiogenic imbalance in both pre-eclamptic and severe IUGR 
pregnancies compared to SGA and controls, supporting the role of these 
angiogenic factors in conditions of pathological placental dysfunction and their 
potential for use as biomarkers of these conditions. Interestingly, a significant 
difference in angiogenic factors was also noted in twins discordant for growth, 
with the IUGR twin placenta having much increased expression of sFlt-1 
compared to the normally sized co-twin (167).  
Following on from this, Ruiz-Sacedon et al published a case controlled study 
in 2013 with 18 discordant (>20%) and 46 concordant dichorionic twin 
pregnancies. An ELISA was utilised for quantification of angiogenic factors 
(VEGF and sFlt-1). Not only did they demonstrate a lower maternal circulating 
level of angiogenic factors in the discordant twin pregnancies, but examination 
of fetal umbilical vein samples at delivery demonstrated reduced angiogenic 




anti-angiogenic environment exists in mothers and fetuses with growth 
discordance, potentially enabling these angiogenic factors to be utilised in 
screening for and monitoring of discordant twin growth (164).  
 
1.4.7 Limitations in current knowledge  
Potential exists for PlGF use in twin pregnancy as a diagnostic aid for pre-
eclampsia/ placental dysfunction, or as a prognostic aid for adverse outcomes. 
However; further research is first required to order to provide clarity and allow 
for its prudent use by clinicians. Reference ranges for PlGF in “normal” twin 
pregnancy need to be established, with consideration given to potential 
variations secondary to chorionicity. Following on from this, adequately 
powered, high quality prospective observational studies of women with a twin 
pregnancy and suspected pre-eclampsia/placental dysfunction are required in 
order to develop and validate clinically useful cut-offs for PlGF +/- sFlt-1 in 
twins. Ideally, studies should examine a number of PlGF platforms at once, in 
order to maximise efficiency and also to allow for comparison of performance 
(141). With rates of twin pregnancy rising over the last number of decades, 
expansion of our current knowledge on these angiogenic factors, especially 
PlGF, in twin pregnancy is paramount and requires our attention (48, 55, 182, 
183). 
As discussed in Section 2.5, hypertensive disorders arising in the setting of a 




75, 77). Use of PlGF in twin pregnancy may facilitate earlier identification of 
hypertensive disorders and prediction of subsequent adverse outcomes, thus 
enabling optimisation of antenatal care for these patients and careful planning 
regarding setting, timing and mode of delivery. In the next section of the 
Introduction, I will discuss the research to date on PlGF as an adjunctive aid 
for pre-eclampsia diagnosis in singleton pregnancies. 
1.5 Placental Growth Factor as a Diagnostic Biomarker 
1.5.1 Observational Studies 
Over the last number of decades, the concept of using PlGF as a potential 
diagnostic marker for pre-eclampsia has been extensively examined (88, 89, 
132). Studies have shown that as a pregnancy progresses, circulating levels 
of PlGF correlate directly with placental function (129, 131). Pregnant women 
with low circulating levels of PlGF are at increased risk for adverse outcomes 
such as pre-eclampsia, HELLP syndrome, eclampsia, fetal growth restriction, 
and stillbirth (184, 185). A number of prospective cohort studies have 
published on clinically relevant cut-offs for PlGF +/- slt-1 using automated 








PELICAN was an international, multi-site, blinded observational trial that ran 
in seven consultant led maternity units throughout the UK and Ireland from 
January 2011 and February 2012. It was the first and largest prospective study 
of PlGF in women with suspected pre-eclampsia (89). Over 600 women were 
enrolled, all >20 weeks gestation and all with signs or symptoms concerning 
for evolving pre-eclampsia. All had quantification of circulating maternal 
plasma PlGF performed at the time point of enrolment. Their PlGF results were 
blinded to their caregivers and their pregnancies continued as per usual 
hospital care practice pathways. The PlGF immunoassay platform employed 
for this study was the Triage® PlGF test (Formerly Alere Inc. now Quidel Inc. 
San Diego). The primary aim of the study was to establish how effective PlGF 
quantification at presentation to the hospital was at determining the 
subsequent need for delivery for confirmed pre-eclampsia within 14 days.  
Approximately half (n=346; 55%) of those recruited developed pre-eclampsia. 
Results published in 2013 positively demonstrated that PlGF testing could be 
beneficial in stratifying care for women presenting with suspected pre-
eclampsia between 20 weeks and 34 weeks plus 6 days of gestation.  For a 
test cut-off  <100 pg/mL, PlGF alone showed 96% sensitivity (95% CI, 89–99), 
56% specificity (95% CI, 49–63), 44% positive predictive value (PPV) (95% 
CI, 36–52), and 98% negative predictive value (NPV) (95% CI, 93–100) in 
determining those that would require delivery for a confirmed diagnosis of pre-




sensitivity for identifying women likely to develop pre-eclampsia needing 
delivery within 14 days of testing. (Table 1.2).  
The study reported that using a cut-off of 100 pg/ml had high sensitivity for 
predicting both preterm pre-eclampsia and also delivery within 14 days of 
testing independent of the pre-eclampsia diagnosis. A cut-off value of 12 pg/ml 
had poor sensitivity but good specificity for predicting preterm delivery 
independent of the pre-eclampsia diagnosis (Table 1.3). Secondary analysis 
of an older gestational cohort (n=137) showed the test had poor diagnostic 




Table 1. 2: Triage® test accuracy for predicting pre-eclampsia needing delivery within 14 days for women presenting between 
20 weeks-34+6 weeks gestation. From BJOG, Duckworth et al (89). 











(0.89 to 0.99) 
0.56 
(0.49 to 0.63) 
0.44 
(0.36 to 0.52) 
0.98 
(0.93 to 1.00) 
≥100 pg/ml 0.96 
(0.89 to 0.99) 
0.56 
(0.49 to 0.63) 
0.43 
(0.36 to 0.51) 
0.98 
(0.93 to 1.00) 
< fifth centile 0.96 
(0.89 to 0.99) 
0.55 
(0.48 to 0.61) 
0.43 
(0.36 to 0.51) 
0.98 
(0.93 to 1.00) 
< 12 pg/ml 0.63 
(0.51 to 0.74) 
0.90 
(0.85 to 0.94) 
0.70 
(0.57 to 0.80) 
0.87 





Table 1. 3: Triage® test accuracy for predicting preterm delivery or delivery within 14 days, independent of diagnosis of pre-
eclampsia for women presenting between 20 weeks-34+6 weeks gestation. From BJOG, Duckworth et al (89). 












(0.83 to 0.95) 
0.65 
(0.58 to 0.73) 
0.65 
(0.57 to 0.72) 
0.90 
(0.83 to 0.95) 
Delivery within 14 days of testing 
≥100 pg/ml 0.94 
(0.87 to 0.98) 
0.57 
(0.50 to 0.64) 
0.47 
(0.39 to 0.55) 
0.96 
(0.91 to 0.99) 
Preterm delivery 
< 12 pg/ml 0.44 
(0.36 to 0.52) 
0.97 
(0.93 to 0.99) 
0.94 
(0.86 to 0.98) 
0.62 





Table 1. 4: Triage® test accuracy for predicting pre-eclampsia needing delivery within 14 days for women presenting between 
35 weeks-36+6 weeks gestation. From BJOG, Duckworth et al (89). 








< fifth centile 0.70 
(0.58 to 0.81) 
0.64 
(0.52 to 0.75) 
0.65 
(0.53 to 0.76) 
0.69 
(0.57 to 0.80) 
< 12 pg/ml 0.22 
(0.13 to 0.34) 
0.91 
(0.82 to 0.97) 
0.71 
(0.48 to 0.89) 
0.55 







The PELICAN study validated a fixed cut-off value for PlGF of <100 pg/ml for 
the Triage® platform as having clinical utility, and similar performance to a 
gestational cut-off of the 5th centile. It also reported a PlGF <100 pg/ml to be a 
better predictor than all other current commonly used predictive tests of pre-
eclampsia, either singly or in combination (blood pressure, urinalysis or 
biochemical markers) with an area under the ROC curve for low PlGF of 0.87 
compared to 0.76 for the next best predictor. 
Of note in the PELICAN study there were seven intrauterine deaths, a higher 
rate than anticipated in the population of 625 women recruited. Post hoc 
analysis identified all seven women as having an abnormal PlGF result. At 
least five of these cases were at gestational ages and birthweights where they 
would have been reasonably expected to survive had the PlGF result been 
revealed to clinicians and the women delivered. 
 
Alvarez et al (2014) 
This Spanish group conducted a retrospective cohort study on 257 pregnant 
women, triaged with suspected pre-eclampsia (185). Each had their PlGF: 
sFlt-1 ratio quantified at time of presentation using the Elecsys® test. 
Researchers collected outcomes data such as development of pre-eclampsia 
and reviewed and time between clinical presentation, diagnosis and delivery 
was calculated. The study showed that the best ratio cut-off to diagnose pre-
eclampsia changed according to gestational age: 23 (92.0% sensitivity, 81.1% 
specificity) and 45 (83.7% sensitivity, 72.6% specificity) for women < 34 and ≥ 




adjusted cut-off values the sFlt-1/PlGF ratio could be used to rule out pre-
eclampsia at obstetric triage and to predict imminent delivery with better 




Table 1. 5: Elecsys® test accuracy for ratio of 85 ratio to diagnose PE using different cut-off values in predicting short-term 
absence of pre-eclampsia within one week. Taken from “New biomarkers in diagnosis of early onset pre-eclampsia and imminent 
delivery prognosis” (185) 
Cut-off value Pregnancies presenting at <34 weeks 
gestation 
Pregnancies presenting at ≥34 weeks 
gestation 
23 85 45 85 
Value (95% CI) Value (95% CI) Value (95% CI) Value (95% CI) 































































The PROGNOSIS study was a prospective, multicentre, blinded, observational study 
conducted across 14 countries from 2011 to 2014 (88). Its aim was to derive and 
validate a ratio of serum sFlt-1 to PlGF that would be predictive of the absence or 
presence of pre-eclampsia in the short term. It included women with singleton 
pregnancies from 24 weeks to 36+6 weeks’ gestation in whom a clinical suspicion of 
pre-eclampsia existed. The Elecsys® immunoassay was the platform used to quantify 
serum levels of PlGF and sFlt-1.  
Results published in 2016 reported on a development cohort of over 500 participants 
and a validation cohort of a further 500 women. It reported a sFlt-1: PlGF ratio ≤ 38 to 
be clinically important, with a negative predictive value in the subsequent week of 
99.3% (95% CI 97.9–99.9) for ruling out pre-eclampsia, with relatively high sensitivity 
and specificity. The positive predictive value; a diagnosis of pre-eclampsia, eclampsia, 
or the HELLP syndrome within 4 weeks, was 36.7% (95% CI, 28.4 to 45.7) using the 
same sFlt-1: PlGF ratio of 38. Post hoc analysis however showed this was still an 
improvement in prediction compared to the use of clinical variables such as blood 








Table 1. 6: Elecsys® test accuracy for ratio of <38 in predicting short-term absence of pre-eclampsia within one week. Taken 




































Interestingly, the same cut off of <38 was predictive of the absence of fetal 
adverse outcomes within 1 week with a negative predictive value of 99.3% 
(95% CI, 97.9 to 99.9). This study showed that an sFlt-1: PlGF ratio of 38 or 
lower could be used to predict the short-term absence of pre-eclampsia and 
adverse fetal events in women in whom the syndrome is suspected clinically. 
 
PETRA (2016) 
The PETRA (Pre-eclampsia Triage by Rapid Assay) Trial was a prospective 
multicentre observational study performed at 24 North American sites (186). 
The study aimed to examine the relationship between PlGF and time-to 
delivery (TTD) among women presenting with signs or symptoms of pre-
eclampsia. From November 2010 to January 2012, 753 women with a 
singleton gestation between 20-34+6 weeks were enrolled. Maternal blood 
was drawn at enrolment and circulating plasma PlGF measured by a central 
lab using the Triage® assay.  Diagnosis of pre-eclampsia was made according 
to ACOG guidelines and adjudicators were blinded to the PlGF result.  
The study showed that in women with suspected pre-eclampsia < 35+0 weeks, 
a low PlGF (<100 pg/ml) strongly correlated with the need for preterm delivery 
independent of a diagnosis of pre-eclampsia or the gestational age at 
presentation (Figure 1.5). It also showed that a normal PlGF (≥100 pg/ml) 
predicted pregnancy prolongation, even in patients destined to acquire a 








Figure 1. 4: Triage® test accuracy for time to delivery (TTD) in days in those 
women with suspected pre-eclampsia at <35 weeks gestational age. From 
AJOG, Barton et al (186). 
 
1.5.2 Interventional Studies  
As discussed, several prospective cohort studies have demonstrated high 
sensitivity and a negative predictive value of automated PlGF-based testing in 
determining the need for delivery in women with suspected pre-eclampsia. In 




pathways, interventional studies are required. This point was highlighted by 
NICE in their 2016 guidance on PlGF testing (141). 
 
MAPPLE (2018) 
The MAPPLE (The Management of pregnancy complications with PIGF 
testing) study aimed to examine the clinical implications of introducing PlGF 
into routine clinical care (155). It prospectively enrolled 397 women with 
suspected pre-eclampsia or fetal growth restriction at <35 weeks gestation 
across four maternity units in Europe and Australia between April 2014 and 
March 2016. PlGF testing was performed as part of usual clinical care using 
the Triage® PlGF test. Clinicians were made aware of the PlGF result and 
were expected to adjust care accordingly. Clinical outcomes were compared 
to the previously discussed PELICAN study where PlGF results were blinded 
to care givers. Although these cohorts were from different centres and different 
time periods, it did allow comparison of revealed PlGF testing to blinded PlGF 
testing for the first time.  
The study published in 2018 and reported that when PlGF is revealed perinatal 
outcomes were significantly altered. Overall, with revealed PlGF testing, there 
was earlier delivery of patients, (on average by 1.4 weeks), no difference in 
maternal morbidity and no difference in rates of caesarean delivery. There 




centile in the revealed PlGF arm but significantly increased perinatal adverse 
outcomes (mainly respiratory) due to prematurity.  
The MAPPLE study highlighted a concern in relation to PlGF testing; that an 
abnormal PlGF result may prompt earlier intervention by clinicians, resulting 
in maternal benefit at the detriment of neonatal outcomes. Hence, the 
importance of adequately powered, ideally randomised controlled trials, to 
determine clinical utility and overall cost effectiveness. The net result of this 
was the randomised controlled UK PARROT trial and the PARROT Ireland 
trial (179, 187).   
 
PARROT Trials UK and Ireland  
In section 6, I will discuss the PARROT Ireland trial. The UK PARROT trial 
recruited from June 2016 to October 2017 across eleven maternity units 
throughout the UK. Over a thousand women with singleton pregnancies, 
between 20 weeks to 36+6 weeks gestation inclusive enrolled, with signs or 
symptoms suggestive of evolving pre-eclampsia. All had immediate PlGF 
quantification performed with the result revealed only in those randomised to 
intervention. The primary outcomes measure was the duration of time required 
to diagnose confirmed pre-eclampsia using the ISSHP 2014 definition. The 
trial reported a reduction in time to diagnose preterm pre-eclampsia (from 4.1 
to 1.9 days) as well as a reduction in maternal adverse outcomes in those with 




UK trial to the PARROT Ireland trial, along with the differences in results is 
discussed further in Chapter 5, Paper 6; “PARROT Ireland: Placental growth 
factor in Assessment of women with suspected pre-eclampsia to reduce 
maternal morbidity: Results of Interim Analysis” as well as in Chapter 7, the 
discussion of this thesis.   
1.6 PARROT Ireland 
1.6.1 Rationale for the PARROT Ireland trial 
Clearly placental growth factor has merit in terms of prediction of preterm pre-
eclampsia and overall placental dysfunction however, in order to adequately 
access its clinical impact before routine adaption into clinical practice, a 
randomised controlled trial (RCT) should be performed (189). The processes 
used during the conduct of an RCT minimise the risk of confounding factors 
influencing the results and therefore a RCT is considered to provide the most 
reliable evidence on the effectiveness of interventions (190, 191).  
The objective of the PARROT Ireland randomised trial is to evaluate the impact 
of knowledge of PlGF measurement on relevant maternal and neonatal 
outcomes. By improving risk stratification antenatally, the addition of PlGF 
measurement to the clinical assessment of women with suspected pre-
eclampsia prior to 37 weeks' gestation may reduce associated maternal 
morbidity through earlier diagnosis and targeted management of women with 




on the fetus hence it is equally important that neonatal outcomes be 
adequately assessed.  Earlier diagnosis of pre-eclampsia may influence 
obstetricians to expedite delivery and may lead to an increase in neonatal 
morbidity and mortality secondary to iatrogenic prematurity. However, 
improved identification of those neonates at highest risk of imminent placental 
dysfunction may reduce neonatal morbidity by allowing for timely intervention.  
 
1.6.2 My role in PARROT Ireland 
When I commenced working as a clinical research fellow in July 2015, funding 
for PARROT Ireland had been secured from the Health Research Board 
Clinical Trials Network (HRB-CTN). As one of the few people to have worked 
on this trial since this time, I have been involved in every aspect of its 
development, organisation and conduct. I drafted the initial trial protocol and 
disseminated it for review and feedback among the principal investigators at 
each participating site. The trial protocol was essential to ensure the feasibility 
of conducting the trial across seven maternity units, and including details on 
every aspect of the trial including its design, statistical power, PlGF 
assessment, clinical management algorithms and outcome measures. Once 
the finalised initial draft  was agreed in 2016, I organised an application for 
ethical approval to each of the seven ethics committees involved. In mid-2016 
a project manager (PM) was hired and together, under the guidance of the 
lead principal investigator (PI) we worked on a variety of essential components 




trial sponsor, development of the electronic trial database, production of 
necessary trial documents, local site files and master files, appropriate training 
of all research staff and site initiation visits as each site, development of plan 
for purchase, use and delivery of consumables and contract negotiations with 
all parties.   
Once the trial was up and running, I continued to work alongside the PM and 
the trial monitor to ensure there were no operational issues. This included; 
troubleshooting any day to day issues with database, test equipment or plgf 
consumables, organisation of meetings for the DMC and TSC, development 
of reports such as the DSR and trial newsletters, hosting regular 
teleconferences with researchers as well as training newly appointed 
researchers. I also spent a week at each site when they transitioned from 
control to intervention so as to support the research staff locally with the 
change in procedure as well as providing education and information to clinical 
staff locally regarding the trial and PlGF itself. 
 
1.6.3 Trial Planning 
Trial Sites 
The trial was planned to be carried out across the seven largest maternity units 
in the Ireland of Ireland; The Coombe Women and Infants University Hospital 
Dublin, Cork University Maternity Hospital, University Maternity Hospital 




Hospital Galway, The National Maternity Hospital Dublin and The Rotunda 
Maternity Hospital. Combined, these seven units have an annual birth rate of 
over 44,000. Some are standalone units while others are co-located alongside 
general hospitals. All receive referrals from peripheral units of complex 
pregnant patients requiring specialised expertise and all have a long tradition 
of clinical research. Further to this, a research collaborative already exists 
between these seven units; the Health Research Board Mother and Baby 
Clinical Trial Network Collaborative.  
 
Trial Design 
Given that those randomised to the intervention in PARROT Ireland trial would 
receive a diagnostic test that may have led to their physician altering their on-
going management, it was agreed that a cluster design would be best utilised 
(Figure 1). In a cluster randomised trial, the unit of randomisation is a 
group/cluster (in our case a maternity hospital) rather than an individual 
pregnant woman. This type of trial design allows for the intervention to be 
implemented at a hospital level rather than at an individual patient level. This 
pragmatic approach is preferential when evaluating an interventional test as it 
allows a true evaluation of what would happen in reality, should the 
intervention be introduced into clinical practice. The effectiveness of the 




Cluster trials are well documented to be beneficial when the intervention is 
aimed at health care professionals (192, 193). In addition to the cluster 
randomisation in PARROT Ireland, a stepped wedge approach was also 
utilised (Figure 1.5). Stepped wedge allows for the phased implementation of 
an intervention. This approach has many benefits. Firstly; it enables the 
intervention to be rolled out in a systematic manner. From a practical point of 
view this is hugely beneficial given the requirement for consumables, 
equipment and staff education necessary to implement the interventional test 
at each site. Having all sites, with their wide geographic distribution, 
commence the interventional test on the same day would be extremely 
challenging and likely unachievable. Secondly, a stepped wedge design 
results in all clusters/maternity units receiving the interventional test at some 
time point during the trial, increasing its acceptability. It was paramount to the 
success of the trial that all units remained committed to the trial and did not 
allow the interventional test to be utilised in their unit outside of the research 
setting (194).  
There are some negatives with stepped wedge cluster design; the foremost 
being fixed time constraints. Given the amount of clusters is fixed and the time 
duration for each step must be equal, the total trial duration is unable to be 
altered once the first cluster has transitioned from control to intervention. The 
result of this is that for trials that under-recruit, extension is not an option. It 
also results in longer duration trials, which are most susceptible to 




Figure 1. 5: Stepped Wedge Cluster Randomised Design for PARROT 
Ireland. From BMJ Open, D Hayes-Ryan et al (179). 
 
PlGF Platform 
Much consideration was given as to which commercial PlGF platform to utilise 
for the trial. Many companies were interested in being involved in the study 
however given the limited performance data on many of the commercial 
platforms we focused our decision only on platforms endorsed by NICE (141). 
Ultimately, the trial management group (TMG) of which I was part of, choose 
to utilise the Triage® PlGF test for the trial. The point of care design of the test 
platform with its quick turnaround time is important for clinical practice, where 
plans regarding ongoing investigations and location of care need to be decided 




Triage® PlGF test, it potentially could be integrated into use in developing 
countries should the trial prove beneficial. 
 
Trial Documentation 
I developed a number of necessary documents prior to the commencement of 
the trial which were reviewed and approved by the TSC. The trial protocol was 
the first of these; a detailed plan as to how the project would be run with 
involvement, input and approval of all the principal investigators and 
collaborators. Included in the protocol was a power calculation (conducted by 
the trial statistician), suggested management algorithm based on PlGF results 
(developed based on the NICE and HSE hypertension guidelines) and a 
detailed definition of planned outcomes measures. Prior to the launch of the 
trial, and following feedback from the sponsor and ethical committees, the 
protocol underwent multiple revisions and was updated from Version 1.0 dated 
9th July 2015 to the final Version 9.0 dated 16th November 2017.  
Along with the trial protocol, I developed a patient information leaflet (PIL) and 
consent form. These documents required the use of plain english with enough 
information to adequately inform the eligible woman regarding the trial but 
without being over-whelming (197). Again, the PIL/Consent form underwent 
multiple revisions, following review at trial site ethical committees, until finally 




In addition to the above, I developed a substantial number of other trial 
documents, outlined in Table 1.7 and included in Appendix 1, with the 
assistance of the project manager. I also wrote a paper detailing the 
methodology of the trial which has since been published in an international 




Table 1. 7: Trial Documentation developed for PARROT Ireland (Appendix 1) 
 
• Trial Steering Committee Charter 
 
• QC Device Results Log 
 
• Data Monitoring Committee Charter 
 
• QC Samples Results Log 
 
• Trial Monitoring Plan 
 
• PlGF Devices Testing Log 
 
• Definitions List V 2.2 
 
• SOP 002: Personnel Training V 1.0 
 
• Enrolment Log V 2.0 
 
• LAB 001 Sample Handling V 1.0 
 
• Pre-Screening Log V 2.0 
 
• SOP CLIN 003: eCRF Parrot V 2.0 
 
• Documentation of enrollment for Participants Chart V 1.0 
 
• Recruitment Guide v 1.0 







As PARROT Ireland was a non-regulated trial, individual approval was 
required from each ethical committee of all seven hospitals involved. The 
project manager and I together submitted applications to each ethics 
committee, some required a written application with multiple copies and others 
were online electronic applications. In general the committees met on a 
monthly basis. Three committees (Limerick, Coombe and Rotunda) invited a 
representative from the trial to present a brief overview in person at their 
meeting, which I did in 2016. Initially we planned to use a no-consent model 
for the trial, however many of the ethics committees were uncomfortable with 
this approach (198). Concerns were also raised over the management 
algorithm potentially increasing work burden for units and intervention for 
patients hence “suggested” was added to it to order to facilitate physician 
flexibility.  Replies from each committee were received 1-3 months following 
meetings and unfortunately, if even one committee did not approve any aspect 
of the protocol or PIL, all seven had to be approached again with amended 
documentation. I worked to alter the protocol and PIL in response to the 
feedback given by the ethics committees, all the while keeping the TSC 
informed of these changes and ensuring they agreed. Full ethical approval 
took many months but finally a consensus from all seven committees was 






A number of groups and committees were established for trial operational 
purposes, all of which I was heavily involved with either through organisation, 
activities or duties.  
 
Trial Management Group 
The composition of the TMG is shown in Table 1.8. Along with myself it 
included the lead site principal investigator (initially Professor Kenny and then 
Dr O Donoghue), the project manager; of which there were four during the 
course of the trial and the trial monitor; appointed in 2017. The TMG was 
responsible for the overall day to day management of the trial and we acted 
on behalf of the sponsor to ensure that all the sponsors’ responsibilities were 
carried out. It was our responsibility as the TMG to confirm all approvals were 
in place before the start of the trial, maintain the Trial Master File, provide 
adequate training, study materials and 24‐hour advice to the research 
assistants. We were also responsible for data management, updating 
collaborators regularly regarding the progress of the study and responding to 
any questions (e.g. from collaborators) about the trial. The TMG also were 
required to ensure data security as well as data quality were maintained while 
observing data protection laws and ensuring the trial was conducted in 




Throughout the trial, the TMG planned to meet weekly, to discuss any 
particular site issues and organise delivery schedules of consumables. We 
conducted monthly phone meetings with researchers at site to troubleshoot 
any issues locally, promote the trial and motivate staff. The TMG was 
responsible for circulating relevant communications and updating the 
investigator site file (ISF), providing quarterly reports to the DMC, ensuring 
adequate recruitment occurs throughout the trial, addressing any safety 
concerns and organising monthly trial steering committee (TSC) meetings. We 
also prepared for regulatory audits from the trial sponsor UCC (held on 
21st/22nd March 2018) and from the HRB quality & regulatory manager (held 
on 21st Feb 2018) as well as developing annual progress reports for each of 
the ethics committees, as well as the sponsor and funder.  
 
Table 1. 8: Composition of the Trial Management Group for PARROT Ireland 
Lead Site-Chief Investigator Dr Keelin O’Donoghue 
Clinical Research Fellow Dr Deirdre Hayes-Ryan 
Site Monitor Ms Nicolai Murphy 






Trial Steering Committee  
The Trial Steering Committee (TSC) was established in March 2016. The 
function of the TSC was to provide overall supervision on behalf of the Trial 
Sponsor and Trial Funder and to ensure that the trial was conducted in 
accordance with Good Clinical Practice (GCP) and all relevant local and 
national regulations and local policies. The composition of the TSC for 
PARROT Ireland is shown in Table 1.9. Due to the widespread geographical 
distribution, the TSC met via teleconference. Meetings were frequent leading 
up to the greenlight for trial commencement and then were held every quarter.      
Table 1. 9: Composition of the Trial Steering Committee for PARROT Ireland 






Professor Fionnuala Breathnach 
Professor Amanda Cotter  
Professor Declan Devane 
Professor Alyson Hunter  
Professor Deirdre Murphy 
Professor John Morrison  
Professor Fionnuala McAuliffe 
Clinical Research Fellow Dr Deirdre Hayes Ryan (DHR) 
Project Manager Dr Sharon Kappala (SK) 




HRB Network Manager Dr Elizabeth Tully 
Research Manager at 
RCSI/Rotunda 
Meadhbh Aine O’ Flaherty 
Lay person representative Elaine Ní Bhraonáin 
Neonatologist Professor Gene Dempsey 
Health Economist Dr Brendan McElroy 
Dr Aileen Murphy  
Sponsor Representative Dr Muiris Dowling 
Dr Ruben Keane 
Statistician Dr Karla Hemming  
Dr Ali Khashan 
Quality & Regulatory Affairs 
Manager 
Jackie O’Leary (JOL) 
 
 
Data Monitoring Committee 
The TMG, with the approval of the TSC, organised for the establishment of an 
independent data monitoring committee (DMC) for PARROT Ireland, to 
safeguard the interests of the study participants, the investigators and the 
Sponsor. The composition of the DMC is shown in Table 1.10.  I 




which time they ratified their charter. They requested a data summary report 
(DSR) be sent every quarter to them from the TMG, detailing numerical 
information on recruitment, maternal and neonatal morbidity, participant 
withdrawals, deviations and violation so as they can monitor trial progression. 
They also requested an interim analysis be conducted when half the 
recruitment target was reached. In line with these requests, I conducted the 
quarterly DSR and amended the statistical analysis plan (SAP), with the 
assistance of the trial statisticians, to include an interim analysis.   
Throughout the trial, the DMC monitored the overall conduct of the study in 
relation to the rights, safety and well-being of the participants and were also in 
place to protect the validity and credibility of the data. Once the interim analysis 
was conducted and the results available, I organised for the second meeting 
of the DMC in April 2019 so as these results could be examined and discussed.   
 
Table 1. 10: Composition of the Data Monitoring Committee for PARROT 
Ireland. 
Neonatologist/Chair-Person Prof. Tony Ryan 
Obstetrician Prof. Richard Greene 
Midwife   Ms Grainne Meehan 




Equipment and Consumables 
In order to perform a PlGF test using the Triage® PlGF test, each site required 
a mini bench top centrifuge and the Triage® PlGF test metre. Following an 
agreement with Alere®, this equipment was provided to each site on loan for 
the duration of the trial. Given the outdated infrastructure and space limitations 
in most of our participating maternity units, identifying and securing a suitable 
area for this equipment was a challenge. When I visited each unit prior to trial 
commencement, I discussed potential locations for placing this equipment with 
the site PI. The location needed to be close to the clinical area where 
participants would be recruited, but also secure from the public. Both machines 
required plug point access and the centrifuge required a stable solid surface 
and could not be moved once it was serviced and balanced. In some units, it 
was necessary to arrange installation of new shelves or to rearrange the 
existing layout of clinical areas to facilitate the installation of the equipment, 
which I co-ordinated with the assistance of the local researcher. Prior to each 
site transiting to the intervention, I ensured the agreed PlGF test area was 
ready and the necessary equipment in place and ready to use.   
The consumables for the test itself needed to be stored at 4-8C therefore each 
unit required access to a fridge. I co-ordinated with local researchers to identify 
suitable fridges in their units. Daily temperature monitoring of these fridges 
was a necessary quality requirement so I organised for those fridges without 
temperature gauges to be equipped with separate validated thermometers and 




required a monthly additional test known as a control for QC purposes. These 
controls required storage at -20C, which necessitated use of a monitored 
medical freezer. Through discussions with local hospital laboratory managers 
and nearby research centre managers, I succeeded in securing freezer space 
for the storage of these controls for the duration of the trial.  
 
Research Staffing 
As PARROT Ireland is a HRBCTN trial, each site was responsible for their 
own staff funds and  hiring decisions. Some sites already had research staff in 
place who were experienced both clinically and in terms of previous research 
exposure. In other sites, staff were newly appointed. Some of these were well 
seasoned midwives/sonographers while others were recent college graduates 
from science/epidemiology/psychology backgrounds as there was no 
requirement to be a registered midwife for the purpose of the trial. Once in 
post, all research assistants required appropriate training from the TMG before 
they could be added to the site delegate log. This included GCP/GDPR 
certification as well as phlebotomy certification and vaccination records. Trial 
specific training (database, protocol, PIL/Consent) was performed locally at 
site by myself during the pre-start up visit. For PlGF specific training, all 
PARROT Ireland researchers attended Cork University Maternity Hospital 
(CUMH) for a training day on 13th July 2017 which I organised. The training 




operational information on the point of care Triage® MeterPro device, provided 
by myself and a representative from the Triage® company.   
 
Green Light 
Once ethical approval was in place, staff hired and competently trained, 
necessary equipment at site and all site start-up visits performed the last 
outstanding issue prior to green light was the contracts. These contracts were 
triparty contracts between the sponsor (University College Cork), each site 
(maternity hospital) and each hospitals university (e.g.; Trinity College Dublin). 
Although legal input and review from each Hospital/University was required 
prior to their signing, the process was not too onerous and was achieved in 
time for a trial start date for all seven sites on 29th June 2017. The official 
launch of the PARROT Ireland trial was held in CUMH on 9th October 2017 








Figure 1. 6: Research Assistants of the PARROT Ireland team meeting for 
PlGF training in CUMH on 9th October 2017. From UCC News (199). 
 
Ongoing Education  
Although approved by each hospital and PI locally, all staff at each site needed 
information and training regarding the trial. This was provided during my site 
initiation visits between January and April 2017. Speaking at events such as 
grand rounds and journal club, I was able to connect with the vast majority of 
medical personnel locally. However ongoing education was required, 
especially when a site transitioned over from control to intervention. Hence 
during each transition week I relocated to the transitioning site so as to support 
the research staff locally with the change in procedure and to provide on-going 




1.7 Research in a Pregnant Population 
1.7.1 Background  
Pregnant women are classed as a vulnerable group and are significantly 
under-represented in terms of clinical research studies (200). In order to 
evaluate safety and efficacy and provide evidence for outcomes, clinical 
research studies are necessary in the pregnant population.  
Pregnancy research has its own unique set of challenges making it more 
complex and challenging to conduct. Pregnant women are unique in terms of 
their circulating hormonal profile and drug metabolism not to mention the 
additional complexity of an unborn fetus to consider in any decisions (201). 
Pregnant women are at risk for medical complications such as infections and 
frequently have complex medical co-morbidities often necessitating the use of 
multiple drugs during pregnancy which may potentially negatively interact or 
have unknown fetal implications (200).  
Historically women of child bearing age have been excluded from clinical trials, 
particularly Phase 1 trials, owing to safety concerns (202). The legacy of drugs 
such as thalidomide and diethylstilbestrol in pregnant populations evokes fear 
in both funders and pregnant women of potential harm to fetuses due to 
unknown teratogenic effects and adverse pregnancy outcomes (203, 204). 
Owing to strict ethical policies and a belief from stakeholders that women will 
not be willing to participate, few clinical trials are designed with the pregnant 




routine clinical practice without robust prior evidence of benefit; examples 
being the use of antenatal cardiotocography for prediction of intrapartum 
hypoxia or fetal fibronectin testing for prediction of preterm labour (205, 206). 
Our perception of what is ethically permissible or necessary often changes 
over time.  Excluding any specific group from participating in medical research 
results in a lack of knowledge about the risks and potential benefits of available 
treatments to them (207). The dearth of information that exists on the safety 
and biophysical profile for most drugs in pregnancy results in many pregnant 
women potentially not receiving optimal treatment, with most drugs being used 
off-label as few have been approved for this population (208).   
In recent years, global policies have shifted towards inclusion of all groups in 
biomedical clinical research. In 1993 a study evaluating gender differences in 
the clinical evaluation of drugs overturned the previous 1977 FDA policy of 
exclusion of all women of child bearing age from clinical trials (202).  Signed 
into law in the US in December 2016; the Task Force on Research Specific to 
Pregnant Women and Lactating Women (PRGLAC) was established to 
identify gaps in current knowledge and to advise the US Department of Health 
and Human Services.  In addition, in April 2017 the FDA issued ethical 
guidance on including pregnant women in clinical trials, advocating an 
informed and balanced approach to gathering data on the use of drugs and 
biological products during pregnancy through judicious inclusion of pregnant 




Over the last decade, pregnancy research has been steadily increasing 
globally. In Ireland alone there are now two dedicated perinatal research 
centres; the INFANT Research Centre, affiliated with University College Cork 
and the Perinatal Research Centre, affiliated with University College Dublin.  
With the advent of these dedicated centres and the promotion of all aspects of 
perinatal research, comes recognition of its requirement and importance.  
 
1.7.2 Current knowledge and limitations 
In order for a clinical trial to successfully recruit participants, its purpose and 
design are key elements to its success. Not only must the potential benefits of 
participation be weighed against any potential risks for the participant, but the 
physical time and emotional burden of participation must be considered (209). 
When developing clinical trials, researchers spend much time determining if 
the proposed design is not only fit for purpose, but will also encourage 
participation amongst those eligible to take part. Equally, when determining 
ethical fitness, ethical committees spend many hours debating if the proposed 
design and conduct of the trial is fundamentally sound. In general, trial designs 
that involve a huge time commitment either in the form of repeated 
attendances or completion of tediously long questionnaires or documents are 
less likely to successful recruit. Similarly, trials that involve risks to the 
participants; for example administration of relatively unknown medications or 




participant eligibility criteria for a trial is also highly important to consider. For 
example, participation in a drug trial of an unlicensed medication would likely 
not be acceptable to most people, however, for those with an advanced cancer 
and no other treatment options available, participation in such a trial may be 
the only potential for treatment and therefore warrant careful consideration 
(210).  
In the late 1990’s a group from the UK (211) interviewed 18 women who had 
declined participation in a trial of a prophylactic tocolytics while pregnant. In 
this double blind randomised controlled trial (RCT), recruitment had been an 
issue with only 26% of eligible women agreeing to participate. The researchers 
reported that risk limitation and apprehension about taking a medication while 
pregnant was a common barrier prohibiting participation.  A lack of interest or 
support from clinical staff in the trial was also reported as a barrier to 
participation in this study.  
A hypothesis exists that pregnant women are reluctant to participate in 
research due to a variety of reasons.  Owing to the lack of inclusion of pregnant 
women in randomised controlled trials to date, there is little in the literature 
regarding feedback on the particular motivators and barriers specific to their 
participation in clinical research (212-215). From the studies that have been 
performed, some common overlap exists; 
The MAGPIE study was a double blind (RCT) of magnesium sulphate for 




countries from 1998 to 2001 (216). As part of the follow-on QUOTE study 
(215), forty women from the UK arm of the trial were invited to share their 
participation experience, on average 3 years following completion of the trial. 
QUOTE specifically focused on the women’s decision to participate in 
MAGPIE. The authors identified limited background knowledge of pre-
eclampsia existed amongst the women enrolled. They also reported that the 
decision to take part in the trial was made independently by the pregnant 
woman herself. Frequently in QUOTE, participants reported confusion and 
ambiguity when the MAGPIE trial was initially explained to them. They 
reported the language used and the approach itself to be complicated and the 
trial information provided to be of very poor quality. The participants of QUOTE 
also reported that at the time of their enrolment in MAGPIE they did not fully 
understand that randomisation meant they might not receive the intervention. 
This may be attributable in part to the approach adopted by the researchers 
who were recruiting however it must be considered that the timing and setting 
when these pregnant women were approached may have also contributed  
given it was recruiting pregnant women with severe pre-eclampsia in a HDU 
setting.  
A 2005 qualitative study by a UK group (213) evaluated 20 women’s 
experiences following their participation in an RCT of antibiotics for preterm 
labour (217). The interviews were conducted in person, following publication 
of the trial results, a number of years after participation. The women reported 




outcome for their baby and the opportunity to help others, but only if there was 
absolutely no risk involved with participation. The women reported the 
information provided by the research team to be of good quality, however they 
reported that the stressful nature of the situation when they were approached 
(in unanticipated preterm labour) affected their ability to absorb the information 
fully, thus again highlighting the importance of timing and setting when 
approaching pregnant women about a trial.  
A large study by a group of Brazilian researchers in 2017, assessed 208 
women 10 weeks following delivery (212). These women had all participated 
in an ongoing RCT recruiting women with a short cervix in the 2nd trimester 
and randomising them to either progesterone alone or progesterone with a 
cervical pessary.  A qualitative follow-up questionnaire was conducted via 
telephone interview. Results showed the main motivators for participation 
among the women to be firstly a familiarity with the condition being 
investigated (premature delivery), secondly the potential to possibly improve 
the outcome of their pregnancy and lastly to access free medicine and 
healthcare providers. This study highlights that in countries where health care 
costs during pregnancy are not provided by the state, participation in clinical 
research may enable those with limited social means greater access to 
medical care and support but may also influence their decision to participate.   
Another 2017 study from a group of researchers from New Zealand (214) 
interviewed 20 women with a history of allergic disease who had participated 




study involved the participation of healthy volunteers as opposed to pregnant 
women with signs/symptoms of a pregnancy complication. Altruism and a 
sense of civic duty were identified as important motivators for participation and 
a deep investment in the value of research was present amongst the women. 
However, time commitment to the trial was perceived as a burden and 
randomisation to the placebo regarded as a disadvantage. The group also 
reported equal involvement of both the women and her partner in the decision 
to take apart in the RCT. This could be attributed to the requirement to take a 
medication as part of the study protocol (pro-biotic or placebo). Interestingly, 
despite this RCT involving taking a tablet, interviewed women perceived it as 
being risk free, as it was a pro-biotic. Researchers reported participants to be 
highly risk adverse with pregnant women reporting they would not take part in 
research if they perceived any potential risk to their unborn baby.  
Collectively these studies identify that the context, purpose and potential risk 
of any research are the most important considerations to an eligible pregnant 
woman when she is considering participation in a trial. The approach and 
explanation adopted by both researchers and clinicians is also paramount in 
aiding women’s understanding of a research trial. The personality, timing and 
language used are key factors influencing women’s decision to participate and 





1.7.3 Qualitative studies exploring women’s experience of research in 
pregnancy 
The participation of pregnant women in clinical research is paramount in order 
to advance global knowledge on preventative and treatment options for this 
specific population. Pregnant women’s perspective on the benefits, risks, 
burdens and experience of taking part in research during pregnancy is crucial 
in order to facilitate recruitment and retention of future participants. Qualitative 
research focuses on understanding why things are the way they are in our 
social world and why people behave in the way that they do (219). For this 
reason, it is the best method of evaluating pregnant women’s experience of 
being involved in clinical research.  
Data collection in qualitative studies usually involves direct interaction with 
individuals on a one to one basis or in a group setting so is well suited to 
ascertainment of participants’ attitudes or beliefs. One on one interviewing 
captures not just the words someone says but the intonation of their voice, 
their mannerisms, their particular style and behaviour and can hence elicit 
much more information than a word-based assessment can ever adequately 
convey (220).   
Frequently in qualitative research studies, a semi-structured interview style is 
adopted. This allows the topic under investigation to be approached with open-
ended questioning, allowing room for deviation in the discussion by either the 




and important. It also allows for on-going analysis by the researcher at each 
interview, with the integration of any newly identified relevant topics at each 
subsequent interview until eventually saturation is reached (220).  
The use of technology such as audio or video recorders, if consented to by the 
participants, facilitates reliable recall of information for the researcher for 
analysis purposes. It also elicits recall of phrases, tone and inflection utilised 
allowing feelings and meaning to be communicated. Moving on from the 
interview itself, accurate transcription of the data obtained is important. The 
same phrase/sentence may have different meanings when stress is placed on 
different words within. Again recoding of interviews facilitates accurate 
transcription of data and also aids content analysis and communication of the 
underlying message being conveyed through behavioural data not just verbal 
data (221).  
Thematic analysis is increasingly now used for analysing qualitative data. 
Through a careful and systematic approach of a dataset, common themes are 
identified, giving meaning to a shared set of experiences. 
1.8 Summary 
Pregnancies complicated by a hypertensive disorder are at increased risk of 
both maternal and neonatal adverse outcomes. Women with a twin pregnancy 
have an inherently higher risk of developing a hypertensive disorder in their 




prematurity. Rates of twin pregnancy as a direct result of ART are not centrally 
monitored or subject to any regulations at present in Ireland. Despite the 
introduction of national clinical guidelines on pregnancy hypertension and on-
going education of clinical staff, hypertensive disorders of pregnancy remain 
an issue. There is often a delay in diagnosis of these conditions and frequently 
the clinical care provided is lacking.  
Angiogenic biomarkers potentially may be a useful adjunct in the diagnosis of 
placental related disorders such as hypertension and fetal growth restriction. 
Observational studies to date have shown good correlation between pre-
eclampsia and circulating maternal PlGF, with a lowering of PlGF many weeks 
prior to the onset of clinical identifiable signs. However, concern exists that the 
introduction of PlGF into clinical care pathways may help diagnosis placental 
dysfunction/pre-eclampsia earlier but may not actually improve maternal 
clinical outcomes. Also of concern is that earlier diagnosis may result in earlier 
intervention by clinicians and with a subsequent rise in iatrogenic prematurity 
and worsening neonatal outcomes.  
Given the research to date on PlGF in preterm singletons, RCTs are now being 
performed to examine the impact of its clinical use on maternal and neonatal 
outcomes. Much less information is available in relation to PlGF in twin 
pregnancy owing to less research on this topic. Potentially PlGF could be a 
very useful addition to investigations for placental dysfunction in this high risk 
cohort, however further research in terms of clinically useful cut-offs in twin 




Pregnant women are generally interested in research and amenable to taking 
part in clinical trials during pregnancy. The approach of the researcher, their 
demeanour and use of language, are key to engaging pregnant women and 
gaining their interest and consent for participation.  
 
1.8.1 Thesis Aims  
The overall aim of my thesis was to explore and expand on current knowledge 
of placental growth factor, especially in relation to a twin pregnancy. I also 
wished to examine the impact of the use of PlGF as a diagnostic test for pre-
eclampsia in the preterm singleton population. Lastly, I wished to explore the 
barriers and facilitators  to pregnant women’s participation in clinical research.  
Overall aims:  
• Identify limitations in our current knowledge on PlGF  
• Expand on current knowledge of PlGF in twin pregnancy 
• Conduct a pragmatic RCT of PlGF as a diagnostic test for preterm pre-
eclampsia in a singleton pregnancy cohort 
• Explore motivators behind pregnant women’s participation in research 
In order to achieve these aims, this thesis is comprised of a number of chapters 






1.8.2 Thesis Outline 
Chapter 2: Hypertensive Disorders and Twin Pregnancy 
Paper 1: The Maternal and Perinatal Implications of Hypertensive Disorders 
of Pregnancy in a Multiple Pregnancy cohort  
• Highlight the origin, structure and function of Placental Growth 
Factor and its receptors 
• Discuss how the pro-angiogenic/anti-angiogenic synergism of these 
biomarkers is critical for successful placentation  
• Discuss how an imbalance in PlGF may be utilised as a diagnostic 
marker of disease or a potential therapeutic target for adverse 
pregnancy outcomes  
 
Chapter 3: Placental Growth Factor  
Paper 2: Placental Growth Factor: A review of literature and future 
applications 
Retrospective review of a large cohort of women delivering a twin 
pregnancy in a single large tertiary unit 
• Evaluate the implications of hypertensive disorders of pregnancy on 
both maternal outcomes 





Chapter 4: Placental Growth Factor and Twin Pregnancy  
Paper 3: A comparative study of two immunoassays of maternal placental 
growth factor  
& 
Paper 4: A prospective study of placental growth factor in twin pregnancy and 
development of a dichorionic twin pregnancy specific reference range 
• Develop a dichorionic twin pregnancy specific reference range for 
placental growth factor  
• Compare gestational specific PlGF levels in twin pregnancies 
complicated by pre-eclampsia or any HDP to controls.  
• Examine the similarities and differences in results obtained from two 
different immunoassays of maternal placental growth factor, 
highlighting the requirements for translating a lab-based test into one 
appropriate for clinical utility 
 
 
Chapter 5: PARROT Ireland Aims  
Paper 5: PARROT Ireland: Placental growth factor in Assessment of women 
with suspected pre-eclampsia to reduce maternal morbidity: a Stepped Wedge 





Paper 6: PARROT Ireland: Placental growth factor in Assessment of women 
with suspected pre-eclampsia to reduce maternal morbidity: Results of Interim 
Analysis 
• By conducting a national multi-site randomised controlled trial evaluate 
the impact of knowledge of PlGF measurement on both maternal 
morbidity & neonatal morbidity  
 
Chapter 6: Research in a Pregnant Population Aims  
Paper 7: An exploration of women’s experience of taking part in a randomised 
controlled trial of a diagnostic test during pregnancy; a qualitative study 
• Identify barriers and facilitators to pregnant women’s participation in 
clinical research 
• Examine pregnant women’s willingness to participate in research while 
pregnant 
• Explore women’s experience about being involved in a clinical trial, 











Paper 1: The Maternal and Perinatal Implications of 
Hypertensive Disorders of Pregnancy in a Multiple 
Pregnancy cohort 
 
Deirdre Hayes-Ryan, Sarah Meaney, Aoibhin Hodnett, Minna 
Geisler & Keelin O’Donoghue 
 
 




2.1 The Maternal and Perinatal Implications of Hypertensive 
Disorders of Pregnancy in a Multiple Pregnancy cohort 
 Abstract 
Introduction: Hypertensive Disorders of Pregnancy are common and may 
result in increased maternal and neonatal morbidity and mortality. Multiple 
pregnancies confer an increased risk of development of a hypertensive 
disorder of pregnancy. The purpose of this study was to examine a large 
cohort of women delivering a multiple pregnancy in a single large tertiary unit, 
and to evaluate the implications of hypertensive disorders of pregnancy on 
both maternal and perinatal outcomes.  
Material and methods: Retrospective study of all twin pregnancies delivered 
at Cork University Maternity Hospital, Ireland over a 9-year period (2009–
2017). The twin pregnancies were divided according to the presence or 
absence of hypertensive disorder of pregnancy and the two groups compared.  
Results: Maternal age >40 years, nulliparity, conception through use of a 
donor oocyte, and presence of obstetric cholestasis are all risk factors for the 
development of Hypertensive Disorders of Pregnancy in women with a multiple 
pregnancy. When a hypertensive disorder complicates a twin pregnancy, it 





Conclusions: This study is informative for clinicians caring for women with a 
multiple pregnancy with its relevant data on perinatal outcomes following a 
diagnosis of hypertensive disorder in pregnancy. 
 
 Introduction 
Variation exists between international bodies on the exact classifications of 
hypertensive disorders of pregnancy (HDP), but general consensus agrees 
that they can broadly categorised as follows; chronic hypertension of all 
causes, gestational (non-proteinuric) hypertension, pre-eclampsia and 
superimposed pre-eclampsia (4). The potential complications that may occur 
in a pregnancy affected by a hypertensive disorder directly relate to the 
underlying pathology of the condition. Late onset gestational hypertension is 
generally a benign condition with minimal increased risk to mother or baby 
(222). In contrast, early onset severe pre-eclampsia can confer a risk of 
morbidity, as well as mortality, especially in developing countries (13).  
Multiple pregnancy occurs spontaneously in approximately one in 80 
pregnancies (33). Both increasing maternal age and access to assisted 
reproductive techniques (ART) have had an impact in the number of twin 
pregnancies globally, with a dramatic increase reported over the past several 
decades (48, 50). Multiple births account for approximately 3% of live births 
(53). Figures from the Central Statistics Office show the number of twins born 




1,000 in 2015, with an increase of 22.5% over the last decade alone (51). 
Similar trends are reported in other countries (55, 56). Multiple pregnancy 
confers increased perinatal risk, including mortality, preterm birth, congenital 
abnormalities, fetal growth restriction and twin-twin transfusion syndrome (56). 
Further, many maternal obstetric morbidities, such as anaemia,  haemorrhage, 
gestational diabetes mellitus and obstetric cholestasis (OC), arise more 
commonly in the setting of multiple gestation (56, 71). In the latest (2016) 
annual report from the national perinatal epidemiology centre (NPEC), multiple 
pregnancy was associated with an almost fourfold increased risk of severe 
maternal morbidity (223). 
Multiple pregnancy is known to be a risk factor for the development of HDP, 
with a reported incidence ranging from 13-37%, which is 2-3 times higher than 
that seen in singletons (74). Most studies to date have focused on the risk 
factors for the development of HDP in a multiple pregnancy cohort (224), but 
reports on the clinical outcomes when these complications arise are fewer. 
Studies have suggested that multiple pregnancy complicated by HDP has a 
higher incidence of adverse pregnancy outcomes, specifically; preterm 
delivery, small for gestational age infants, caesarean delivery and placental 
abruption, when compared to HDP in singletons (77). It is reported that when 
these complications arise, they are likely to occur at an earlier gestation in 
multiple pregnancy compared to singleton pregnancy, which further increases 
potential perinatal morbidity (75). The aim of this study was to review a large 








This was a retrospective study of all twin pregnancies delivered at Cork 
University Maternity Hospital (CUMH), Ireland over a 9-year period (2009–
2017). All women attending CUMH had a booking appointment and dating 
ultrasound performed between 11-13 weeks gestation.  If the dating scan 
identified a multiple pregnancy, chorionicity was immediately determined and 
the women referred to the hospital’s dedicated multiple pregnancy clinic. A 
Maternal-Fetal Medicine (MFM) specialist consultant, experienced in the 
management of multiple pregnancy, directs the clinic and creates a unique 
management plan for each patient dependent on their obstetric history and 
personal preferences. A dedicated midwife sonographer for multiple 
pregnancy saw all women and performed ultrasounds in accordance to a 
routine scan schedule as per national guidelines (67) to assess for evolving 
growth discrepancy or twin-twin transfusion syndrome. In Ireland women have 
the option of public or private antenatal care. Those attending privately had a 
consultant obstetrician of their choice review them at each visit and the same 
Consultant present to oversee the delivery. Those attending the public multiple 
pregnancy clinic in CUMH were under the care of a single Consultant 




multiple pregnancy births in CUMH are attended by an obstetrician; for public 
patients this is the Obstetrician assigned to cover the labour ward on the day 
of the delivery.   
 
Outcome Measures 
Maternal obstetric information was obtained from obstetric charts, hospital 
birth registers, ultrasound reports and laboratory data.  Demographic data 
included; maternal age and body mass index (BMI) at booking, parity, mode 
of conception (spontaneous conception vs. all ART and type of antenatal care 
received (public vs. private). Chorionicity was assigned in all twin pregnancies 
based on ultrasound findings at 11-13 weeks gestation; this was reviewed in 
charts and after birth for confirmation of scan findings. Gestation at delivery, 
onset of labour (i.e. spontaneous or induced labour) mode of delivery and 
indications for induction/assisted delivery were also captured.  
Specific maternal outcome measures were; OC (pruritus with deranged liver 
transaminases (>70 U/L) with elevated fasting serum bile acids (>10mmol/L)), 
gestational diabetes (diagnosed by oral glucose tolerance test at 24 - 28 
weeks’ gestation) or presence of a hypertensive disorder of pregnancy; either 
pre-eclampsia or gestational hypertension. Pre-eclampsia was defined as; 
“sustained hypertension with systolic BP ≥ 140 or diastolic BP ≥ 90 (on at least 
two occasions at least 4hrs apart) with significant quantified proteinuria 




>30mg/mmol or ≥ 3+ on dipstick urinalysis)” occurring after 20 weeks’ 
gestation. Gestational hypertension was defined as “persistent blood pressure 
readings ≥140/90 mmHg, without associated proteinuria” occurring after 20 
weeks’ gestation.  
Perinatal outcomes were obtained from birth records, neonatal charts and the 
neonatal intensive care unit (NICU) database. Specific perinatal outcome 
measures included; Stillbirth of one twin (24 weeks’ gestation and/or weighing 
500 g or more), suspected SGA (Small for gestational age; defined as an 
estimated fetal weight less than tenth percentile for gestational age, detected 
antenatally on ultrasound based on accurate dating) (16), Prematurity (defined 
as birth occurring at less than 37 weeks’ gestation) and the degree of 
prematurity; very preterm (<32 weeks’ gestation), moderately preterm (32+1–
33+6 weeks’ gestation) and late preterm (34–36+6 weeks’ gestation).  
Other parameters recorded were; Birth weight (measured in grams), presence 
of a low Apgar score (defined as <7 at 1 minute or <7 at 5 minutes), NICU 
admission and the length of stay (days) in the NICU. The possible  indications 
for NICU admission were; prematurity, low birth weight, SGA at birth 
(birthweight <10th customised centile), suspected infection, poor feeding, 
apnoea of the newborn, transient tachypnoea of the newborn (TTN), 
respiratory distress syndrome (RDS), hypothermia, hypoglycaemia or other.  
Complications in the neonatal period included any of the following; respiratory, 
haematological, hypoglycaemia, jaundice, respiratory distress syndrome, 




Serious neonatal morbidity was not frequent. A composite measure of 
perinatal morbidity was chosen and included the following: hypoxic ischaemic 
encephalopathy of any grade (HIE), necrotising enterocolitis of any grade 
(NEC), intraventricular haemorrhage grade two or higher (IVHG2) or sepsis 
(based on positive blood cultures or cerebrospinal fluid).  
 
Statistical Analyses 
Initially the entire cohort was examined for trends, and then the twin 
pregnancies were divided according to the presence or absence of 
hypertensive disorder of pregnancy and the two groups compared. Descriptive 
and inferential statistics were employed to analyse the data utilising SPSS 
version 23. Differences between the hypertensive and non-hypertensive 
groups were compared using Chi square tests and t-tests where appropriate. 
Logistic regression analysis was used to assess the impact of HDP on the 
likelihood of outcomes. Adjusted analysis, for known risk factors for HDP such 
as maternal BMI >35 Kg/m2, maternal age >40 years and nulliparity, in 
accordance with  national clinical guidelines were also employed (1). 
Monochorionic twins are more frequently associated with congenital 
anomalies as well as having an inherently increased risk of adverse perinatal 
outcomes when compared with dichorionic twins (225). Therefore, the analysis 
was then repeated with the monochorionic twin pregnancies removed from the 





Ethical Approval for the study was granted by the Cork Research Ethics 
Committee (ECM 4 (zz) 05/06/18). 
 
 Results 
One thousand five hundred and sixty six women (n=1566) delivered a multiple 
pregnancy in CUMH from the 1st January 2009 until the 31st December 2017. 
The majority of the group were dichorionic twin pregnancies (81.2%; n=1271). 
Almost a fifth of these (17%; n=270) were diagnosed with a Hypertensive 
Disorder of Pregnancy (HDP). The incidence among dichorionic twin 
pregnancies was 17% compaired to 15% among the monochorionics. Three 
thousand one hundred and thirty two neonates (n=3132) were delivered from 
these pregnancies, with the vast majority (98%; n=3078) of these delivered 
live born.  
 
Maternal Demographics (Table 2.1) 
The maternal and pregnancy characteristics of the twin pregnancies included 
in the study are shown in Table.  When comparing those that developed HDP 
against those that did not, those that developed a HDP were twice as likely to 
be greater than 40 years of age (aOR 2.3, 95%CI 1.1-4.69) and more than 




difference in the incidence of HDP between public and private antenatal care 
(aOR 2.3, 95%CI 0.8-6.4), BMI >35 Kg/m2 (aOR 2.0, 95%CI 0.8-5.0) nor with 
placental chorionicity (aOR 0.8, 95%CI 0.4-1.7). Overall, the incidence of HDP 
was not increased by the use of ART (aOR 1.4, 95%CI 0.8-2.4). However, 
when ART was examined by mode of conception, oocyte donation conferred 
a threefold increased risk of HDP (aOR 2.7, 95%CI 1.4-5.3) while with 
ovulation induction (any medication without use of  IVF) it was eight times more 
likely to occur (aOR 8.1, 95%CI 2.5-26.5). 
 
Maternal Outcomes (Table 2.1) 
Overall, the incidence of gestational diabetes mellitus and OC were 7.9% and 
6% respectively. Concomitant gestational diabetes mellitus and OC occurred 
in just 1% (n=16).  Diagnosis of gestational diabetes mellitus did not increase 
the likelihood of a diagnosis of HDP (aOR 1.1, 95%CI 0.4-2.7) however women 
with OC were almost four times more likely to develop HDP, even when  
adjusted for confounding risk factors (aOR 3.7, 95%CI 1.3-10.3). Antenatal 
steroids for fetal lung maturation were administered to over a quarter of women 
(28.5%, n=447). When the group was dichotomised by the presence or 
absence of HDP, those with HDP were almost twice as likely to receive 






Onset of labour & Mode of Delivery (Table 2.2) 
Delivery was by pre-labour caesarean for almost half the cohort (49.6%, 
n=1553), with the mothers of a third of the babies having a spontaneous onset 
of labour (30%, n=941). Overall two thirds of the cohort delivered by caesarean 
section (66.8%, n=2092). No differences were noted in terms of onset of 
labour, indication for caesarean section or grade of caesarean section when 
the two groups were compared. Analysis on mode of delivery revealed the 
HDP group to be three times more likely to undergo an emergency caesarean 
in labour (aOR 2.9, 95%CI 1.1-3.20) compared to having a spontaneous 
vaginal delivery. The HDP group was less likely to have a vaginal breech 
delivery (aOR 0.5, 95%CI 0.3-0.8) or an elective caesarean delivery (aOR 0.5, 
95%CI 0.2-0.9). We found that the HDP group were nine times more likely to 
require an emergency caesarean section for delivery of the second twin (aOR 
9.0, 95%CI 1.4-58.9) however it is important to note that the number in this 
group is very small.  
 
Preterm Delivery (Table 2.3 & Table 2.4) 
Over half (57.2%, n=1761) of all live-born twins in the study delivered preterm 
with the aetiology for the prematurity shown in Table 2.3. Comparing the two 
groups, those with HDP were more than twice as likely to deliver preterm (aOR 
2.5, 95%CI 1.6-3.7). A difference in gestational age between the two groups 




more likely to deliver then (aOR 2.9, 95%CI 1.9-4.3). Induction of labour was 
five times more likely (aOR 4.9, 95%CI 2.8-8.7) while emergency pre-labour 
caesarean delivery was increased fourfold (aOR 3.9, 95%CI 2.3-6.6) in the 
HDP group with premature delivery compared to controls. Delivery prior to 37 
weeks is not uncommon for monochorionic twins. When monochorionic 
pregnancies were removed and the analysis repeated the conclusions were 
unchanged (Table 2.4).  
 
Perinatal Outcomes (Table 2.5 & Table 2.6) 
Perinatal outcomes for the entire twin pregnancies’ study (n=3132) are shown 
in Table 5. Just over a tenth of cases (12.1%, n=379); were suspected of being 
small for gestational age on antenatal ultrasound (estimated fetal weight <10th 
gestational centile using the Hadlock formula). Low birth weight (<2500g) was 
present in almost half of cases (49%, n=1527) but very low birth weight 
(<1500g) occurred in very few (7.7%, n=242). Fetal anomaly was present in 
approximately one in twenty cases (6%, n=190). After birth the incidence of 
SGA was 2.7% among women with HDP compared to 3.5% among women 
without HDP. Of those babies born alive (98%, n=3078) admission to the NICU 
occurred in almost half (42.6%, n=1333), with prematurity (77.6%, n=1027) 
and low birth weight (<2500g) (59.8%, n=800) being the main reasons for 
admission. Length of stay was beyond 14 days in almost half of those admitted 




n=337) complications were the most commonly occurring in the neonatal 
period. A composite measure of neonatal morbidity was low (4.6%, n=140).  
The incidence of perinatal mortality for the group was low (1.2%, n=39).  This 
figure reflects the combination of intrauterine (1%, n=31) and neonatal (0.9%, 
n=29) deaths that occurred in the study. The corrected perinatal mortality rate 
for the entire cohort was 12.3, 5.4 for the dichorionic group and 41.0 for the 
monochorionic group.  
Rates of  low Apgar scores, mean birth weight and fetal anomaly did not differ 
between the two groups (Table 2.5).  Low birth weight was four times more 
frequent in the HDP group compared to the non-HDP group (aOR 3.9, 95%CI 
2.3-6.6). Requirement for NICU and length of stay in NCU did not differ either. 
Indication for admission to the NICU was similar between both groups.  HDP 
was protective against admission for suspected infection (aOR 0.5, 95%CI 0.3-
0.9) while apnoea of the newborn was three times more likely in the presence 
of HDP (aOR 3.0, 95%CI 1.0-8.7). Overall, complications in the neonatal 
period were similar for both groups with no difference in the composite 
measure of neonatal morbidity. However significant difference were noted in 
the incidence of hypoglycaemia with a threefold (aOR 3.3, 95%CI 2.5-7.3) 
increase respectively seen when HDP was present. Perinatal mortality was 
not common and although a trend towards lower mortality was present in the 
HDP, low numbers prevented comparative analysis between the two groups. 
When monochorionic pregnancies were removed and the analysis repeated 





This study highlights that nulliparity, maternal age over 40 years, conception 
though use of donor oocyte and presence of OC are important risk factors for 
the development of HDP with a multiple pregnancy. It also outlines that when 
HDP does complicate a multiple pregnancy, it more commonly results in 
iatrogenic late premature delivery and neonatal hypoglycaemia. Almost a fifth 
of our twin cohort developed a HDP. This rate is in keeping with the higher 
incidence of HDP quoted in the literature for multiples; usually in the order of 
a 3 fold increased risk for pre-eclampsia alone. This rate may even be an 
underestimation, with a recent study comparing incidence of pre-eclampsia  in 
gestationally matched singletons to twins, all at <37 weeks, reporting a nine 
fold increased risk of pre-eclampsia  in twins (78). The reason behind this 
increased risk of HDP in multiple pregnancy is not fully understood, but is likely 
due to a combination of maternal risk factors and the presence of a larger 
placental mass; which may predispose to an angiogenic imbalance. 
Circulating angiogenic factors, such as placental growth factor (PlGF) and its 
soluble receptor sFlt-1 are well described as being significantly altered in 
women prior to the clinical onset of pre-eclampsia (88, 89). With a larger 
placenta comes higher levels of these circulating angiogenic factors, and 
studies have shown increased risk of pre-eclampsia with each for each two 
fold elevation in sFlt-1 (90). Prediction of pre-eclampsia using these 




diagnoses of pre-eclampsia in multiple pregnancy warrants further research 
(179, 188).  
Maternal age >40 years, nulliparity and conception through use of a donor 
oocyte are all well-established risk factors for HDP in both singleton and 
multiple pregnancies (3). Over the last number of decades, use of assisted 
reproductive therapy (ART) has increased  and pregnancy through use of 
donor oocyte is now common (86). The popular media portrayal of ART is that 
it is a viable risk free option for achieving pregnancy at any age with little 
recognition is given to the increased risks associated with pregnancy at an 
older age or through use of ART (83).   
The higher incidence of HDP in our cohort in those conceiving through 
ovulation induction needs to be interpreted with caution as the numbers are 
small (n=22) and when adjusted the confidence interval is very large. We did 
observe significantly more HDP when conception arose through use of a donor 
oocyte which is well described by other studies in both singletons and multiples 
(70, 85). It is worth noting that mode of conception in our cohort is self-reported 
by women at their booking visit and hence may indeed be under reported.  The 
high rate of twins proves the Irish ART sector needs regulation and protocols 
aimed at minimising the risk of multiple pregnancy should be advocated (57). 
Internationally, countries which have had success increasing their rates of 
single embryo transfer such as Belgium, Norway and Denmark have generous 




to multiple fresh and frozen IVF cycles, was also seen to radically reduce the 
rate of multiple embryo transfer province in Quebec (61). 
Our study found no difference in the incidence of HDP between either 
monochorionic or dichorionic twin pregnancies. The relationship between 
chorionicity and HDP is unclear and sometimes conflicting. A study in 2016 
showed dichorionicity to be an independent risk factor for the development of 
pre-eclampsia but not gestational hypertension (226) while other studies have 
reported no association between chorionicity and hypertensive disease (224). 
Ideally, we would like to examine our cohort further by comparing chorionicity 
against type of HDP present but a limitation of our study is that this is not 
possible from our data.  
A number of studies have reported higher incidence of hypertensive disease 
with increased maternal BMI and the protective effect against this seen with 
the use of aspirin (10). Practice on use of aspirin in our unit did not change 
during the time-period of this review. Women with pre-existing medical co-
morbidities (such as hypertension, renal disease, lupus or antiphospholipid 
syndrome) or concomitant moderate risk factors (IVF, oocyte donation, 
maternal age >40 years, BMI >30 Kg/m2 or previous poor obstetric history) 
were prescribed aspirin 75mg once daily from their booking visit in line with 
national guidelines (1). Unfortunately, a significant limitation of the study is the 
lack of data on use of aspirin in women in our cohort, limiting analysis on the 




Our study reports an almost fourfold likelihood of OC in multiple pregnancies 
complicated by HDP. This predilection for the development of pre-eclampsia 
with OC is a relatively new concept, with the majority of studies to date 
reporting on singleton pregnancies (71, 227). Some research has suggested 
that the pathological mechanisms causing hepatic impairment in women with 
pre-eclampsia may predispose to cholestasis (228). Further research is 
warranted to assess if it is the same mechanism responsible in cases of 
multiple pregnancy. With this evolving knowledge of the predisposition for HDP 
in those with OC, it is reasonable for clinicians to consider increased 
surveillance for early sings of HDP in women with a multiple pregnancy 
diagnosed with OC.  
The overall incidence of vaginal breech birth was an interesting finding of the 
study. Since publication of the Term Breech trial almost twenty years ago, 
(229) vaginal breech birth in high income countries generally only occurs in 
cases  of a second twin delivery or premature delivery. Our findings illustrate 
that for every vaginal twin birth that occurred, 1 out of  5 second twins were 
delivered breech. 
HDP is recognised as arising on a background of placental dysfunction, thus 
those with HDP may have a reduced capacity for placental function when 
labouring and may require expedited delivery (230). This is a potential 
explanation for the increased likelihood of caesarean section in labour and 
caesarean section for second twin that was noted in women with HDP in our 




group, differences in gestational age at delivery was only significant at later 
preterm gestation (34-36+6 weeks). This likely reflects an overall later onset 
of HDP in our cohort which is in contrast to many studies that have reported 
HDP to arise earlier in multiples than in singletons (75, 224, 231). It is well 
described that early onset pre-eclampsia (<34 weeks) is more severe and 
frequently results in poorer perinatal outcomes (232, 233).  A limitation of our 
study is the lack of knowledge of gestational age at time of diagnosis of HDP.  
Given the population under review it is not surprising a high incidence of 
administration of antenatal steroids for fetal lung maturation was present 
however the increased incidence of administration when HDP was present 
reflects the increased risk of premature delivery it confers. The prematurity 
noted in the HDP group of our cohort was iatrogenic in nature. Other studies 
have reported similar findings (74, 77), highlighting the potential for fetal and/or 
maternal morbidity and requirement for medical intervention when HDP 
complicates a multiple pregnancy. The higher incidence of low birth weight 
babies with HDP correlates with the higher rates of pre-maturity seen while the 
similar rates of very low birth weight babies supports the prematurity arising  
at a later gestational age.  
Overall the perinatal outcomes between the HDP groups were largely 
comparable. A composite measure of perinatal morbidity did not show any 
difference between the two groups, a similar finding to other researchers (234). 
We noted an increased incidence of neonatal hypoglycaemia in the infants 




between the administration of antenatal steroids and neonatal hypoglycaemia 
(235, 236). Timing of antenatal steroids is important with late administration of 
steroids (≥34 weeks ) associated with a 2-fold higher risk of neonatal 
hypoglycaemia compared to early administration (<34 weeks) (237). 
Potentially this may be the cause of the hypoglycaemia noted however 
neonatal hypoglycaemia has also been linked with maternal administration of 
beta-blockers in late pregnancy (238). Labetalol, a beta-blocker, is the first line 
anti-hypertensive medication utilised in our unit. Use of labetalol or another 
anti-hypertensive and the gestational age when administration of antenatal 
steroids occurred, are data points unfortunately not recorded for our cohort. 
This is a limiting factor of our study however it highlights a potential area for 
future prospective research.  
Presence of HDP conferred a protective effect against admission to the NICU 
for reasons of suspected infection. Infection in multiples most usually arises in 
the case of premature spontaneous onset of labour (239). Given that 
prematurity in the HDP group in our cohort was iatrogenic, it would be in 
keeping with less likelihood of infection. A retrospective study by a group of 
Irish researchers focusing on multiple pregnancies from 1996-2012 has shown 
a reduction in overall perinatal mortality with multiple pregnancy over the 17 
year period examined (69). In our study a trend towards higher incidence of 
perinatal mortality in the non-hypertensive group was noted, however the 
numbers are too small to allow a meaningful comparison. A US retrospective 




gestational hypertension to be beneficial for fetal survival in twin pregnancies, 
but advocated further prospective studies be conducted to assess for 
confounding variables (240).  
Limitations of this study are included in our discussion. In summary the 
absence of some population data (eg; type of HDP diagnosed, use of aspirin 
or anti-hypertensive agents or women transferred in from a peripheral unit), 
given that it was conducted retrospectively, limits analysis and comparison to 
other published work. Ideally, to fully appreciate the impact of HDP in multiple 
pregnancy it would be sensible to compare our outcomes to those of singleton 
pregnancies affected by HDP in women in our unit during the same time-
period. Unfortunately, we do not have this information available to us and it is 
not feasible to obtain, therefore we must rely on the published work of others 
for comparative purposes. The strength of this work is that it is a collective of 
nine years’ worth of obstetric data from a tertiary maternity unit, with over 8000 
deliveries annually and availability of a large neonatal outcome database. The 
unit also has a dedicated multiple pregnancy clinic, which has been advocated 
in order to harmonise management and reduce morbidity for multiple 
pregnancy (53, 241).  
 
 Conclusion 
In summary, we examined a large cohort of women with a multiple pregnancy 




Women must be appropriately counselled by healthcare professionals in 
relation to potentially increased risks when embarking on a pregnancy at an 
advanced age, especially through use of ART and/or donor oocyte. It is 
imperative that women who do conceive multiples, especially if they are older 
or have medical co-morbidities, are risk assessed and appropriately referred 
antenatally for more intense maternal and fetal screening and surveillance. 
Early recognition of complications allows referral to an experienced clinician, 
ideally within a dedicated multiple pregnancy clinic, and appropriate 
management employed.  Should a hypertensive disorder occur in a twin 
pregnancy, it is encouraging from this study to note perinatal outcomes overall 





Table 2. 1a: Maternal characteristics and antenatal complications according to presence of hypertensive disorder of pregnancy 
(HDP). 
Maternal Characteristics Total population  
(n = 1566)b 
HDP  
(n = 270) b 
No HDP  





Age Range (years) 17-51 18-51 17-51 - - 
Maternal Age >35 years 766 (48.9) 142 (52.6) 624 (48.1) 1.18 (0.9-1.5) - 
Maternal Age >40 years 173 (11) 43 (15.9) 130 (10) 1.6 (1.1-2.4) 2.3 (1.1-4.6) 


























































Mode of conception 
Spontaneous 
















Mode of ART 
Ovulation Induction 
Intrauterine Insemination 



















































Antenatal Steroids 447 (28.5) 99 (36.7) 348 (26.9) 1.5 (1.1-2.0) 1.7 (1.0-2.8) 
aAdjusted Odds Ratio (for BMI >35 Kg/m2, Maternal Age >40 and Nulliparity). Results demonstrating significant differences are 
highlighted in bold. 
bValues are shown in n (%) unless otherwise stated 
cReference is Spontaneous Conception. 
dReference is no Antenatal Complication 






Table 2.1b: Maternal characteristics and antenatal complications by chorionicity. 
Maternal Characteristics Total population  





Age Range (years) 17-51 17-51 17-45 
Maternal Age >35 years 766 (48.9) 659 (51.8) 107 (36.3) 
Maternal Age >40 years 173 (11) 159 (12.5) 14 (4.7) 













































































Table 2. 2: Mode of delivery 
 Total population  
(n = 3132) b 
HDP  
(n = 541) b 
No HDP  





Onset of labour 
Spontaneous 
Induced 







































Detailed Mode of delivery 




Emergency CS in labour 
Emergency CS pre labour 







































2.9 (1.1 -3.2) 

























1.7 (0.8-3.3)  
2.2 (1.7-2.8)  





























































aAdjusted Odds Ratio (for BMI >35, Maternal Age >40 and Nulliparity). Results demonstrating significant differences are highlighted in 
bold.bValues are shown in n (%) unless otherwise stated. cGrade of Caesarean Section is defined as per the RCOG Classification of Urgency of 
Caesarean Section 2011. 
dElective/ Previous CS/Non-vertex presentation . 
eFetal Complications/Non reassuring CTG/ Intrauterine death/Failure to progress. 





Table 2. 3: Preterm delivery entire cohort 
 Total population  
(n= 3076)c 
HDP 
(n = 540)b 
No HDP 













Ref (1.0) d 
2.1 (1.7-2.6) 
Ref (1.0) d 
2.5 (1.6-3.7) 



































































aAdjusted Odds Ratio (for BMI >35 Kg/m2, Maternal Age >40 and Nulliparity). Results demonstrating significant differences are highlighted in 
bold. 
bValues are shown in n (%) unless otherwise stated  
c56 cases of Miscarriage/Stillbirth were removed leaving 3076 livebirths  
d Reference used is delivery at/after 37 weeks gestation  





Table 2. 4: Preterm delivery dichorionic twins only 
 Total population  
(n= 2519) c 
HDP 
(n = 451) b 
No HDP 













Ref (1.0) d 
2.2 (1.8-2.8) 
Ref (1.0) d 
2.3 (1.5-3.6) 




























































aAdjusted Odds Ratio (for BMI >35 Kg/m2, Maternal Age >40 and Nulliparity). Results demonstrating significant differences are 
highlighted in bold.bValues are shown in n (%) unless otherwise stated  
c24 cases of Miscarriage/Stillbirth were removed leaving 2519 livebirths  
d Reference used is delivery at/after 37 weeks gestation.  




Table 2. 5: Perinatal outcomes entire cohort 
 Total population  
(n = 3132) b 
HDP  
(n = 541) b 
No HDP 





SGA  suspected 
antenatally 
379 (12.1) 62 (11.5) 317 (12.2) 0.9 (0.7-1.2) 1.4 (0.9-2.2) 
Low Apgar Score 
1 minute <7 
















LBWc 1537 (49.1) 300 (55.5) 1237 (48.3) 1.3 (1.1-1.6) 1.6 (1.1-2.4) 
VLBWd 242 (7.7) 41 (7.6) 201 (7.9) 0.9 (0.7-1.4) 0.9 (0.4-1.8) 













































1332 (42.5) 266 (49.2) 1067 (41.2) 1.4 (1.1-1.7) 1.2 (0.8-1.8) 


















Indication for NICU 
Prematurity 
Low Birth Weight 
SGA at birth 
Infection 
Poor Feeding 














































































































1.4 (0.8 -2.7) 
1.5 (0.6-3.8) 
3.3 (1.5-7.3) 




































aAdjusted Odds Ratio (for BMI >35 Kg/m2, Maternal Age >40 and Nulliparity. Results demonstrating significant differences are highlighted in bold. 
bValues are shown in n (%) unless otherwise stated 
cLow Birth Weight (<2500g),  
dVery Low Birth Weight (<1500g),  
eFetal Anomaly includes all anomalies except patent ductus arteriosus (PDA) in a premature infant,  
HDP, hypertensive disorder of pregnancy; SGA, small for gestational age;  IUD, Intrauterine Fetal Demise; NND, Neonatal Death; NICU, Neonatal Intensive 
Care Unit; TTN, Transient tachypnoea of the newborn; RDS, Respiratory Distress syndrome; ROP, Retinopathy of prematurity; CLD, Chronic Lung Disease; 




Table 2. 6: Perinatal outcomes dichorionic only. 
 Total population  
(n = 2543) b 
HDP  
(n = 451) b 
No HDP 





SGA suspected antenatally 287 (11.3) 47 (10.4) 240 (11.5) 0.9 (0.6-1.3) 1.4 (0.9-2.1) 
Low Apgar Score 
1 minute <7 
















LBWc 1163 (45.7) 242 (53.7) 921 (44.3) 1.5 (1.2-1.8) 1.8 (1.2-2.6) 
VLBWd 147 (5.8) 32 (7.1) 115 (5.5) 1.3 (0.9-2.0) 0.8 (0.3-1.9) 






















Corrected Perinatal Mortality 
Rate 
5.4 2.2   6.2   
NICU Admission 
 






















Indication for NICU 
Prematurity 
Low Birth Weight 
SGA at birth 
Infection 
Poor Feeding 



























































































































Neonatal Morbidity Composite 





























aAdjusted Odds Ratio (for BMI >35 Kg/m2, Maternal Age >40 and Nulliparity. Results demonstrating significant differences are highlighted in bold. 
 bValues are shown in n (%) unless otherwise stated. 
cLow Birth Weight (<2500g). 
dVery Low Birth Weight (<1500g). 
eFetal Anomaly includes all anomalies except patent ductus arteriosus (PDA) in a premature infant. 
HDP, hypertensive disorder of pregnancy; SGA, small for gestational age;  IUD, Intrauterine Fetal Demise; NND, Neonatal Death; NICU, Neonatal 
Intensive Care Unit; TTN, Transient tachypnoea of the newborn; RDS, Respiratory Distress syndrome; ROP, Retinopathy of prematurity; CLD, 






Table 2.7: Perinatal outcomes monochorionic only 
 Total population  
(n = 589)* 
HDP  
(n = 90)* 
No HDP 
 (n = 499)* 
SGAb suspected antenatally 92 (15.6) 15 (16.7) 77 (15.4) 
Low Apgar Score 
1 minute <7 










LBWc 374 (63.4) 58 (64.4) 316 (63.3) 
VLBWd 95 (16.1) 9 (10) 86 (17.2) 





















Corrected Perinatal Mortality Rate 42.4 - 50.1 
NICUh Admission 307 (52.1) 52 (57.8) 255 (51.1) 











>14 days 176 (29.8) 24 (26.7) 152 (30.5) 
Indication for NICU 
Prematurity 
Low Birth Weight 
SGAb at birth 
Infection 
Poor Feeding 

















































































Neonatal Morbidity Composite 



















*Values are shown in n (%) unless otherwise stated 
aAdjusted Odds Ratio (for BMI >35 Kg/m2, Maternal Age >40 and Nulliparity. Results demonstrating significant differences are highlighted in bold. 
 bValues are shown in n (%) unless otherwise stated. 
cLow Birth Weight (<2500g). 















D. Hayes-Ryan, F.P. McCarthy, K. O'Donoghue, & L.C. Kenny 
 




3.1 Placental Growth Factor: A review of literature and future 
applications 
 Abstract 
Placental growth factor is an angiogenic protein, highly expressed during 
pregnancy, which correlates well with placental function. In this review, we 
highlight the origin, structure and function of Placental Growth Factor and its 
receptors. We discuss how their pro-angiogenic/anti-angiogenic synergism is 
critical for successful placentation and how their imbalance may be utilised as 
a diagnostic marker of disease or a potential therapeutic target for adverse 
pregnancy outcomes.  
 
 Introduction 
Discovery, Structure & Function   
Placental growth factor (PlGF) is a member of the vascular endothelial growth 
factor (VEGF) family of proteins. Crystallography resolution at 2.0 Å resolution 
shows PlGF to have a three-dimensional structure comprising of 149–amino-
acids. Comparison with that of VEGF-A shows a remarkable similarity between 
the two proteins, with  53% sequence identity between amino acids from 
positions 39-132 of PlGF and amino acids from positions 38-131 of VEGF-A 
(96, 97). PlGF was the second member of the vascular endothelial growth 




103). PlGF, like all proteins of the VEGF family, is a secreted dimeric 
glycoprotein with a distinctive cystine knot. This knot is characterised by a 
common motif of eight spatially conserved cysteines, which are involved in 
intra and inter molecular disulfide bonds (98, 99). The two monomers are 
oriented side-by-side and head-to-tail and held together by one interchain 
disulfide bond. The dimeric structure is also stabilised by a hydrophobic core 
region (96, 100). Its discovery is credited to Italian scientist Dr. Maria Graziella 
Persico who first described PlGF in 1991. She identified it while investigating 
the angiogenic potential of human term placental tissue which is why this 
protein was termed “the placental growth factor”. (95). In 1993 the location of 
the human PlGF gene on chromosome 14q24 was isolated and reported to 
consist of seven exons spanning 13.7 kb (242). 
PlGF can exist in multiple isoforms due to alternate splicing encoded by the 
human PlGF gene. Four isoforms of human PlGF are described, PlGF-1, 
PlGF-2, PlGF-3, and PlGF-4 composed of 131, 152, 203 and 224 amino acids 
respectively. PlGF-1 and PlGF-2 are believed to be the major isoforms (104, 
105, 121, 242, 243).  Apart from in size, the PlGF isoforms differ in terms of 
both their secretion properties and their binding affinities. PlGF-1 and PlGF-3 
are non-heparin binding diffusible isoforms while PlGF-2 and PlGF-4 have 
additional (highly basic 21 amino acids) heparin binding domains (105, 106, 
242). Both VEGF-A and PlGF can exist as homodimers and heterodimers 
(PlGF:PlGF, PlGF:VEGF-A, VEGF-A:VEGF-A), with PlGF:VEGF 
heterodimers displaying 20-50-fold less mitogenic activity than VEGF 




Initial studies conducted in healthy mice in the 1990’s reported a lack of PlGF 
did not appear to confer any negative impact on vascular development. 
However, when mice deficient in PlGF (knockout) were subjected to 
pathological conditions such as ischaemia, inflammation or cancer, they 
demonstrated severely impaired angiogenic ability. Their inability to adapt and 
compensate to these pathological conditions highlighted the role of PlGF in 
pathological angiogenesis (117). 
Receptors 
All members of the VEGF family bind and activate one of the following three 
homologous tyrosine kinase receptors: VEGFR1 (also called fms-like-tyrosine-
kinase receptor/Flt-1) VEGFR2 (also called Flk-1/KDR) or VEGFR3.  Each of 
these receptors has a similar structure; a tyrosine kinase extracellular seven 
Ig-like domain connected to an intracellular tyrosine kinase domain via a single 
transmembrane helix (111-113). Binding induces the mitogenic action of the 
cell with KDR being 10 fold stronger than Flt-1 in this regard (244, 245). VEGF-
A can bind to either Flt-1 or KDR (246). Despite the structural similarity with 
VEGF-A, PlGF has been shown to only bind to Flt-1, but it does so with a 
higher affinity than VEGF-A (114).  In 1996, a non-membrane bound soluble 
receptor known as soluble VEGFR-1 (sFlt-1) was identified. This endogenous 
protein, synthesised by placental cells amongst others, arises from alternative 
splicing of Flt-1. It retains structural similarity to Flt-1 except that it lacks its 
transmembrane helix and tyrosine kinase intracellular domain, meaning that it 
can circulate freely (116). Levels of sFlt-1 rise under hypoxic conditions (125). 




proteins available to the anchored cell membrane receptors Flt-1 and Flk-1 
(Figure 1).   
 
 Function 
PlGF exerts its angiogenic effects by both direct and indirect mechanisms, 
inducing receptor dimerisation and phosphorylation. PlGF directly activates 
endothelial cells, macrophages and haematopoietic progenitor cells by binding 
to the membrane receptor anchored Flt-1, and in doing so may increase the 
sensitivity of the cell to VEGF-A.  PlGF acts indirectly by displacing VEGF-A 
from Flt-1, allowing VEGF-A to bind instead to the more potent FDK. Lastly, 
by forming a heterodimer with VEGF in mutually expressed cells, PlGF 
antagonises the angiogenic action of VEGF. (109, 117-121) sFlt-1 has anti-
angiogenic potential, binding and neutralising PlGF and VEGF in the 
circulation, reducing their bio-availability and thus interaction with the cell 
membrane bound Flt-1 and Flk-1 (122, 123). In vitro effects of sFlt-1 include 
vasoconstriction and endothelial dysfunction (124). 
 
Pre-eclampsia 
As far back as the late 1980’s it had been hypothesised that a circulating factor 
existed in pre-eclampsia, which was responsible for the widespread 
endothelial dysfunction observed (134). Vasculogenesis and angiogenesis are 
two essential components in development of the utero-placental circulatory 




utero occurs in a relatively hypoxic environment with a partial pressure of 
oxygen as low as 18 mm. At approximately 10 weeks gestation, an increase 
in the partial pressure of oxygen up to 60 mm occurs, triggering the 
proliferation of the cytotrophoblast. This process facilitates invasion of uterine 
spiral arteries of the decidua and myometrium by the cytotrophoblast, allowing 
these vessels to become functionally capable of supplying the high volumes 
of well-oxygenated blood necessary for nourishing a growing fetus (247, 248).   
Should this rise in oxygen pressure fail to occur, the hypoxic environment 
persists, compromising the invasion of the cytotrophoblast. This leads to 
impaired placentation and results in inadequate placental perfusion, hypoxia 
and potential clinical fetal and maternal manifestations: impaired fetal growth 
and pre-eclampsia later in pregnancy (133, 135). 
Studies investigating this circulating factor hypothesis reported significant 
damage occurring in cultured human umbilical vein endothelial cells 
(HUVECs) exposed to serum from pregnant women with pre-eclampsia 
compared with controls (133, 135, 136).  
Following the discovery of PlGF and its receptors, reports of increased levels 
of sFlt-1 and reduced levels of PlGF and VEGF in pre-eclamptic cases 
compared to controls were published (128-131).  Higher levels of sFlt-1 have 
also been reported in; first versus second pregnancies, multiples versus 
singletons, molar and trisomy 13 affected pregnancies, all of these being well 
established independent risk factors for development of pre-eclampsia (137). 
Patients receiving VEGF antagonists for cancer treatment may develop 




endothelial cell dysfunction (249, 250). In the early 2000’s, a number of 
publications reported circulating levels of sFlt-1 and PlGF to be altered several 
weeks before the clinical onset of disease in pre-eclampsia. They also showed 
correlation of these angiogenic factors with the severity of disease (87, 132). 
Hypoxia alone is enough to trigger sFlt-1 over expression by the placenta, in 
a self-defence type response, to VEGF-A produced by maternal decidual cells 
(140). A three stage disorder has now been proposed for pre-eclampsia. 
Initially in early pregnancy from approximately week 8-18 abnormal 
remodelling of the spiral arterioles and trophoblast invasion occurs due to a 
deficiency in the pro-angiogenic PlGF and VEGF (Stage 1). The net result of 
this is impaired placental perfusion, which in turn leads to hypoxia and 
oxidative damage from 20 weeks gestation (Stage 2).  The pathological 
placenta then induces apoptosis, inflammation, and releases anti-angiogenic 
factors (sFlt1) and other inflammatory agents such as cytokines in a bid to 
induce vasoconstriction and increase oxygen supply to the hypoxic placenta. 
The net result of the release of these factors is systemic endothelial cell 
dysfunction and end-organ ischemia, which leads to the classical clinical signs 
and symptoms of pre-eclampsia (Stage 3) which may occur from as early as 
20 weeks gestation (138, 139). 
 
 Application 
In the last 15 years, the concept of using sFlt-1 or PlGF, either singly or in 
combination, as a potential screening tool or diagnostic marker for pre-




sense. The ability to stratify women in early (11-13 weeks gestation) 
pregnancy as high risk and appropriately tailor antenatal care has huge clinical 
and economic benefits. Currently a huge amount of our antenatal resources 
are targeted towards routine clinic visits including measurement of blood 
pressure and urinalysis in women at low or moderate risk for pre-eclampsia. 
An effective early screening test would enable those at low risk to be identified, 
and stratified to community based care, with less frequent hospital review. 
Simultaneously, the early identification of women at risk of pre-eclampsia 
would enable their antenatal care to be appropriately tailored and hospital 
resources to be focused to them. In order to be effective, a screening test must 
demonstrate both clinical and health economic benefits. Clinically relevant 
outcomes would include both maternal and neonatal morbidity. A health 
economic model analysis should assess the cost-effectiveness of a screening 
strategy relative to no screening at all (251). 
The recently published ASPRE trial showed a reduction of more than 60% in 
rates of preterm pre-eclampsia when aspirin is commenced prior to 14 weeks 
in women at high risk of same (177). Identification of who exactly is high risk 
is paramount. The ASPRE trial screened over 25,000 women between 11-13 
weeks gestation and dichotomised them to high (> 1 in 100) or low risk (<1 in 
100) of preterm pre-eclampsia.  The predictive model used incorporated 
maternal serum PlGF, pregnancy associated plasma protein–A (PAPP-A), 
mean arterial pressure (MAP) and uterine artery pulsatility index (UtA-PI) as 
well as maternal factors.  The authors reported a detection rate of 76.7% for 
preterm pre-eclampsia with a false positive rate (FPR) of 10%. This compares 




maternal characteristics and medical history alone recommended by leading 
international bodies The National Institute for Health and Clinical Excellence 
(NICE) and the Americana College of Obstetricians and Gynaecologists 
(ACOG). This study highlights the potential utility of PlGF as part of combined 
early pregnancy screening. However prior to the introduction of any screening 
test, both external validation and a health economic analyses are necessary, 
to confirm utility and reproducibility. 
The main use of PlGF in pregnancy currently is in short term prediction of time 
to delivery in women with suspected pre-eclampsia. Having an effective 
diagnostic test for pre-eclampsia would eliminate protracted hospitalisations 
of women and allow resources to be better utilised.  A systematic review in 
2015 evaluated trials on placental growth factor (alone or in combination with 
sFlit-1) as an aid to the assessment of women with suspected pre-eclampsia 
(147). Four prospective (cohort) studies were identified and examined. Meta-
analysis was not possible because the studies employed different outcome 
measures, test cut-off points and gestational periods. The PELICAN study 
showed that the PlGF test alone had a very high accuracy for predicting pre-
eclampsia requiring delivery within 14 days for women presenting with 
suspected pre-eclampsia between 20 - 35  weeks  of  gestation.  For  a  test  
cut-off  <100 pg/mL, PlGF alone showed 96% sensitivity (95% CI, 89–99), 56% 
specificity (95% CI, 49–63), 44% positive predictive value (PPV) (95% CI, 36–
52), and 98% negative predictive value (NPV) (95% CI, 93–100)  (89).  The 
PROGNOSIS  study  evaluated whether the sFlt-1:PlGF ratio is predictive of  
the  short-term  absence  or  presence  of  pre-eclampsia  in  women  with 




reported a sFlt-1:PlGF ratio ≤ 38 had a NPV in the subsequent week of 99.3% 
(95% confidence interval [CI] 97.9–99.9). In 2016 NICE published guidance 
on the use of PlGF testing based on this review. The Triage PlGF test and the 
Elecsys immunoassay sFlt-1:PlGF ratio, used with standard clinical 
assessment and subsequent clinical follow-up, were recommended to help 
rule-out pre-eclampsia in women presenting with suspected pre-eclampsia 
between 20 weeks and 34 weeks plus 6 days of gestation.  
NICE recommended that these tests should not yet be used to diagnose pre-
eclampsia until further research is available, specifically on how an abnormal 
PlGF result would affect management decisions regarding timing and 
gestation of delivery and the outcomes associated with this (141). 
Interventional studies were recommended to confirm the clinical utility of the 
results to date. Some smaller cohort studies (MAPPLE) with unblinded PlGF 
testing have reported a lowering of gestational age at delivery and an increase 
in neonatal prematurity related morbidity.  This highlights the importance of 
conducting appropriately powered trials before PlGF testing is routinely 
adapted into clinical practice. (252) A number of randomised controlled trials 
are currently ongoing, the UK PARROT trial and the PARROT Ireland trial 
among these, with results expected in 2019 (253).  
The prospect of using PlGF as a therapeutic agent has also begun to be 
considered.  Recent studies in mice have demonstrated that administration of 
VEGF early in pregnancy prevents the development of pre-eclampsia (254) 
and reduction in circulating sFlt-1 alleviated pre-eclampsia like symptoms 




therapeutic apheresis for preterm pre-eclampsia was conducted on 11 
pregnant women with pre-eclampsia ranging from 23 to 32 weeks gestation. 
A reduction in levels of circulating sFlt-1 was achieved with combinations of 
single or multiple plasma apheresis. Overall a prolongation of pregnancy 
without major adverse maternal or fetal consequences was seen (162). A case 
controlled prospective study is currently ongoing, collecting maternal plasma 
and serum from patients with both pre-eclampsia and normal pregnancy for in 
vitro validation of new therapeutics based on extra-corporal removal of sFlt-1 
(APHERESE) (256). Also currently recruiting is an interventional trial of a 
medical apheresis device for Flt-1 in pre-eclamptic women (SAVE) (257). 
These studies suggest the potential utility of early pro-angiogenic therapies in 
treating pre-eclampsia in the future.  
 
Assays 
A variety of different assays are now commercially available for quantification 
of PlGF alone or in combination with sFlt-1; Triage PlGF test, Elecsys 
immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test,  The 
Quantikine Human PlGF Immunoassay (R&D systems) and BRAHMS sFlt-1 
Kryptor/BRAHMS PlGF plus Kryptor PE ratio. Most of these are laboratory 
based and require significant infrastructure available to use while the Triage 
PlGF test is  point of care and could be easily integrated to antenatal clinical 
care algorithms in developing countries. Importantly to note, the normal 
reference values of PlGF obtained with one platform may not be 




studies, and cost effective analyses comparing these platforms are required 
as the performance and costs of these may differ between assays.  
 
Outside Pregnancy  
PlGF is more than just a pregnancy specific biomarker. Although originally 
identified in the placenta, PlGF is also expressed in heart, lung, thyroid, 
adipose tissue and skeletal muscle. Its absence impairs angiogenesis and 
arteriogenesis during tumour growth and heart, limb and ocular ischaemia 
(117, 258-263). Patients with sickle cell disease are noted to have increased 
levels of PlGF, expressed by bone marrow erythroid cells under hypoxic 
conditions, with levels of PlGF correlating with degree of disease activity. An 
association between PlGF and β-thalassaemia has also been reported, with 
levels of PlGF positively correlating with other markers of haemolysis such as 
lactate dehydrogenase, uric acid and reticulocyte counts in this group  (264-
266). Whether PlGF may act as a biomarker of disease activity or have a role 
in potential targeted therapies in patients with haemaglobinopathies remains 
the subject of ongoing research (267).  More recently, PlGF has been identified 
as a possible contributor in haematologic malignancies, with both PlGF and 
sFlt-1 expression increased in samples from patients with chronic myeloid 
leukaemia (CML), acute myeloid leukaemia (AML) and acute lymphoid 
leukaemia (ALL). This is in contrast to the increased PlGF and reduced sFlt-1 
expression seen in patients with pre-eclampsia. The exact mechanism of 
action of the angiogenic PlGF and anti-angiogenic sFlt-1 in these malignancies 




is being explored (268-270). A recent study on thyroid carcinoma found 
significantly higher levels of PlGF in metastatic disease, suggesting that 
antagonising PlGF in this setting may be a promising therapy to suppress 
cancer metastasis (271). In the pathological models studied, the absence of 
PlGF impairs the associated inflammation and angiogenesis and confers a 
general reduction in pathological changes (272).   
 
 Conclusion 
PlGF plays an integral role in the development of a normal pregnancy and 
aberrations in PlGF concentrations are associated with adverse pregnancy 
outcomes, in particular pre-eclampsia. The universal integration of PlGF into 
antenatal assessment of women with suspected preterm pre-eclampsia is 
dependent on results of current RCTs.  The role of PlGF as a biomarker of 
disease outside of pregnancy shows promise while its potential as a possible 













Figure 3. 1: PlGF and VEGF hetero and homodimer protein structures and 
their respective membrane bound receptors Flt-1 ad Flk-1 and the freely 
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4.1 A comparative study of two immunoassays of maternal 
placental growth factor 
 Abstract 
Background: Circulating maternal levels of placental growth factor correlate 
well with placental function and numerous studies advocate its role to help 
rule-out preterm pre-eclampsia. A number of automated immunoassay 
platforms to quantify placental growth factor are currently available. The aim 
of this study was to compare the results obtained from an ELISA to an 
automated immunoassay of maternal placental growth factor in a twin 
pregnancy cohort. 
Methods: Prospective study conducted in a single large tertiary maternity unit 
over a two year period. Consenting pregnant women with a twin pregnancy, 
across a variety of gestations, had a single blood sample taken at one time 
point only during their pregnancy. The plasma was initially biobanked and then 
later analysed in batches using both immunoassays.  
Results: Although the placental growth factor values of the two 
immunoassays correlated well, the actual results obtained were significantly 
different. Poor concordance between the two immunoassays was present, 
with one assay recording 36 cases as <100 pg/ml whereas the second 
immunoassay identified only 4 as <100 pg/ml.  
Conclusion: Biomarker levels may vary significantly between different 
immunoassay platforms, highlighting the importance of developing validated 




These differences need to be understood to facilitate clinical utility given that 




Placental growth factor (PlGF) is an angiogenic protein and a member of the 
vascular endothelial growth factor (VEGF) family (96). Like all proteins of the 
VEGF family, PlGF is a secreted dimeric glycoprotein with a distinctive cystine 
knot (97). Both PlGF and VEGF can exist as homodimers or heterodimers 
(109). They each contain two monomers, oriented side-by-side and head-to-
tail, held together by one interchain disulfide bond (98). PlGF was the second 
member of the VEGF family identified in 1991 by an Italian scientist Dr Maria 
Graziella Persico who identified it while investigating the angiogenic potential 
of human term placental tissue; hence the name “the placental growth factor” 
(95).  PlGF binds to an anchored cell membrane receptor, FLT-1, inducing 
angiogenesis and is an important requirement for successful placentation in 
early pregnancy (121, 243).  
Over the last number of decades, the concept of using PlGF as a potential 
diagnostic marker for pre-eclampsia has been extensively examined (88, 89, 
132). Studies have shown that as a pregnancy progresses, circulating levels 
of PlGF correlate directly with placental function (129, 131). Pregnant women 
with low circulating levels of PlGF are at increased risk for adverse outcomes 
such as pre-eclampsia, HELLP syndrome, eclampsia, fetal growth restriction, 




As with any newly identified biomarker, initial studies employed laboratory 
based immunoassays, such as an ELISA, to quantify circulating maternal PlGF 
(87, 142). Over time, owing to a plethora of studies demonstrating the potential 
for PlGF as an adjunct to clinical care, interest in this angiogenic biomarker 
grew exponentially (273-275). Studies involving PlGF have now transitioned 
from laboratory based to a clinical setting and from observational to 
interventional (88, 155, 179, 188).  Coinciding with this translation from 
laboratory to clinical, commercial interest in PlGF grew and automated 
immunoassay platforms that allow rapid and easy quantification of PlGF were 
developed (141).  
The purpose of this study was to compare the results obtained from two 
different immunoassays of maternal placental growth factor; one a laboratory 
based manual assay and the other a point of care-automated assay, in a twin 
pregnancy cohort. We aimed to examine the similarities and differences 
between the immunoassays and highlight the requirements for translating a 
lab-based test into one appropriate for clinical utility, necessary for the 









Setting and Design 
This study was conducted in a single large maternity hospital in Ireland with 
over 8000 deliveries per annum. The study was a secondary sub-group 
analysis of samples collected as part of a prospective cross-sectional study of 
PlGF in twin pregnancy. Ethical approval was granted from a national research 
ethics committee (ECM 3 (PPP) 19/05/15). From July 2015 to December 2017, 
women that were over 20 weeks gestation attending the hospital’s dedicated 
twin pregnancy clinic were approached to participate in the study.  If recruited 
to the study, a 3ml ethylenediaminetetraacetic acid (EDTA) blood sample was 
taken, centrifuged, divided into aliquots and the plasma biobanked at -80C 
within 3 hours of sampling. All sampling, processing and biobanking was 
carried out within the same building. Women had venepuncture performed at 
one random time point only. PlGF testing is not part of routine clinical care and 
was not performed separately in this population.   
Anonymised clinical and demographic data pertaining to the participant was 
recorded in the study database. Relevant clinical outcomes, such as the 
development of pre-eclampsia (defined as; “sustained hypertension with 
systolic BP ≥ 140 or diastolic BP ≥ 90 (on at least two occasions at least 4hrs 
apart) with significant quantified proteinuria (>300mg protein on 24hr collection 
or urine protein creatinine ratio >30mg/mmol or ≥ 3+ on dipstick urinalysis)” 
occurring after 20 weeks’ gestation) were recorded from the clinical notes 






Biobanked samples were analysed for circulating levels of PlGF using two 
immunoassays; the lab based Quantikine® ELISA PlGF kit (R&D Systems, 
USA) and the point of care Triage® PlGF Test (Quidel, San Diego). Both 
immunoassays were performed as per manufacturer’s instructions.  
The ELISA® assay uses a monoclonal antibody specific for human PlGF that 
has been pre-coated onto a 96 well polystyrene microplate. The colour 
development was measured using a Thermo Fisher VarioSkan microplate 
reader. All samples were analysed in duplicate using this platform. The 
ELISA® reports a measureable range of 15.6-1000 pg/ml of PlGF, with an 
assay completion time of 3.5 to 4.5 hours. The Intra-Assay Precision 
(coefficient of variation) on EDTA plasma controls at concentrations of 54.3 
and 658 pg/mL is 7% and 5.6%, while the Inter-Assay Precision at 
concentrations of 55 and 724 pg/ml are 11.8% and 10.9%  respectively (152). 
The Triage® PlGF Test (Quidel, San Diego) is a CE marked platform and 
involves a single use, point of care, fluorescence immunoassay device. The 
lateral flow assay uses a fluorescently conjugated antibody that binds to host 
PlGF and is automatically analysed once the cartridge is inserted into the 
metre. The results are displayed on the metre screen in approximately 15 
minutes and have a measureable range from 12-3000 pg/ml. The assay has 
a total precision on plasma controls; at concentrations of 85.2 and 1300 pg/mL 
is 12.8% and 13.2% (148). For the purposes of this study any result obtained 








Descriptive statistics were employed to examine the maternal demographics 
and PlGF distribution in the cohort. A Bland Altman plot was used to compare 
PlGF results and Cohen’s Kappa was calculated to provide a measure of 
agreement between the two tests. Analysis were undertaken with SPSS 




The majority of eligible women approached to take part in the trial consented, 
resulting in one hundred and seventy eight women with a twin pregnancy 
included in this cohort study (Table 1). In Chapter 2 of this thesis, detailed 
demographics pertaining to the twin pregnancy population in our unit has been 
described. As this study was conducted among this population, a similar 
demographic distribution is apparent. Maternal age ranged from 20-46 years, 
Body Mass Index (BMI) ranged from 19-45 Kg/m2 and almost half the group 
(n=81; 45.5%) were nulliparous. Ethnicity was very homogenous with the vast 
majority (92.1%, n=164) Caucasian. Almost a third of the group (30.1%, n=52) 




The majority of these were through In Vitro Fertilisation (IVF) with either their 
own oocyte (17.4%, n=31) or through use of a donor oocyte (9%, n=16). The 
majority of the group (84.3%, n=150) was a dichorionic twin pregnancy. Very 
few concomitant medical conditions that would predispose to placental 
dysfunction existed within the cohort such as chronic renal disease or essential 
hypertension (2%, n=4). Of the multiparous women, very few had previous 
pregnancies complicated by intrauterine growth restriction (3.4%, n=6) or pre-
eclampsia (3.9%, n=7) which would also predispose to placental dysfunction. 
There was good representation of each gestational age category among the 
cohort (Table 2).  
 
PlGF Distribution 
The distribution of PlGF using each of the two assays was first examined. The 
range of PlGF using the Triage® was narrower given the limits of the platform; 
10-3000 pg/ml with a median of 297 pg/ml. PlGF levels using the ELISA® 
assay ranged from 52-4720 pg/ml with a median of 537 pg/ml.  
 
Correlation 
In laboratory analysis studies such as this, it is common to need to assess the 
level of agreement between two methods of measurement. Before these 
checks of agreement can be performed, the level of correlation between the 
two methods of measurement must first be assessed. Using a Spearman’s rho 




two assays examined (r=0.88, n=178, p <0.001) (Figure 4.1 a & 4.1 b). This 
strong correlation indicated that a PlGF result that measured low using one 
platform also measured low in the other platform. However, correlation studies 
only assess the relationship between the variables and not the differences 
between them. Therefore, a Bland Altman plot was used to evaluate the mean 
difference between the PlGF results from the two assays and estimate their 
level of agreement (Figure 4.2 a & 4.2 b). The Bland Altman plot identified a 
mean difference (238.1 pg/ml) that is clinically relevant, highlighting that the 
PlGF results obtained from the two assays are not interchangeable. In 
addition, a simple linear regression was calculated to predict the results from 
the Triage® based on the results from the ELISA®, b = 0.41, t(178) = 6.0, p < 
0.001.  Combined, these results indicate that there is proportional bias and the 
two assays are systematically producing different results.  
 
Comparison 
The Triage® is intended for use in women with a singleton pregnancy 
presenting at ≥ 20 weeks gestation with suspected preterm pre-eclampsia. 
Previous studies using this platform have validated a cut-off of >100 pg/ml as 
having a high negative predictive value for requirement for delivery due to pre-
eclampsia in the subsequent 14 days (89). In our cohort, the Triage® identified 
36 cases with a PlGF of <100 pg/ml whereas the ELISA® identified only four 
as <100 pg/ml. Concordance between the results of the two immunoassays 
was examined and a kappa value of 0.17 obtained, indicating a very poor level 

















Scientists are continuously identifying new biomarkers with potential for 
improving screening, diagnosis and monitoring of diseases. The journey from 
laboratory identification to their clinical application can be lengthy, requires 
prudence, cautious interpretation and suitable clinical application. This study 
shows that although there is good correlation between the laboratory and point 
of care immunoassays examined, there is a significant difference in the results 
in terms of both the range and in the PlGF values obtained. This crucially 
highlights that clinical cut-offs developed and validated using one biomarker 
immunoassay are not transferrable to another immunoassay for the same 
biomarker. A very recent publication, comparing three different automated 
PlGF immunoassays (Brahms®, Elecsys® and Delfia®) has also shown that 
PlGF values obtained on automated immunoassay platforms are manufacturer 
specific, not interchangeable and require separate validation (157). 
The difference in PlGF values obtained may possibly be explained by the use 
of different antibodies in each assay and their cross reactivity with different 
PlGF isoforms. PlGF can exist in multiple isoforms due to alternate splicing 
encoded by the human PlGF gene (104). At least four different isoforms of 
human PlGF are known to exist, differing in the number of amino acids present 
(105). PlGF-1 and PlGF-2 are believed to be the major isoforms and share 
88% sequence identity (106). PlGF isoforms differ in terms of their size, their 
secretion properties and their binding affinities (121). The manufacturers 
report that the Triage® (Quidel, San Diego) immunoassay predominantly 




detects PIGF-2 and PIGF-3 isoforms in addition to PlGF-1 (276). Other 
potential causes for the difference in PlGF values seen are; the variation in 
material used for calibrating, different matrix effects and the potential for hook 
effects at high concentrations.  
Currently four platforms for quantification of PlGF are commercially available, 
with comparable negative predictive values for preterm pre-eclampsia, in 
singleton pregnancy (158). Automated platforms are more suitable for use in 
a clinical setting than a laborious plate ELISA (147, 152). A recently published 
randomised controlled trial of integration of PlGF testing into clinical care, has 
shown benefit, with a reduction in time to diagnosis of preterm pre-eclampsia 
as well as a subsequent reduction in maternal morbidity (188). On foot of this 
the National Health Service (NHS) has endorsed PlGF testing in maternity 
units in the UK (187).  Given that PlGF testing is poised to be integrated into 
clinical practice, it is imperative that clinicians and stakeholders are informed 
and aware of the differences between automated immunoassay platforms cut-
offs when considering which company and product to utilise locally.  
Our study was not designed to assess clinical performance of the assays in 
diagnosing pre-eclampsia. Participants in our study were not recruited at a 
time when a clinical suspicion of pre-eclampsia was present. Our cohort 
included only women with a twin pregnancy. A clinically meaningful cut-off for 
PlGF in twin pregnancy is not yet established and likely differs substantially to 
that in singletons given the larger placental volumes present (90, 160, 165, 
166, 168). A PlGF cut-off validated for the Triage® (was utilised in our study 




established given the development of automated immunoassay platforms 
more suitable for clinical utility.  
Important limitations of our study are the lack of inclusion of additional 
automated PlGF immunoassays for comparison, as advocated by NICE (141). 
The homogeneity of our cohort, with a primarily Caucasian population from a 
single centre, may be considered a minor limitation. The strengths of this study 
are that it includes a large number of pregnancies across a variety of 
gestational time points, so is a good representation of the pregnant population. 
Adherence in our unit to a high international biobanking standard, and 
specimen analysis within three years of biobanking, ensures good quality 
plasma samples with minimum protein denaturation (277-280).   
Dichotomisation of our cohort into < or ≥ 100 pg/ml PlGF appears to 
demonstrate a better performance of the Triage® compared to the ELISA® , 
in terms of prediction of subsequent pre-eclampsia. However, given a cut-off 
specific to the Triage® was utilised, it further illustrates the importance of using 
an appropriate validated cut-off specific to the immunoassay rather than 
superiority of the Triage® over the ELISA®. Communication of this key point 
is an essential component of translational research (281-283). 
 
 Conclusion 
This study highlights the variation that may exist in PlGF levels between 
immunoassay platforms. Appropriate clinical cut-offs must be developed and 




to preserve research integrity, the transition from laboratory to clinical use of 
biomarkers needs to be appropriate by both scientists and clinicians, with 








Table 4. 1: Maternal Demographics of the Cohort (n=178) 
Maternal Age 20 to 46 years (median 34.1) 
BMI 19-45 Kg/m2 (median 25.4) 
Nulliparous 45.5% (n=81) 
Caucasian 92.1% (n=164) 
Assisted conception 30.1% (n=52) 
Method of Assisted Conception 
Ovulation Induction 
Intra Uterine Insemination 
In Vitro Fertilisation with own oocyte 






Maternal Chronic Renal Disease or Chronic Hypertension 2.3% (n=4) 
History of IUGR* in a previous pregnancy  
(multiparous women only, n=97) 
6.2% (n=6) 
History of PET** in a previous pregnancy  
(multiparous women only n=97) 
7.2% (n=7) 
Dichorionic Placenta 84.3% (n=150) 




Table 4. 2: Gestational age at sampling  
Gestational Age Interval at Sampling (weeks) n (%) Mean Gestational Age (weeks) 
20-20+6 21 (11.8%) 20 
21-24+6 56 (31.5%) 21 
25-28+6 35 (19.7%) 27 
29-32+6 38 (21.3%) 31 
33-36+6 28 (15.7%) 35 
 
Table 4. 3: Concordance of PlGF between the two platforms 
  Diagnosis using ELISA Total 
  <100 pg/ml ≥100 pg/ml  
Diagnosis using Triage® <100 pg/ml 4 32 36 
≥100 pg/ml 0 142 142 
Total  4 174 178 





4.2 A prospective study of placental growth factor in twin 
pregnancy and development of a dichorionic twin pregnancy 
specific reference range 
 Abstract 
Introduction:  Circulating maternal levels of placental growth factor (PlGF) 
correlate well with placental function and used as an adjunct, aid the diagnosis 
of preterm pre-eclampsia. Current reference values were constructed from 
singleton pregnancy cohorts. Given the larger placental volume present in a 
twin pregnancy, separate reference ranges are required. The aim of this study 
was twofold; to develop a dichorionic twin pregnancy specific reference range 
for placental growth factor, and to compare gestational specific placental 
growth factor levels in twin pregnancies later complicated by pre-eclampsia, 
hypertensive disorder of pregnancy or fetal growth restriction to controls.   
Methods: Prospective study conducted in a single large tertiary maternity unit 
over a two year period. Consenting pregnant women, across a variety of 
gestations, had a single blood sample taken at one time point only during their 
pregnancy. The plasma was initially biobanked and PlGF was measured later 
in batches using the point of care Triage® PlGF test.  
Results:  PlGF levels in uncomplicated dichorionic twin pregnancies were 
significantly lower in the women who later developed pre-eclampsia than in 
the controls at all gestational intervals.  In those that later developed any HDP, 




while in infants with a customised birthweight below the 3rd centile, PlGF was 
lower only in those sampled after 24 weeks’ gestation.  
Conclusion:  PlGF levels in twin pregnancy differ significantly between those 
women with a pregnancy that will later be complicated by pre-eclampsia and 
those that will not. This difference is present many weeks before clinical signs 
or symptoms of disease are present. Using cross sectional values from 
uncomplicated twin pregnancies, we have developed a dichorionic twin 
pregnancy specific reference range for PlGF. 
 
 Introduction 
Pre-eclampsia is a common complication of pregnancy characterised by new 
onset hypertension and either proteinuria or other maternal organ dysfunction 
after 20 weeks’ gestation (4). Along with other hypertensive disorders of 
pregnancy (HDP), it is a major contributor to maternal and neonatal morbidity 
and mortality (13, 27). Potentially serious maternal morbidity may arise in the 
form of seizures, cerebral haemorrhage, renal failure, liver rupture and 
disseminated intravascular coagulation (17).  The only definitive treatment for 
pre-eclampsia is removal of the placenta, often resulting in iatrogenic preterm 
delivery and subsequent fetal morbidity (284).  Women with a twin pregnancy 
are at a two to three fold increased risk of developing pre-eclampsia, possibly 
due to a combination of larger placental mass and use of assisted reproductive 
therapy (ART), especially use of non-autologous gametes (35, 161, 285). 
Rates of twin pregnancy have risen over the last number of decades globally 




Although the exact aetiology of pre-eclampsia is not fully understood, a 
growing body of evidence suggests that an imbalance of angiogenic factors of 
placental origin play a crucial role in its development (128, 286-289). Placental 
growth factor (PlGF) is an angiogenic protein and a member of the vascular 
endothelial growth factor family (95).  Studies in singleton pregnancies have 
shown lowered levels of PlGF and increased levels of its soluble receptor sFlt-
1 in maternal plasma, weeks prior to the clinical onset of pre-eclampsia (87, 
132). The UK National Institute for Clinical Excellence (NICE) advocates PlGF 
testing, combined with routine clinical care, to help rule out preterm pre-
eclampsia in singleton pregnancies  (141). A number of international 
randomised control trials (RCTs) are currently on-going, investigating the 
clinical impact of the integration of PlGF into clinical care pathways (253). The 
first of these, the UK PARROT study, demonstrated a reduction in time taken 
to diagnosis pre-eclampsia and reduced maternal morbidity when PlGF is 
integrated into clinical care algorithms (290). 
Few studies to date have evaluated the levels of circulating angiogenic factors 
during twin pregnancy. In those that have been described, huge variations 
exist in; the primary outcome (i.e pre-eclampsia, fetal growth restriction or 
other adverse clinical outcome); the definition/classification of the primary 
outcome; the gestational age at time of sampling; and the immunoassay used 
for quantification. (73, 164, 167-173). The aim of this study was twofold; to 
develop a dichorionic twin pregnancy specific reference range for PlGF and 
secondly to compare gestational specific PlGF levels in twin pregnancies 
complicated by pre-eclampsia, any hypertensive disorder of pregnancy (HDP) 




 Materials & Methods 
Setting and Design 
This study was conducted in a single maternity hospital in Ireland with over 
8000 deliveries per annum. The study was a prospective cross-sectional 
cohort study of PlGF in twin pregnancy. From the start of July 2015 to the end 
of December 2017, women attending the hospital’s dedicated twin pregnancy 
clinic were approached to participate in the study. Any woman with an 
uncomplicated twin pregnancy from 12+0-36+6 weeks’ gestation inclusive, 
without signs/symptoms or a diagnosis of pre-eclampsia was eligible for 
inclusion. Those with complications such as a known congenital anomaly in 
either baby, severe early onset growth restriction or twin-to-twin transfusion 
syndrome (TTTS) were excluded from recruitment. Following informed patient 
consent, a 3ml ethylenediaminetetraacetic acid (EDTA) blood sample was 
taken, centrifuged, divided into aliquots and the plasma biobanked at -80C 
within 3 hours of sampling. All sampling, processing and biobanking was 
carried out within the same building according to previously published 
Standard Operating Procedures (SOPs) (291). Women had venepuncture 
performed at one random gestational time point only. Clinically relevant 
outcome data such as the diagnosis of any HDP (chronic hypertension, 
gestational hypertension, pre-eclampsia or superimposed pre-eclampsia) and 
infant birthweights were taken from medical notes following delivery. 
Anonymised clinical and demographic data pertaining to the participant and 
their offspring were recorded in the study database. For our study, the NICE 




growth restriction was calculated based on actual birthweight, gestation at 
birth, fetal gender and maternal ethnicity, parity and BMI using the Gestation 
Related Optimal Weight (GROW) centile calculator (292).   
 
Placental Growth Factor Immunoassay 
Biobanked plasma samples were analysed in batches for circulating levels of 
PlGF using a point of care immunoassay; the Triage® PlGF test (Quidel Inc., 
San Diego). This test is not routinely available in the hospital for clinical use. 
It was purchased by our research centre for the purpose of this study. The test 
manufacturers had no part in the study design, conduct, analysis or manuscript 
development. The immunoassay was performed as per manufacturer’s 
instructions, in a single freeze thaw cycle to minimise protein denaturation. 
The results are displayed on the meter screen in approximately 15 minutes 
and have a measurable range from 12-3000 pg/ml. The Triage® has a 
reported measurable range from 12-3000 pg/ml. The manufacturers report 
total precision on plasma controls at concentrations of 85.2 and 1300 pg/mL 
as 12.8% and 13.2% respectively. For the purposes of this study, any result 
obtained <12 pg/ml was allocated the value of 10 pg/ml.  
 
Statistics 
SPSS Version 23 and Stata 15 were used to analyse the data.  
Part 1: Descriptive statistics were employed to examine the baseline maternal 




Initially all abnormal cases as well as all monochorionic twin pregnancies were 
removed, in order to facilitate development of a reference range for PlGF in an 
uncomplicated dichorionic twin pregnancy. Abnormal cases included women 
where a stillbirth was diagnosed in either of the twins, as well as women who 
later developed any form of HDP, or women who developed fetal growth 
restriction resulting in both twins having a customised birthweight of less than 
the 3rd centile. The remaining women were divided into five groups dependent 
on weeks’ gestational age at recruitment; 12-20+6, 21-24+6, 25-28+6, 29-32+6 
and 33-36+6. PlGF ranges for each gestational group were calculated. Log 
PIGF was modelled as a function of gestational age at recruitment using 
restricted cubic spline regression with heterogeneous variance. Results were 
used to estimate the 5th and 95th centile of PIGF as a function of gestational 
age to develop a reference range for PlGF in uncomplicated dichorionic twin 
pregnancies.  
Part 2: To examine the effect of hypertensive disorders and placental 
dysfunction on PlGF, the entire cohort including abnormal cases, was divided 
into 2 groups based on the woman’s gestational age at time of her enrolment 
to the study and hence sampling of maternal plasma PlGF; <24 weeks’ 
gestation and ≥ 24 weeks’ gestation. This gestational cut-off was employed as 
pregnancy related hypertensive complications are unusual prior to this 
timepoint and also it equated well with the median of the cohort.  The groups 
were stratified by presence of pre-eclampsia, HDP or customised fetal 
birthweight <3rd centile and PIGF level in the two groups were compared using 
a non-parametric Wilcoxon rank-sum test. A proportional odds models, with 




adjusting for ART, oocyte donation and maternal age >35. Twins were 
analysed as clusters in the multivariate models. 
 
Ethics 
Ethical approval was granted from a national research ethics committee (ECM 
3 (PPP) 19/05/15). 
 
 Results 
In total, 275 women with a twin pregnancy were recruited. There were no 
withdrawals or losses to follow up. Three women (1% of the cohort) had a 
stillbirth occur in one of the twins while in 4.7% (n=12) of women, an anomaly 
of one or both twins was diagnosed. Given with twin pregnancy there is 
differing placental volumes present dependent on chorionicity, circulating 
levels of PlGF may also vary in line with chorionicity. We found that PlGF was 
lower in monochorionic twin pregnancy (data not shown) but given the high 
incidence of complications as well as the small numbers present (n=40) in this 
subgroup, further analysis was not possible. We limited our analysis to 








Part 1:  
Reference Range Demographics 
Removal of those with an abnormal pregnancy outcome (pre-eclampsia or 
HDP in the mother, stillbirth of either twin or where both twins had a 
customised birthweight of <3rd centile at delivery), or a monochorionic 
pregnancy left 173 women with an uneventful dichorionic twin pregnancy for 
inclusion in the reference range analysis (Figure 1: Flowchart). Median 
maternal age was 34 years, booking BMI was <30Kg/m2 for the majority 
(81.5%; n=141) and most were Caucasian (93.6%; n=162). Over half of the 
group were multiparous (56.1%; n=97), just over a third (35.1.1%; n=60) had 
conceived the twin pregnancy with use of ART. All women with pre-existing 
renal disease or essential hypertension developed superimposed pre-
eclampsia in their pregnancies and hence were not included in the reference 
range cohort (Table 4.4). Comparison of participant characteristics between 
each gestational group showed no significant difference in enrolment 
characteristics (Table 4.5).  
 
Reference Range Development  
The distributions of PlGF concentrations and the 5th-95th centiles within each 
gestational age (GA) interval were calculated (Table 4.6). With progressing 
gestational age the median PlGF was seen to rise, simultaneously to the 
development and maturation of the placentae, and then steadily decrease 
towards term. In the GA intervals studied, median PlGF concentration peaked 




analysis, the lowest acceptable PlGF value for each gestational age was 
calculated and is presented. These data provide a valid reference range for 
PlGF in a normal dichorionic twin pregnancy (Figure 4.4). Removal of those 
women where both twins had a customised birthweight <3rd centile did not alter 
the reference range significantly (Figure 4.5). 
 
Part 2: 
Comparison of Gestational PlGF  
The second aim of this study was to compare gestational PlGF in twin 
pregnancies complicated by pre-eclampsia, HDP or customised birthweight of 
both twins <3rd centile, to controls. To this end, the entire cohort (n=275) was 
divided into 2 groups based on the woman’s gestational age at time of her 
enrolment to the study and hence gestational age at time of sampling of 
maternal plasma PlGF; <24 weeks’ gestation and ≥ 24 weeks’ gestation.  Just 
under half the cohort (43.6%; n=120) were recruited at <24 weeks’ gestation 
with the remainder (56.4%, n=155) recruited at ≥ 24 gestational weeks.  The 
groups were then stratified by presence of pre-eclampsia, HDP or customised 
birthweight <3rd centile for both infants.  
 
Demographics of Entire Cohort 
The maternal age of the study group ranged from 20 to 50 years, with 134 
women (48.7%) aged >35 years at booking (Table 4.7). The majority of the 




and were of Caucasian ethnicity (93.8%; n=258). Just under half the cohort 
were nulliparous (46.9%; n=129). The majority of the group were dichorionic 
twin pregnancies (81.5%; n=224) and approximately two thirds (65.5%; 
n=180) of the population studied had conceived the twin pregnancy 
spontaneously. Where assisted reproductive therapy (ART) was utilised, 
almost a fifth (17.1%; n=47) had conceived through the assistance of In Vitro 
Fertilisation (IVF) and a large proportion of these using a donor oocyte (12%; 
n=33).  There was a small number of women with pre-existing renal disease 
or hypertension (1.8%; n=5). The two gestational groups were well matched, 
with no differences seen in BMI <30, ethnicity, parity or chorionicity. However, 
there were significantly more women with ART assisted pregnancies (40.2%; 
n=48 v 27.8%; n=42, p=0.04), oocyte donation (18.5%; n=22 v 7.3%; n=11, 
p=0.009) and those with a maternal age >35 years (57.5%; n=69 v 41.9%; 
n=65, p=0.01) sampled in the <24 weeks’ gestational group compared to the 
≥ 24 weeks group (Table 4.7).  
 
Clinical Outcomes  
Overall, the incidence of a subsequent diagnosis of HDP was 15.3% (n=42) 
and 11.3% (n=31) developed pre-eclampsia (Table 4.8). Of the 532 infants 
with maternal BMI information available, 11.8% (n=65) who had a customised 
birthweight <3rd centile with both twins <3rd customised birthweight in eleven 
cases. Gestation at delivery ranged from 23 to 38 weeks’ gestation, with two 
thirds of the cohort delivered via Caesarean section (66.5%, n=183). Preterm 




and in over half of cases was iatrogenic (59.2%, n=20). Preterm delivery at 
<32 weeks was less common (6.9%, n=19), and again half of cases were 
iatrogenic (47.4%, n=9). There were no significant differences between the 
two gestational groups in terms of incidence of HDP or pre-eclampsia, nor 
were there any differences in preterm delivery or mode of delivery. 
 
Comparison of PlGF   
The median PlGF was 230.5 pg/mL when sampling occurred at <24 weeks 
and 276 pg/mL when sampling was ≥24 weeks. Following stratification by 
subsequent diagnosis of pre-eclampsia,  HDP or customised birthweight <3rd 
centile in both twins, a Wilcoxon Rank Sum test revealed PlGF levels were 
significantly lower in the women who later developed pre-eclampsia than in 
the controls (153 pg/ml vs. 247 pg/ml, p = 0.04, 99.8 pg/ml vs. 304 pg/m, p = 
0.01) independent of gestation at sampling. Adjusting for the higher incidence 
of ART, oocyte donation and maternal age >35 in this group, the association 
between PlGF and the later development of pre-eclampsia remained 
significant in the ≥24 group only. In those that subsequently developed any 
HDP, PlGF was lower in the <24 weeks group only (150 pg/ml vs 250 pg/ml, 
p = 0.02) and was unaffected by adjustment for confounders. In those that 
subsequently had either twin born at a birthweight <3rd customised centile, 
PlGF was only lower in the group recruited >24 weeks (170 pg/ml vs 304 
pg/ml, p=0.04), and again was unaffected by adjustment for con-founders 






This study shows that maternal plasma PlGF in twin pregnancy follows the 
same gestational pattern as described in singletons (126, 127); a steady rise 
corresponding with development of the placenta, peaking slightly earlier at 
approximately 28 weeks’ gestation, and then declining thereafter. It also 
shows that maternal plasma PlGF is significantly lower in twin pregnancies 
that will later develop pre-eclampsia but not other HDP, independent of 
gestational age at time of sampling of PlGF, compared to controls.  
To our knowledge, this is the largest prospective study of PlGF in twin 
pregnancy from a single site. This allows us to describe the twin pregnancy 
specific distribution of gestational PlGF, as well as develop a dichorionic 
specific reference range for PlGF in twin pregnancy, which has not been 
previously described. This is also the only study to date examining PlGF in 
twin pregnancies specifically using the Triage® PlGF test. The Triage® PlGF 
test is currently the only point of care test on the market for measuring PlGF, 
is CE marked and has been endorsed by NICE for use in further research 
(141).  
Previous studies of angiogenic factors in twin pregnancy have had limited 
numbers of participants, varied gestations at quantification, varied outcome 
measures and often involve pooled results from a number of sites or countries 
across a variety of time periods (160, 165, 166). Often these studies require 
shipment of specimens to laboratories in other countries, which may affect the 




performed on site, by a single researcher, in a single freeze thaw cycle, to 
minimise the chance of protein denaturation.  
A Spanish study in 2011 examined first trimester levels of circulating 
angiogenic factors in 61 women with a twin pregnancy (165). Using a R&D 
systems immunoassay, they reported higher serum concentrations of both 
PlGF and sFlt-1 in twins compared to matched singletons. They also reported 
maternal serum sFlt-1 levels were higher in twin pregnancies conceived 
through ART compared to spontaneous twin conceptions, supporting the well-
accepted concept that ART pregnancies are at increased risk of pre-eclampsia 
development.  
A study from Boston in 2012 (160) described 79 women with a twin pregnancy 
presenting with suspected pre-eclampsia in the third trimester. Serum PlGF 
and sFlt-1 from the women was quantified using the Roche Elecsys 
immunoassay Ratio test.  The outcome measure utilised was the diagnosis of 
an adverse clinical event in the subsequent fortnight, of which 52 women met 
the criteria. The authors reported median PlGF was significantly reduced, 
while median sFlt-1 was elevated in those that did develop an adverse event 
indicating that these angiogenic factors have potential utility as prognostic 
indicators in twin pregnancies with suspected pre-eclampsia. 
A German group in 2014 published on a small cohort of 49 women with a twin 
pregnancy, 18 of which developed pre-eclampsia. Maternal serum PlGF and 
sFlt-1 was quantified again using the Roche Elecsys immunoassay Ratio test. 
The researchers reported PlGF levels were decreased and sFlt-1 levels 




eclampsia symptoms compared to the twin controls, indicating the potential for 
integration of angiogenic factors into clinical care pathways for investigation of 
suspected pre-eclampsia in twin pregnancy (166).  
Clearly, potential exists for use of PlGF and sFlt-1 as biomarkers for prediction 
of pre-eclampsia in twin pregnancies. However, before these biomarkers are 
introduced into clinical use for twins, it is important that relevant cut-offs are 
developed and validated specifically for this group. Several large prospective 
observational studies have published on clinically relevant cut-offs for use in 
singletons. The PROGNOSIS study, using the Roche Elecsys immunoassay 
Ratio test in 550 women with suspected pre-eclampsia, reported a sFlt-1:PlGF 
ratio of ≤38 as having a negative predictive value for pre-eclampsia in 
singletons in the subsequent 7 days of 99.3% (88). The PELICAN study, using 
the Triage® PlGF test in 625 women with suspected pre-eclampsia, reported 
a PlGF of >100 pg/ml as having a 98% negative predictive value for pre-
eclampsia in the subsequent 14 days in singletons presenting at < 35 weeks’ 
gestation (89).  
A 2018 Dutch study compared PlGF and sFlt-1 levels in normotensive and 
pre-eclamptic singleton and twin pregnancies using the Roche Elecsys 
immunoassay Ratio test (181). Numbers were small, with only 22 twin 
pregnancies included. Again, differences in serum sFlt-1 and PlGF levels were 
noted in the normotensive twins compared to the matched singletons and in 
the pre-eclamptic twin cases compared to the twin controls. Importantly, they 
demonstrated that the previously defined sFlt-1/PlGF ratio cut-off of ≤38 for 
predicting short-term absence of pre-eclampsia in singleton pregnancies is not 




reference ranges for PlGF/sFlt-1 in singletons are not transferrable to twin or 
higher order multiple pregnancies. This highlights the need for quality 
prospective observational studies of women with twin pregnancy presenting 
with suspected pre-eclampsia, in order to develop and validate clinically useful 
cut-offs for PlGF/sFlt-1 in twins.  
We recognise there are limitations to our study specifically the use of a 
customised birthweight centile not specific to twin pregnancy and the exclusion 
of cases where only both twins were <3rd customised centile. This choice was 
pragmatic given our numbers however we recognise that reduced placental 
volume in either twin may affect the circulating maternal PlGF levels. Normal 
twin growth patterns are the subject of much debate with differing opinion as 
to which is the most appropriate growth curve to use in clinical  practice (293, 
294). Concerns exist that twin specific growth charts, adjusted to reflect the 
smallness of twins compared to singletons, may not identify growth restricted 
twins with underlying placental pathology, thereby resulting in increased 
perinatal morbidity (295). There is no consensus as to whether fetal growth 
charts should be customised by factors such as ethnicity, height, weight and 
parity or not and there is also no agreement regarding which is the most 
appropriate growth calculator to use (296-301).  
A second limitation of the study was single sampling of participants. Serial 
sampling of maternal PlGF may have provided a much more robust, 
informative account of PlGF distribution. However, it would have deterred 
many women from and given that participation was truly altruistic, a single 
timepoint only approach was adopted. Our population is largely homogenous; 




minority ethnic groups. Although a large number of women with a twin 
pregnancy were enrolled, we do not have sufficient power at present to 
develop a monochorionic twin pregnancy specific reference range, although it 
would be possible to expand on the study and add to our numbers in the future 
to achieve this.  An additional limitation of our study is the use of only one 
automated commercial platform for quantification of PlGF rather than on 
multiple commercially available platforms such as the DELFIA Xpress PlGF 1-
2-3 test, Brahms Kryptor and the Roche Elecsys ratio test, as advocated by 
NICE (141). Comparative studies performed in singleton pregnancies have 
shown similar performance of all three platforms in ability to rule out pre-
eclampsia (158). As sufficient plasma remains biobanked in our site, this is an 
area for potential future research subject to funding and ethical approval.  
 
 Conclusion 
We have shown that PlGF levels in twin pregnancy differ significantly between 
those pregnancies that later will be complicated by pre-eclampsia and those 
that will not. This difference is present many weeks before clinical signs or 
symptoms of disease are present. We provide a valid overall reference range 
for PlGF in a normal twin pregnancy and specifically in a normal dichorionic 
twin pregnancy. With further research, PlGF has potential as an adjunct to 
clinical care as a predictor of evolving pre-eclampsia and/or adverse clinical 






Table 4. 4: Demographics of the dichorionic reference range cohort of participants at recruitment (n=173) 
Patient Characteristics at Recruitment  
(n=173) 
Mean (SD) / % (n) 
Age (years) 34.0 +/- 4.9 
BMI < 30 (Kg/M2) 81.5 (141) 
Caucasian Ethnicity 93.6 (162) 
Multiparous 56.1 (97) 
Fertility Assisted Conception 
Ovulation Induction 
Intra Uterine Insemination 
In Vitro Fertilisation  






Maternal Morbidity at Recruitment 













Table 4. 5: Characteristics of reference range cohort of participants at recruitment divided by gestational age interval (n=173) 
APre-eclampsia BIntra-Uterine Growth Restriction 
 















% (n) % (n) % (n) % (n) % (n) % (n) 
Age (years) mean (SD) 34.0 +/- 4.9 36.1 +/-4.9 33.4+/-5.5 34.2 +/- 4.6 32.9 +/-4.9 33.4 +/- 4.1 
BMI < 30 (Kg/M2) 81.5 (141) 76.5 (26)  87.5 (35)  87.8 (36)  85.3 (29)  78.9 (15)  
Causasian Ethnicity 93.6 (162) 97.1 (34)  95.0 (38)  97.6 (41)  82.9 (29)  95.2 (20)  
Multiparous 56.1 (97) 57.1 (20)  50.0 (20)  50 (21)  68.6 (24)  57.1 (12)  
Fertility Assisted Conception 34.7 (60)  42.9 (15)  
35.0 
(14)  
40.5 (17)  22.9 (8)  28.6 (6)  
Previous PEA 
Previous IUGRB 
2.9 (5)  
3.5 (6) 
2.9 (1)  






5.7 (2)  
4.8 (1) 





























12-20+6 35 17.2 11 14.9 57.2 154 260 556.80 748.6 
21-24+6 40 21.9 69.3 139.3 257.8 410.0 773.3 1016.9.8 1177.0 
25-28+6 42 26.9 67.5 138.6 278.3 501.0 1072.5 1717.0 2250.5 
29-32+6 35 30.8 34.2 46.2 102 305 708 1426 1972 







Table 4. 7: Demographics of entire cohort of participants at recruitment (n=275) A Pre-eclampsia B Intra-uterine Growth Restriction 
 




Gestation at recruitment  
( < 24weeks) 
 (n=120) 
Gestation at recruitment  




% (n) % (n) % (n) 
Maternal Age Range (years) 20-50 20-50 21-50  
Median Age 34 35 33  
Maternal Age ≥ 35 48.7 (134) 57.5 (69) 41.9 (65) 0.01 
BMI < 30 (Kg/M2) 78.9 (217) 74.1 (89) 85.3 (128) 0.1 
Causasian Ethnicity 93.8 (258) 95 (114) 92.9 (144) 0.64 
Multiparous 53.1 (146) 51.7 (62) 54.2 (84) 0.76 
Fertility Assisted Conception 
  IVF 














  Renal Disease or Essential HTN 
  Previous PEA 


















  Dichorionic 



























































































Table 4. 9: PlGF by gestational group at enrolment in twin pregnancies complicated by A Pre-eclampsia (de novo or superimposed) 




Median (IQR) PlGF  
pg/mL  
(n=275) 
Median (IQR) PlGF  
 PEA present pg/mL  
(n=31) 
Median (IQR) PlGF  
 PE not present pg/mL  
(n=244) 
p-value1 p-value2 
<24 230.5 (79.4-437.8) 153 (54-224) 247 (81-489) 0.01 0.06 
≥24 276 (71.6-577) 99.8 (24-273) 304 (73-652) 0.02 0.03 
1. based on a Wilcoxon Rank Sum test 









Table 4. 10: PlGF by gestational group at enrolment in twin pregnancies complicated by B Hypertensive Disorder of Pregnancy    




Median (IQR) PlGF  
pg/mL  
(n=275) 
Median (IQR) PlGF 
 HDPB present pg/mL  
(n=42) 
Median (IQR) PlGF  




<24 230.5 (79.4-437.8) 150 (45-229) 250 (84-490) 0.001 0.03 
≥24 276 (71.6-577) 123 (32-425) 304 (73-598) 0.09 0.09 
1. based on a Wilcoxon Rank Sum test 














Figure 4. 4: Scatter plot of gestational PlGF for the uncomplicated dichorionic 
twin pregnancy cohort. Shaded area represents the reference range from the 







Figure 4. 5: Scatter plot of gestational PlGF for the uncomplicated dichorionic 
twin pregnancy cohort without those with a customised birthweight <3rd centile 







Figure 4.6: Scatter plot of gestational PlGF. Shaded area represents the 
reference range from the 5th to 95th percentiles (n=222) ○ uncomplicated 
dichorionic twin pregnancy cohort, ▲HDP and PET present, ▲ HDP present, 




Figure 4.7: Scatter plot of gestational PlGF in dichorionic twin pregnancy. 
Shaded area represents the reference range from the 5th to 95th percentiles 
○ uncomplicated dichorionic twin pregnancy cohort (n=147) ● growth 




Figure 4.8: Scatter plot of gestational PlGF in dichorionic twin pregnancy. 
Shaded area represents the reference range from the 5th to 95th percentiles 
○ uncomplicated dichorionic twin pregnancy cohort (n=154) ● growth 




Figure 4.9: Scatter plot of gestational PlGF. Shaded area represents the 
reference range from the 5th to 95th percentiles ○ uncomplicated dichorionic 
twin pregnancy cohort (n=195) ● uncomplicated monochorionic twin 
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5.1 PARROT Ireland: Placental growth factor in Assessment 
of women with suspected pre-eclampsia to reduce maternal 
morbidity: a Stepped Wedge Cluster Randomised Control Trial 
Research Study Protocol 
 Abstract 
Introduction 
Women presenting with suspected pre-eclampsia are currently triaged on the 
basis of hypertension and dipstick proteinuria. This may result in significant 
false positive and negative diagnoses resulting in increased morbidity or 
unnecessary intervention. Recent data suggests that placental growth factor 
testing may be a useful adjunct in the management of women presenting with 
preterm pre-eclampsia. The primary objective of this trial is to determine if the 
addition of placental growth factor testing to the current clinical assessment of 
women with suspected preterm pre-eclampsia, is beneficial for both mothers 
and babies.  
 
Methods and Analysis 
This is a multicentre, stepped wedge cluster, randomised trial aiming to recruit 
4000 women presenting with symptoms suggestive of preterm pre-eclampsia 
between 20 and 36+6 weeks’ gestation. The intervention of an unblinded point 




plasma placental growth factor.  The intervention will be rolled out sequentially, 
based on randomisation, in the seven largest maternity units on the island of 
Ireland. Primary outcome is a composite outcome of maternal morbidity 
(derived from the modified fullPIERS model). To ensure we are not reducing 
maternal morbidity at the expense of earlier delivery and worse neonatal 
outcomes, we have established a co-primary outcome which will examine the 
effect of the intervention on neonatal morbidity, assessed using a composite 
neonatal score. Secondary analyses will examine further clinical outcomes 
(such as mode of delivery, antenatal detection of growth restriction and use of 
antihypertensive agents) as well as a health economic analysis, of 
incorporation of placental growth factor testing into routine care.  
 
 Introduction 
Pre-eclampsia is characterised by hypertension and proteinuria, complicates 
2-8% of pregnancies, and is associated with significant maternal and neonatal 
morbidity and mortality (17). Currently women who present with suspected 
pre-eclampsia are triaged on the basis of hypertension and dipstick 
proteinuria. Both of these clinical endpoints are subject to observer error and 
poor test accuracy, with false positive and negative diagnoses of pre-
eclampsia occurring in clinical practice (302-305)  Current biochemical tests 
are imperfect at stratifying women for more intensive surveillance as they only 
identify advanced disease where there is already marked end-organ damage 




improving detection, none have adequate sensitivity and/or specificity for the 
diagnosis of pre-eclampsia (306). 
Placental growth factor (PlGF) belongs to the vascular endothelial growth 
factor (VEGF) family and represents a key regulator of angiogenic events in 
pathological conditions (95). PlGF exerts its biological function through the 
binding and activation of the receptor Flt-1 (111, 244). In pre-eclampsia, it is 
thought that endothelial dysfunction leads to an increased level of a circulating 
decoy receptor, known as soluble Flt-1, (sFlt-1), a soluble receptor for both 
vascular endothelial growth factor type A (VEGF-A) and PlGF (133). 
Circulating levels of sFlt-1 are increased in pre-eclampsia and particularly in 
the early onset form of the disease, resulting in reduced levels of free VEGF-
A and PlGF in the maternal circulation. Thus, the endothelial dysfunction 
observed in pre-eclampsia may be due to excess neutralisation of VEGF-A 
and PlGF by circulating sFlt-1. Levine et al. showed that in normal pregnancy, 
PlGF levels track the development of the placenta, peaking at about 32 weeks’ 
gestation when the placenta is developed fully and then declining until delivery 
(87). However, in pre-eclampsia, this rise and fall is considerably lower 
throughout pregnancy, and levels are strikingly lower when the condition 
presents clinically. 
The PELICAN study was the first and largest prospective evaluation of PlGF 
in women presenting with suspected pre-eclampsia (89). This blinded 
observational cohort study was conducted in seven consultant-led maternity 
units in the UK and Ireland between January 2011 and February 2012. It 
enrolled women being investigated for suspected pre-eclampsia, quantified 




but did not reveal the result to their clinician. The study found that a PlGF value 
<100 pg/ml, in women presenting prior to 35 completed weeks’ gestation had 
a negative predictive value of 98% (95% CI, 93 to 99.5) and a positive 
predictive value of 44% (95% CI, 36 to 52) in determining those that would 
require delivery for a confirmed diagnosis of pre-eclampsia within the next 14 
days. The study reported a PlGF <100 pg/ml to be a better predictor than all 
other current commonly used predictive tests of pre-eclampsia, either singly 
or in combination (blood pressure, urinalysis or biochemical markers) with an 
area under the ROC curve for low PlGF of 0.87 compared to 0.76 for the next 
best predictor.  
The PROGNOSIS study was a prospective, multicentre, blinded, 
observational study conducted in 14 countries from 2011 to 2014 (88). Its aim 
was to derive and validate a ratio of serum sFlt-1 to PlGF that would be 
predictive of the absence or presence of pre-eclampsia in the short term. It 
included women with singleton pregnancies from 24 weeks to 36+6 weeks’ 
gestation in whom a clinical suspicion of pre-eclampsia existed. The Elecsys 
immunoassay was used to quantify levels of PlGF and sFlt-1. The 
development cohort of over 500 participants identified a sFlt-1:PlGF ratio of 38 
as having an important predictive value. The subsequent validation cohort, 
again with over 500 participants, reported a negative predictive value of 99.3% 
(95% CI 97.9–99.9) for ruling out pre-eclampsia within one week. Interestingly, 
the same cut off of 38 was predictive of the absence of fetal adverse outcomes 
within 1 week; negative predictive value of 99.3% [95% CI, 97.9 to 99.9]. The 
study showed that an sFlt-1: PlGF ratio of 38 or lower can be used to predict 




in whom the syndrome is suspected clinically (88). The positive predictive 
value; a diagnosis of pre-eclampsia, eclampsia, or the HELLP syndrome within 
4 weeks, was 36.7% (95% CI, 28.4 to 45.7) using the same sFlt-1: PlGF ratio 
of 38. Post hoc analysis however showed this was still an improvement in 
prediction compared to the use of clinical variables such as blood pressure 
and urinalysis alone.  
NICE (The National Institute for Health and Clinical Excellence, UK) has 
recently published guidance on incorporation of PlGF testing, in addition to 
clinical assessment, in women presenting with suspected pre-eclampsia from 
20-34+6 weeks’ gestation. It advises that the Triage PlGF test or Elecsys 
immunoassay sFlt‐1/PlGF ratio test may be used, in combination with clinical 
assessment, to “rule-out” pre-eclampsia in this group of women. However, it  
advises that these tests should not yet be used to diagnose pre-eclampsia 
until further research is available, specifically on how an abnormal PlGF result 
would affect management decisions regarding timing and gestation of delivery 
and the outcomes associated with this (141). 
The objective of this randomised trial is to evaluate the impact of knowledge 
of PlGF measurement on clinically relevant outcomes. We hypothesise that 
adding PlGF measurement to current clinical assessment of women with 
suspected pre-eclampsia prior to 37 weeks' gestation will reduce associated 
maternal morbidity through improved risk stratification, earlier diagnosis and 
targeted management of women with the disease. Any intervention in late 
pregnancy may have an impact on the fetus. On the one hand, earlier 
diagnosis of pre-eclampsia may precipitate earlier delivery and lead to an 




prematurity. Conversely, improved identification of those neonates at highest 
risk of imminent placental dysfunction may reduce neonatal morbidity by 
allowing for timely intervention. It is therefore imperative that full evaluation of 
both potential benefit and harm is conducted before PlGF testing is 
implemented routinely into clinical practice. If this trial demonstrates a 
beneficial impact on maternal morbidity and/or neonatal morbidity, alongside 
a favourable health economic assessment, then there would be a strong case 
for incorporating PlGF testing into routine clinical investigations for women 
presenting with suspected pre-eclampsia before 37 weeks’ gestation in a wide 
variety of healthcare settings.  
 
 Methods 
Study Design  
PARROT Ireland is a multi-centre, stepped wedge cluster-controlled trial of 
PlGF measurement in women presenting with suspected pre-eclampsia from 
20 weeks and prior to 37 weeks' gestation. As implementation of a diagnostic 
test may alter physician management, a cluster design was chosen rather than 
individual randomisation. This allows for a change in management to occur at 
a hospital rather than at an individual woman level, which is preferable in trials 
involving a diagnostic test and allows the clinical influence of the additional 
test to be evaluated in a pragmatic fashion  (192). Each maternity hospital acts 
as a cluster. All clusters commenced the trial in the control arm and in turn, 
each cluster transitions at random from the control to the intervention at pre-




continues as such for the remainder of the trial so that by the end of the trial 
all clusters will be in the intervention arm (Figure 5.1). A stepped wedge design 
was chosen so as to increase the social acceptability of the trial to the 7 
hospitals (the stake holders /decision makers in all of the hospitals expressed 
a desire to participate in a trial in which they were guaranteed to get the 
intervention); and because a trial with just 7 clusters risks baseline imbalance 
in a parallel design.  
The trial will continue for a period of twenty-two months, and with seven 
clusters the interval between transitions is approximately three months in 
duration. A restricted method of randomisation was used to provide a balance 
in total (expected) number of observations across intervention and control 
periods (details below) (307-309). There is a short transition period of one 
week whenever a new cluster transitions from control to the intervention. Data 
collected during this transition period will not be included in any analysis of 
outcomes. Recruitment will stop on a pre-specified fixed date in late April 2019 
and the study will end when the last recruited participant and neonate are 
discharged and all outcome data collected.  
 
Setting & Participants 
The trial is being conducted within the Health Research Board Mother and 
Baby Clinical Trial Network Collaborative. The Coombe Women and Infants 
University Hospital Dublin, Cork University Maternity Hospital, University 
Maternity Hospital Limerick, The Royal Jubilee Maternity Hospital Belfast, 




and The Rotunda Maternity Hospital Dublin are the seven largest consultant-
led maternity units on the island of Ireland. Combined, they have over 44,000 
births annually, representing over half of the country’s total annual births.  
Women attending these maternity units who present with suspected preterm 
pre-eclampsia are eligible for inclusion in this trial. Detailed inclusion and 

















Table 5. 1: Inclusion Criteria for Parrot Ireland  
Pregnant women between 20+0 and 36+6 weeks of gestation (inclusive) 
with a; 
o Singleton pregnancy 
• Aged 18 years or over 
• Able to give informed consent. 
• Presenting with suspected pre-eclampsia: (one or more of the 
following). 
• Hypertension  
• Dipstick proteinuria 
• Headache 
• Visual disturbances 
• Epigastric or right upper quadrant pain 
• Increasing oedema 
• Suspected fetal growth restriction 
If the healthcare provider deems hat the woman requires further valuation 
for possible pre-eclampsia 
 
Table 5. 2: Exclusion Criteria for PARROT Ireland  
Confirmed pre-eclampsia at point of enrolment;  
“sustained hypertension with systolic BP ≥ 140 or diastolic BP ≥ 90 on at 
least two occasions at least 4hrs  apart) with significant quantified 
proteinuria (>300mg protein on 24hr collection or urine protein creatinine 
ratio >30mg/mmol) or abnormal pre-eclampsia bloods” 
• ≥37 weeks gestation 
• Multiple pregnancy 
• Abnormal pre-eclampsia bloods (new onset reduced number of 
platelets or deranged liver function/renal function tests, identified 
during routine care prior to enrolment and  not attributable to 
anything other than pre-eclampsia). 
• Decision regarding imminent delivery already made 
• Lethal fetal abnormality present 
• Previous participation in PELICAN trial in a prior pregnancy 
• Participation in a conflicting trial at the same time as PARROT 
Ireland. 







The trial statisticians for the study developed a randomisation sequence for 
site transition from control to intervention; however, the order of site 
transitioning is concealed from sites and principal investigators until 12 weeks 
prior to the sites transition date. An allocation sequence was randomly 
selected (i.e. a cross-over order for the 7 clusters) from a set of random 
sequences constrained so that the sum of the total cluster sizes in the 
intervention status was similar to the total sum of the cluster sizes in the control 
status. Similar was defined to be a difference in the total sums exposed to 
intervention and control statuses being no different than the expected middle 
25th percentile range of differences.  To implement this, 10,000 simulations of 
possible (unique) allocation sequences were performed. From this, the 
difference in number exposed to intervention and control for each sequence 
was determined. An allocation sequence was then selected at random from 




Eligible women are approached and provided with detailed information about 
the trial, both verbally and written, by a trained researcher. Eligibility is 
determined by review of symptoms and signs at the time of presentation to the 
maternity hospital by the local researcher. Participants are not aware of their 
maternity hospitals current randomisation prior to their enrolment on the trial. 




Once an eligible woman has given written informed consent for inclusion in the 
study, her maternity hospitals current group allocation is revealed (Figure 5.2). 
Participants enrolled in the control arm receive usual hospital care as per 
National guidelines; these are Health Service Executive/Institute of Obstetrics 
and Gynaecology Irish guidelines for those in the Republic or the NICE 
guidelines for those in Northern Ireland (Figure 5.3a and 5.3b) (3, 14). Eligible 
women who are approached but who decline to participate in the trial will 
continue to receive usual hospital care.   
 
Intervention 
Participants enrolled in the intervention arm have their plasma PlGF quantified 
in addition to routine hospital investigations. The PlGF result is made 
immediately available to the participants clinical team and documented clearly 
in the participant’s medical notes. A suggested further management algorithm 
is provided to the clinician based on both the degree of hypertension present 
and the PlGF result. (Figure 5.4). This algorithm advocates increased 
frequency of review for those participants identified as having an abnormal 
PlGF result. The final decision regarding frequency of review remains with the 
treating clinician. If 4 weeks or more pass and the participant re-presents with 
symptoms suggestive of pre-eclampsia, a repeat PlGF quantification may be 
performed as long as the inclusion/exclusion criteria are still satisfied. In 
certain sites the option of plasma Biobanking will be available. Participants will 
be consented separately for this. For those who give consent, a portion of the 








Maternal plasma PlGF quantification is performed on an 
ethylenediaminetetraacetic acid (EDTA) venous blood sample obtained in the 
standard fashion. Plasma is obtained through centrifugation and the sample is 
then processed immediately using a CE marked validated point of care 
platform; the automated Triage® Meterpro (ALERE San Diego, CA). Each 
hospital has the necessary equipment in situ and appropriately trained 
researchers in place, to perform this test as per manufacturer’s guidelines. The 
PlGF measurement is reported as the absolute value in pg/ml within 30 
minutes of commencing processing of the sample. All samples taken will be 
analysed without delay by the researcher after venepuncture has occurred and 
in accordance with manufacturers instructions. The Triage© PlGF test platform 
and consumables necessary to perform testing are brought to the cluster just 
at the point of transition to intervention. It is therefore not available at site for 









Patient and Public Involvement 
Patients/ public were not involved in the development of this trial.  
 
Outcome Measure 
Primary Outcome Measure 
To evaluate if the intervention is beneficial to both women and their babies and 
more importantly to ensure it is not harmful to either, the study has two equally 
important co-primary outcome measures. These are maternal morbidity and 
neonatal morbidity. For maternal morbidity assessment, an adaption of the 
fullPIERS score is used (Table 5.3).  The definition of hepatic dysfunction is 
based on ALT rather than INR, requirement for ICU admission is included as 
well as the presences of severe hypertension. Severe systolic hypertension is 
an independent risk factor for stroke in pregnancy and in high resource 
settings uncontrolled hypertension is the main cause of death in women with 
pre-eclampsia. (312-314) The interval from diagnosis of pre-eclampsia to 
delivery is not a suitable outcome measure to use, as we are  aware that 
knowledge of PlGF result may alter clinician management and expedite 
delivery (252). For neonatal morbidity assessment, babies are dichotomised 
into having or not having identified neonatal morbidity by means of a 
composite neonatal score (Table 5.4).  In order to avoid subjectivity in the 
diagnosis of morbidity, the majority of components of the neonatal composite 
score are objective measures; pH < 7.2, positive cultures, admission to NICU. 




hence why all stages of each disease will be captured and will comprise the 
composite outcome; NEC Stage 1-3, IVH Grade 1-4 and ROP Stage 1-5.  
Neonatal outcomes and morbidity will be captured from local case note review, 
as documented by the treating neonatologist. In cases where any uncertainty 
is present, the researcher will discuss the case with the local PI and or the trial 
clinical fellow and a consensus will be reached. 
 
Table 5. 3: Components of the Maternal Morbidity Composite Score  
• Confirmed placental abruption 
• Intensive Care Admission 
• CNS compromise; Generalized tonic clonic seizure due to eclampsia, 
GCS <13, cerebral haemorrhage/ infarct, cortical blindness, retinal 
detachment, Transient ischaemic attack, reversible ischaemic 
neurological deficit 
• Cardiorespiratory compromise; myocardial ischaemia/ infarction, 
SpO2 <90%, >50% FiO2 for >1hr, intubation (other than for 
Caesarean section), pulmonary oedema, need for positive inotrope 
support  
• Haematological compromise; transfusion of any blood product, 
platelet count <100 x 109/l; 
• Liver compromise; hepatic dysfunction (ALT or AST >70 IU/L, 
haematoma, rupture; 
• Kidney compromise; acute renal insufficiency (creatinine >150 
micromol/l); hemodialysis 







Table 5. 4: Components of the Neonatal Morbidity Composite Score  
• Perinatal death or death before hospital discharge 
• NICU admission for ≥48 hrs. 
• Birthweight ≤ 5th customised centile* 
• Apgar score <7 at 5 minutes 
• Umbilical artery acidosis at birth (cord pH <7.2) 
• Admission to neonatal unit 
• Respiratory distress syndrome 
• Interventricular haemorrhage 
• Retinopathy of prematurity 
• Confirmed infection (confirmed on blood or CSF cultures) 
• Necrotising enterocolitis 
*Customised birth weight at delivery is calculated using the GROW centile 
 
Secondary outcome measure 
Secondary outcomes include each component of the primary outcome 
reported individually as well as further maternal and neonatal assessments 
such as mode of delivery and use of antihypertensive agents (Table 5.5 & 5.6). 
Fetal growth restriction, identified on antenatal ultrasound, has been included 
as a secondary outcome measure of neonatal morbidity. As PlGF correlates 
well with placental dysfunction it may be able to differentiate between those 
babies with pathological growth restriction rather than constitutional growth 






Table 5. 5: Secondary Outcomes -Maternal 
• Final diagnosis of hypertensive disorder of pregnancy (Chronic HTN, 
Gestational HTN or pre-eclampsia) 
• Gestation at diagnosis of pre-eclampsia 
• use of 1 or more antihypertensive drugs 
• Instrumental Delivery (Ventouse or Forceps) 
• Severe hypertension (systolic BP ≥ 160 mmHg on at least one 
occasion) 
• Maternal morbidity by fullPIERS model 
• Confirmed placental abruption 
• Intensive care admission 
• Central Nervous System Compromise 
• Cardiorespiratory Compromise 
• Haematological Compromise 
• Liver Compromise 
• Kidney Compromise  
• Progression to severe pre-eclampsia as defined by ACOG practice 
bulletin 
• Systolic BP ≥ 160mmHG or diastolic BP ≥ 110mmHG on 2 
occasions at least 4 hours apart while the patient is on bed rest 
(unless antihypertensive therapy is initiated before this time) 
• Thrombocytopenia (Platelet count <100 x 109/L) 
• Impaired liver function as indicated by abnormally elevated blood 
concentrations of liver enzymes (to twice normal concentration), 
severe persistent right  upper quadrant or epigastric pain 
unresponsive to medication and not accounted for by an 
alternative diagnoses, or both. 
• Progressive renal insufficiency (serum creatinine concentration 
greater than 1.1mg/dL (150 μmol/L) or a doubling of the serum 
creatinine concentration in the absence of other renal disease) 
• Pulmonary oedema 
• New onset cerebral or visual disturbances 
• Elective delivery: induction of labour or Caesarean section 





Table 5. 6: Secondary Outcomes -Neonatal   
• Fetal growth restriction identified on antenatal ultrasound*  
(Estimated Fetal Weight and/or abdominal circumference <10th customised 
centile, abnormality in umbilical artery doppler velocity or reduced level of 
amniotic fluid) 
• Gestation at delivery 
• Perinatal death or death before hospital discharge 
• Admission to NICU 
• NICU admission for ≥48 hours 
• Birthweight ≤ 5th customised centile 
• Apgar score <7 at 5 minutes 
• Umbilical artery acidosis at birth (arterial cord pH <7.2) 
• Respiratory distress syndrome 
• Interventricular haemorrhage 
• Retinopathy of prematurity 
• Confirmed infection (confirmed on blood or CSF cultures) 
• Necrotising enterocolitis 
*Antenatal detection of Fetal Growth restriction is based on formal 
ultrasound assessment of fetal biometry using the Hadlock formula. 
 
A separate health economic evaluation is assessing the intervention’s 
economic impact.  This  is achieved through the use of participant quality of 
life (QoL) questionnaires (EQ-5D & SF-36), (315, 316) a specially designed 
study specific participant costing questionnaire and by assessment of costs to 
the health service of community based/ inpatient/day case care, through chart 






Trial data captured locally at site by researchers are transmitted securely using 
an electronic clinical record form (eCRF) to a specific database developed by 
MedSciNet. Baseline demographic data, QoL questionnaires and the PlGF 
result are entered live to the eCRF at point of recruitment. The full eCRF is 
completed after discharge from the maternity hospital post-delivery, and 
includes neonatal and maternal medical outcome, costing questionnaire & 
repeat QoL questionnaires. All data entered to the eCRF is pseudo-
anonymised with each participant identified by a unique study number. The 
identifier key is kept separately locally at site in a secure location. The data 
system is built to the same security and confidentiality standards as those of 
hospital electronic health records. The data at each participating centre are 
handled in accordance with local regulatory legislation and Ethics Committee 
approval. A detailed description of schedule and timing of data collection is 





Table 5. 7: SPIRIT Flow Diagram for Schedule of events in PARROT Ireland 




and 36+6 weeks 
From enrollment to discharge 
post delivery 
Discharge post delivery 
In-person visit Chart In-person visit Chart In-person completed 
Randomisation- 
Institutional level 
X     
Inclusion/Exclusion X     
Informed Consent X     
Demographics  Xa    
History, Comorbidities  Xa    
Con Medications  Xa  X  
Physical Measurements  Xa    
Clinical readings  Xa    
PlGFb measurement X  Xc   
Biobank sampled X     
Fetal assessments    X  





Table 5. 7: (Continuation) SPIRIT Flow Diagram for Schedule of events in PARROT Ireland 




and 36+6 weeks 





In-person visit Chart In-person visit Chart In-person completed 
Maternal PET bloods    X  
Newborn data    X  
Neonatal outcome    X  
Maternal outcome    X  
Complications    X  
Postnatal admissions    X  
Clinical Management    X  
Final Outcomes    X  
EQ-5D, SF-36 X    X 
Costing questionnaire     X 
In person visits X  Xc   
a May be captured in chart review or in consultation with participant at any time following enrolment.b PlGF testing depends on Institutional randomisation 
allocation.  c PlGF testing will be repeated if readmission for suspected pre-eclampsia. May be repeated more than once. No more often than 4 weekly. d Only 






The sample size was fixed by the number of sites and the study duration. It is 
anticipated that the total sample size will be in the region of 4000 participants; 
split across 7 clusters and the 8 time periods in the design (equivalent to a 
cluster-period size of about 71). With a sample size of 4000 and using a two-
sided type I error rate of 0.025 (to allow for two co-primary outcomes), we 
determined the power to detect a 7% reduction in maternal morbidity (relative 
risk reduction of 20%) from 35% to 28% in the intervention i.e. ‘active’ group 
(based on a reported rate of adverse maternal outcome in the region of 35% 
in the PELICAN trial) (89). This is assuming an ICC in the region of 0.01; but 
also consider Sensitivity to a range of ICC values between 0.005 and 0.05. 
The second co-primary outcome is adverse neonatal outcomes. Due to 
scarcity of information on the ICC, the same ICC as for the maternal outcome 
is assumed. Current rates of adverse events are around 10%. We determine 
power to detect an absolute change in neonatal adverse outcomes of 6%.  
To allow for the longitudinal nature of the trial, where correlations may differ 
between observations in the same cluster-period; and those measured in 
different cluster periods, we incorporate cluster-auto correlations (CAC). There 
is little information to support likely values for the CAC, so we are guided by 
values in the literature and explore sensitivity across a range of values (0.64, 
0.80 and 0.96). (320, 321) 
The power has been estimated using an online RShiny App. (322, 323) We 
have not included transition periods in the calculation but given the transition 




power. There has been no allowance for varying cluster sizes as this is 
currently not something which is technically possible in a stepped wedge 
study. Sample size calculations were performed assuming linear mixed 
models with categorical effects for time; random cluster and random cluster by 
period effects. (310) Under these assumptions, we constructed power curves, 
which reveal that under most anticipated scenarios the trial will have in the 




The primary aim of the study is to evaluate whether there is a difference in the 
two composite outcomes before and after exposure to the intervention. There 
will be no double counting of outcomes, individuals not events will be 
presented for the composite . Mixed effects regression models will be used to 
allow for the clustering within sites. Calendar time will also be adjusted for 
since the intervention is sequentially rolled-out both by including fixed 
categorical time effects and random cluster by categorical time effects (195).  
The primary estimate of the treatment effects will therefore be cluster and time 
adjusted. Time adjustment is essential, as it is a stepped wedge trial. Log 
Poisson regression models with robust variance estimation (to allow for 
misspecification of binomial errors) will be used so as to allow estimates of 
relative risks (324); to estimate risk differences corresponding Binomial 
models with log links will be fitted. Secondary analysis will adjust for individual 




differences between groups will be adjusted for variables used in the 
randomisation procedure (eg; site, time and hospital size). Further, more fully 
adjusted analyses, will also be performed. These more fully adjusted analyses 
will adjust for gestational age at recruitment, maternal age, smoking status, 
maternal BMI, public versus private obstetric care and maternal co-morbities 
such as Chronic Renal Disease, SLE/APS & Diabetes. It will also adjust for 
hospital size (< or >5000 deliveries/annum).  Categorised continuous variables 
(e.g. age) will be treated as continuous variables in this adjustment. If covariate 
adjustment is not practical, unadjusted estimates will be produced and it will 
be made clear in the output why this occurred (e.g. not possible due to low 
event rate lack of model convergence). Null hypotheses and analyses for 
secondary outcomes take a similar form to that for the primary outcome, and 
where outcomes are not binary, analysis will be using the generalized linear 
mixed model. Transformations will be performed where data are markedly not 
normally distributed.  For the analysis adjusted for covariates and for the 
secondary outcomes (unadjusted) multiple imputation methods will be used if 
the proportion of missing data is more than about 5%, and this multiple 
imputation will also allow for the clustered and temporal nature of the trial. It is 
not expected that there will be any missing data in the primary outcome; as it 
will be assumed that if the outcome is present then it will be recorded and if it 
is not recorded we will assume it is absent. This is a standard and realistic 
assumption. Results will be presented as adjusted risk ratios with confidence 
intervals (CI) and risk differences to allow full appreciation of clinical effect. To 




this multiplicity using a Bonferroni correction and so report 97.5% confidence 
intervals.   
For secondary continuous outcomes mean differences will be reported and 
99% confidence intervals for secondary outcomes. We will report latent intra-
cluster correlations for all outcomes, along with 95% confidence intervals.  Pre-
specified subgroup analysis will be undertaken on the primary outcome based 
on women presenting <35 weeks' gestation versus >35 weeks' gestation; size 
of unit and final confirmed diagnosis. The stepped wedge trial design will also 
allow investigation of treatment effect heterogeneity across clusters and time. 
These exploratory analyses will be reported using 99% confidence intervals. 
Analysis will be conducted by intention to treat and sites will be considered 
exposed to the intervention post randomised cross-over date.  
 
Health Economic Outcome 
The economic evaluation will be informed by a decision analytical model, 
which will be designed and constructed for the study to reflect the maternal 
and fetal pathway and health states. Employing a decision analytical model 
allows for the extrapolation of existing data and the opportunity to 
systematically synthesise evidence from various sources. Primary data on 
maternal health outcomes will be available from the study with the distribution 
of EQ-5D-5L & SF-3F6 questionnaires which will inform the estimation of 
Quality Adjusted Life Years (QALYs). Neonatal outcomes will be informed by 
secondary sources. A systematic literature review will be conducted to identify 




will be incorporated into the decision analytical model to estimate QALYs.  
Primary data on resource utilisation will be collected using the costing 
questionnaire (Appendix 2).  The costs and effects of the intervention and 
comparator will be compared to estimate an incremental cost effectiveness 
ratio in a Cost Utility Analysis. To address parameter and structural 
uncertainties, a probabilistic sensitivity analysis (PSA) will be performed. 
 
Trial Management 
Day to day running of the trial will be coordinated by the Trial Management 
Group (TMG). The TMG consist of the lead site investigator plus the project 
manager and the clinical fellow. The TMG will act on behalf of the Sponsor 
and will be responsible to the Trial Steering Committee (TSC) to ensure that 
all Sponsors’ responsibilities are carried out. The TSC  is comprised of all 
Principal Investigators as well as the TMG, sponsor, HRB and representatives 
from Statistics, economics, neonatology, laboratory and a lay person. The role 
of the TSC is to provide overall supervision of the trial. In particular, the TSC 
will concentrate on the progress of the trial, adherence to the protocol, 
participant safety and consideration of new information.  
 
Data Monitoring 
To provide protection for study participants an independent data monitoring 
committee (DMC) has been appointed for this trial. The DMC comprises of 4 




an Obstetrician, a neonatologist, a statistician and a midwife. The DMC met 
and ratified their charter and have advised that all serious adverse events such 
as stillbirth/neonatal death or profound maternal morbidity in the Intervention 
arm of the study be reported to them immediately. The DMC will receive 
regular updates on the progress of the trial every quarter from the trail 
management group (TMG). The purpose of these updates is for the DMC to; 
1) ensure the quality of data collection 2) ensure that the intervention is being 
rolled out according to the randomisation plan 3) monitor balance between 
arms to monitor for potential selection biases and 4) ensure PlGF testing is not 
overwhelmingly better or worse than no PlGF testing with respect to maternal 
morbidity with neonatal morbidity. Once outcomes for 1500 participants are 
available, an interim analysis will be conducted and reviewed by the DMC. The 
interim analysis will report on the co-primary outcomes, follow the same 
methods as those of the primary analysis, and examine if there is proof beyond 
reasonable doubt that one particular intervention is definitely indicated or 
definitely contra-indicated in terms of a net difference of a major endpoint. 
There will be no formal stopping criteria put in place, but the DMC will be 
guided by the knowledge that proof beyond reasonable doubt cannot be 
specified precisely, but a difference of at least three standard deviations in an 
interim analysis of the primary outcome would be consistent with strong level 
of evidence. No allowance for this interim analysis has been made in power 
calculations. There will be no stopping of the trial for futility as the study will be 





Based on previous experience during the PELICAN study, an analysis of 
success criteria and barriers to our proposed study was conducted. Potential 
barriers include the overestimation of (i) identification of eligible women by the 
research team, (ii) primary outcome event rate (iii) and retention / attrition i.e. 
gaining outcomes data on all women included.  
A recruitment feasibility audit conducted in Cork University Maternity Hospital 
(CUMH) over the course of a typical week in July 2016 identified 21 women 
who would be eligible for inclusion in the PARROT Ireland study. This would 
equate to almost 1100 women per annum in CUMH, approximately 13% of its 
annual delivery rate. This is in keeping with the quoted 10% incidence of 
hypertensive disorders of pregnancy (HDP) in the population (27). It is 
anticipated that over the 22 month duration of the study across the 7 hospitals 
approximately 10,486 women will meet the study inclusion criteria (13% of the 
combined annual delivery rate), and of these 4,000 will be recruited into this 
trial (approximately 38% of those eligible). As inclusion in the trial will be 
optional and require informed consent from participants, not all eligible women 
in each unit will be included. Projected inclusion rates will be apparent via a 
dedicated MedSciNet database pre-programmed, available online and 
contemporaneously updated, allowing prompt action to intervene when not 
optimal. A conservative requirement of <50% of all eligible women to be 
recruited in order to reach targets has deliberately been chosen and 
successful recruitment of the same population in the PELICAN study is 




primary outcome of interest than anticipated. We should get an early indication 
of this at the interim analysis.  
As participation in the trial does not require any extra attendances/input from 
the participant for the remainder of the pregnancy, it is likely that retention of 
participants will not be an issue. Similarly, the data outcome to assess for 
maternal and neonatal morbidity can be readily obtained post-delivery 
following discharge of the participant from their stored medical records locally 
at each unit. However, in order to fully examine the health economic outcomes 
there exists a reliance on the return of completed questionnaires by the 
participant post-delivery. To minimise attrition rates, the researcher at each 
site will endeavour to meet with each participant post-delivery prior to their 
discharge and encourage them to complete the health economic 
questionnaires. In the PELICAN study only 1% of the cohort were lost to follow 
up. The risk of incomplete data collection of outcomes in studies such as this 
is more relevant if women deliver in a different unit to that which they are 
recruited in to the trial. However, all seven clusters in our trial are large tertiary 
referral units and patient transfer during pregnancy is rare. We are therefore 
confident that the likely rate of loss to follow up will be similar and in the order 
of 1%. 
There are a number of advantages with the use of stepped wedge design. It 
allows a phased implementation of the intervention, which is preferable when 
commencement in all clusters simultaneously would be challenging. As all 
clusters ultimately receive the intervention, it increases willingness of the 
clusters to partake in the trial.  We acknowledge that seven clusters is a small 




is a limitation because it will mean that the findings have questionable 
generalisability. But, if these clusters are representative then the findings may 
still be generalizable in part. The other limitation that seven clusters brings 
about is questionable internal reliability. However, because all of the clusters 
receive both the intervention and control condition, the clusters serve as their 
own controls. Not only does this lessen the impact of chance imbalance but it 
also increases the power of the study (particularly so when the ICC is large, 
as is the case here). The study does only have in the region of 80% power and 
should parameters such as the ICC be very different to that which we have 
assumed, then it is correct that the study might be underpowered. To ensure 
that this is properly accounted for at the analysis stage, we will report 
appropriate CIs around all point estimates, so the impact of any impression is 
properly reported.  
Another potential limitation worth noting is the slightly different management 
algorithm for one cluster, Belfast, in the control arm. The Belfast control arm 
algorithm is taken directly from the NICE Hypertension in Pregnancy 
guidelines. All other clusters are using an algorithm taken from the HSE 
Guidelines for Hypertension in Pregnancy. The two are essentially the same 
except the HSE algorithm also includes a recommendation for a fetal 
ultrasound in cases where the participant is <34 weeks gestation. It is not 
anticipated that the difference in these algorithms should have any bearing on 
the overall trial results.  We will conduct a sensitivity analysis with the Belfast 
site removed and see if the result remains consistent.  
Ideally PlGF testing should be performed for all participants enrolled in the 




for test performance statistics to be performed. Unfortunately, testing of control 
participants will not be conducted in our trial, which is a notable limitation of 
the study.  
The primary aim of the PARROT Ireland trial is to establish the effectiveness 
of revealed plasma PlGF measurement in reducing maternal morbidity (with 
assessment of neonatal safety in parallel) in women presenting with suspected 
pre-eclampsia prior to 37 weeks' gestation. Should the trial show a reduction 
in maternal morbidity without an increase in neonatal morbidity, or indeed a 
reduction in neonatal morbidity with no change in maternal morbidity, it would 
provide a strong argument for its incorporation into routine obstetric practice. 
The long-term aim of the trial is to demonstrate if PlGF measurement enables 
appropriate antenatal stratification of women presenting with suspected pre-
eclampsia.  
Avoiding unnecessary hospital admission would be both clinically and 
economically beneficial. In contrast, those at increased risk of imminent 
adverse events, identified by an abnormal PlGF result, would have hospital 
resources re-directed to them. We anticipate that this trial will provide a 
definitive result on the benefits of PlGF testing which will act to influence 
international clinical practice.  
 
A separate RCT, also entitled “PARROT”, has completed recruitment in the 
United Kingdom since the end of 2017. Although recruiting a similar population 
of women and using the same PlGF platform, the primary outcome measure 




enrolment to diagnosis. Both studies are using the same electronic clinical 
record forms developed by MedSciNet and thus will have a large cross-over 
of data. The advantage of having these two similar RCT’s conducted almost 
simultaneously is that robust information on the impact of incorporation of 
PlGF into clinical care will be generated. In addition the potential exists for a 



















Figure 5. 3a & Figure 5.3b: Management Algorithm for Control arm based on 

































5.2 PARROT Ireland: Placental growth factor in Assessment 
of women with suspected pre-eclampsia to reduce maternal 
morbidity: Results of Interim Analysis 
 Abstract 
In order to evaluate the impact of incorporation of PlGF testing into routine 
clinical care, a national multi-site randomised control trial was conducted. 
PARROT Ireland recruited from 29th June 2017 to 26th April 2019 in which 
timeframe over 2000 eligible pregnant women with suspected preterm pre-
eclampsia were enrolled. The result of this confidential interim analysis is of 
no significant reduction in either maternal or neonatal morbidity with the 
integration of point of care PlGF based testing. These results however, are 
based on an interim analysis, performed on just the first 1092 participants. Our 
trial has finished recruitment, outcome data is collected, and shortly we will 
analyse the clinical outcomes and report the primary endpoints.  Should our 
trial demonstrate a positive impact on maternal morbidity, without a negative 
impact on neonatal morbidity, we intend to advocate the incorporation of PlGF 
testing into routine clinical investigations for women presenting with suspected 
pre-eclampsia before 37 weeks’ gestation. 
 
 Introduction 
Pre-eclampsia is a clinical manifestation of placental dysfunction. 




and neonatal morbidity and mortality (17). Current diagnosis of pre-eclampsia 
or placental dysfunction is reliant on objective signs of end stage disease such 
as; maternal hypertension, significant proteinuria, abnormal 
biochemical/haematological indices or ultrasound evidence of fetal growth 
restriction (302-306). A robust diagnostic test for pre-eclampsia/placental 
dysfunction would prevent unnecessary hospitalisations and investigations for 
many pregnant women while also enabling earlier identification and focusing 
of resources on those who require it the most (325). Herein lies the potential 
of placental growth factor (PlGF); as a diagnostic biomarker for pre-
eclampsia/placental dysfunction (110).  
As a member of the vascular endothelial growth factor (VEGF) family, PlGF 
regulates angiogenic events in pathological conditions (95). Circulating levels 
of PlGF in the maternal plasma increase alongside development of the 
placenta, peaking at about 32 weeks’ gestation then declining until delivery 
(87). However, in pre-eclampsia due to the endothelial changes that exist, this 
rise and fall is considerably lower throughout pregnancy, and maternal plasma 
levels are significantly lower when the condition presents clinically. 
Observational studies have demonstrated the potential for PlGF in aiding 
diagnosis of pre-eclampsia in those presenting preterm with signs or 
symptoms of the disease (88, 89). However, an abnormal PlGF result may 
prompt earlier intervention by clinicians, resulting in maternal benefit at the 
expense of neonates,  neonates, highlighting the need for adequately 
powered, ideally randomised controlled trials, to determine the clinical utility 




In 2016 The National Institute for Health and Clinical Excellence, UK (NICE) 
published guidance on PlGF testing, in addition to clinical assessment, in 
women presenting with suspected pre-eclampsia from 20-34+6 weeks’ 
gestation. It advocated that PlGF testing should not be used to diagnose pre-
eclampsia until further research was available, on how an abnormal PlGF 
result would affect management decisions regarding timing and gestation of 
delivery and specifically the consequent outcomes associated with this (326).  
The objective of this randomised trial was to evaluate the impact of knowledge 
of PlGF measurement on both maternal and neonatal outcomes. Our 
hypothesis was that the addition of PlGF measurement to current clinical 
assessment of women with suspected pre-eclampsia prior to 37 weeks' 
gestation would reduce associated maternal morbidity, without increasing 
neonatal morbidity, through improved risk stratification, earlier diagnosis and 
targeted management of women with the disease. 
 
 Methods 
Chapter 5, section 5.1.3 describes in detail the methodology of the trial and 
links with paper 5 “.PARROT Ireland: Placental growth factor in Assessment 
of women with suspected pre-eclampsia to reduce maternal morbidity: a 







Study Design  
PARROT Ireland was a multi-centre, stepped wedge cluster-controlled trial of 
PlGF measurement in women presenting with suspected pre-eclampsia and a 
singleton pregnancy from 20 weeks and prior to 37 weeks' gestation. The 
seven largest maternity units in the country were involved in this trial; The 
Coombe Women and Infants University Hospital Dublin, Cork University 
Maternity Hospital, University Maternity Hospital Limerick, The Royal Jubilee 
Maternity Hospital Belfast, University College Hospital Galway, The National 
Maternity Hospital Dublin and The Rotunda Maternity Hospital Dublin. The trial 
ran for a period of twenty-two months, commencing 29th June 2017 and 
ceasing 26th April 2019. Detailed inclusion and exclusion criteria are 
presented in section 5.1.3 (Table 5.1 & 5.2). All units transitioned from control 
phase to intervention phase over this time period, with a short transition week 
in between (Figure 5.1). Data collected during this transition period were not 
included in any analysis of outcomes. Outcome data were collected until the 
last recruited participant was 12 weeks postnatal and the last neonate was 
discharged.  
 
Ethical approval and consent  
The trial was conducted in accordance with ethical principles that have their 
origin in the Declaration of Helsinki and are consistent with Good Clinical 
Practice and applicable regulatory requirements. The local ethics committee 
at each participating site reviewed the trial protocol, including the patient 




(Table 5.8). Each eligible woman identified was required to give written 
informed consent prior to her inclusion in the trial. A GCP trained researcher 
at the local site obtained this consent.  
 
Table 5. 8: Ethical approval from the clinical research committee at each 
participating site  
Cork Clinical Research Ethics Committee Cork: ECM 3 (h) 08/11/16 
Galway University College Hospital Galway EC: Ref 50/12 
Coombe Coombe Womens & Infants University Hospital EC: Study No 
20-2016 
Limerick University Hospital Limerick EC: Ref: 68/16 
Rotunda Rotunda Hospital EC: REC-2016-020 
National 
Maternity 
National Maternity Hospital EC: EC 20.2016 




Once an eligible woman had given written informed consent for inclusion in 
the study, the site researcher revealed her maternity hospitals randomisation 




per National Guidelines; Health Service Executive/Institute of Obstetrics and 
Gynaecology Irish guidelines for those in the Republic or the NICE guidelines 
for those in Northern Ireland (3, 14). Participants enrolled in the intervention 
phase had immediate maternal plasma PlGF quantified in addition to routine 
hospital investigations. The PlGF test was performed by an appropriately 
trained researcher at each site, using a CE marked validated point of care 
platform; the automated Triage® Meterpro (Quidel, San Diego, CA). The PlGF 
result was made immediately available to the participants’ clinical team and 
documented clearly in the participant’s medical notes. A suggested further 
management algorithm was provided to the clinician based on both the degree 
of hypertension present and the PlGF result (Figure 5.3b). 
 
Outcome Measures  
The primary outcome was a composite measure of both maternal morbidity 
(Table 5.33) and neonatal morbidity (Table 5.4). This co-primary approach was 
chosen to ensure maternal morbidity is not reduced at the expense of earlier 
delivery and worse neonatal outcomes.  
Data Monitoring 
A detailed monitoring plan (MP) was developed for PARROT Ireland by the 
project manager and myself (Appendix 2). The trial had an assigned study 
monitor who ensured that the trial was adequately monitored in conjunction 
with the procedures outlined in the MP. Onsite trial monitoring visits were 




visits the monitor performed a number of tasks to ensure protocol adherence 
was maintained (Table 5.9). 
Table 5. 9: Data monitoring tasks at each local site visit  
Necessary % required as per 
MP 
Monitoring Task 
100% QC check on the ICFs 
100% Protocol Deviations/Violations 
100% Investigator Site File 
100% PlGF quantification (frequency, result) 
5% Participant Source Data Verification  
- Recruitment targets locally 
- Site Staff, Facilities and Equipment: 
 
To provide protection for study participants an independent data monitoring 
committee (DMC) was appointed for this trial. Any serious adverse events, 
such as stillbirth/neonatal death or profound maternal morbidity, in the 
Intervention arm of the study was reported immediately to the DMC. No major 
clinical concerns with morbidities occurred. The DMC also received regular 
updates on the progress of the trial every quarter for the purpose of;  
• ensuring the quality of data collection  
• ensuring that the intervention was rolled out according to the 
randomisation plan  
• monitoring balance between arms to monitor for potential selection 




ensuring PlGF testing is not overwhelmingly better or worse than no PlGF 
testing with respect to maternal morbidity & neonatal morbidity 
 
Analysis 
The trial statisticians conducted this Interim Analysis in accordance with the 
DMC charter, when over one thousand participants had been delivered and 
their final clinical outcomes were available.    
 
 Results 
The trial started recruiting on 29th June 2017 and finished on 26th April 2019. 
In this timeframe, 2313 eligible pregnant women consented to enrollment. In 
this confidential interim analysis, I present the results of the first 1092 
participants (Figure 5.7). At the time of writing this paper, clinical outcome data 
for the remainder of the participants is ongoing, with the final data analysis 
planned for early 2020. This confidential interim analysis was presented to the 
DMC of PARROT Ireland, as per their charter, in May 2019. It is also being 
presented here for the purposes of my thesis.  
There were no significant differences between the control and intervention 
groups in terms of maternal age, ethnicity, type of antenatal care, pre-existing 
medical co-morbidities, booking blood pressure or proteinuria at booking 
(Table 5.10). However, there was some disparity between the two groups in 
terms of parity and smoking status with significantly more multiparous women 




the intervention arm (14.35%, n=32 v 11.89%, n=103; p=0.004) compared to 
the control.    
Median gestational age at the time of recruitment was 33 weeks, and did not 
differ between the two arms (Table 5.11). No differences were noted in 
diagnosis of gestational diabetes, dipstick level of proteinuria prior to study 
entry, nor presence of fetal growth restriction prior to enrolment between the 
two groups. In the intervention cohort, significantly more participants were 
taking aspirin when recruited (23.8%, n=87 v 19.9%, n=173; p<0.0001). There 
was disparity in location of recruitment, with more recruitment occurring from 
antenatal clinic (40.36%, n=90 v 23.01%, n=200; p<0.0001) among those in 
the intervention arm. Both systolic (132.7mmHg, n=220 v 136.1, n=855; 
p=0.013) and diastolic (82.1mmHg, n=220 v 84.5mmHg, n=855; p=0.014) 
blood pressures were also lower among those in the intervention arm at time 
of recruitment. 
All participants recruited to the trial were eligible based on the presence of 
signs or symptoms concerning for evolving pre-eclampsia or placental 
dysfunction. The main clinical outcome, as well as any additional adverse 
diagnosis, for all participants are shown (Table 5.12). Gestational age at the 
time when final outcome diagnosis was reached ranged from 29 to 36 weeks 
with a median of 33.5 weeks and did not differ significantly between the two 
arms. There were also no differences in the rates of each clinical outcome 
between the two groups, with less than 5% of participants having no pathology 
subsequently identified. The control arm was noted to have significantly higher 




v 89.24%, n=199; p=0.004) however individual numbers are small and need 
to be interpreted with caution. 
Results were adjusted for cluster and time given the stepped wedge design 
and then more fully adjusted analysis was performed taking into account; 
maternal age, BMI, smoking, ethnic origin, gestational age at booking, public 
versus private obstetric care and maternal co-morbities such as chronic 
hypertension/renal disease, systemic lupus erythematous (SLE) or 
antiphospholipid syndrome (APS) and pre-existing diabetes.  
The overall incidence of maternal morbidity observed in the trial was 37% 
(n=411) with no significant difference between the two groups (34.25%, n=75 
v 39%, n=336; RR 0.82, 95% CI 0.61-1.12) even when adjusted (RR 0.84, 
95% CI 0.62-1.14) (Table 5.13).  
The overall incidence of neonatal morbidity present in the trial was 46% 
(n=501) with those in the intervention arm trending towards less morbidity 
(41.3%, n=92 v 47.1%, n=409; RR 0.81, 95% CI 0.64-1.02) however this was 
not statistically significant even when adjusted (RR 0.78, 95% CI 0.60-1.02) 













 Table 5. 10: Baseline characteristics of participants  





Age, y, mean (SD) 31.9(5.79) 31.3(5.74) 0.178 
Ethnicity   0.571 
European 787(90.56) 211(94.62)  
African Caribbean  1 (0.12) 0 (0)  
African  23 (2.65) 3(1.35)  
Bangladeshi   2(0.23) 1(0.45)  
Indian 14(1.61) 1(0.45)  
Middle Eastern 5(0.58) 0(0)  
Pakistani 5(0.58) 0(0)  
South East Asian  11(1.27) 2(0.9)  
Other   21(2.42) 5(2.24)  




Nulliparous 354(40.74) 72(32.29)  
Multiparous 515(59.26) 151(67.71)  
Previous PET    
Previous Stillbirth    
Medical Co-morbidities    
Chronic Renal Disease 28/869(3.22) 6/223 (2.69) 0.684 
Chronic HTN 76/869 (8.75) 23/223(10.31) 0.467 
SLE/APS 4/869(0.46) 0/223 (0) 0.310 
Pre pregnancy Diabetes 23/869(2.65) 7/223(3.14)  
Obstetric Care   0.156 
Public  797 (91.71) 211(94.62)  
Private 71(8.17) 11(4.93)  
Unknown  1(0.12) 1(0.45)  
Gestation at booking (weeks, days), mean (SD) 13.23(3.82), n(861) 12.53(3.14) 0.0114 




Smoking N=866 N=223 0.004 
Current smoking 103(11.89) 32(14.35)  
Quit smoking 34(3.93) 20(8.97)  
Never smoked 729(84.18) 171(76.68)  
Booking BP reading  
Systolic mm Hg, mean (SD) 120.7(15.25), n=860 121.0(12.90), n=223 0.79 
Diastolic mm Hg, me mean (SD) 73.5(10.64), n=860 74.3(9.89), n=223 0.28 
Proteinuria at booking   0.066 
No 763(87.90) 208(93.27)  
Not done 64(7.37) 8(3.59)  
Yes 41(4.72) 7(3.14)  
Proteinuria at booking, Yes   0.562 
Trace 17(41.46) 3(42.86)  
+1 11(26.83) 3(42.86)  





Table 5. 11: Participant characteristics at time of enrollment to the study 
 Control Intervention p-Value 
Gestation at enrollment (weeks), median (IQR) 33(30, 35) 33(30, 35) 0.30 
Aspirin use in current pregnancy 173/869(19.9) 87/223(23.8) <0.0001 
Gestational Diabetes in current Pregnancy 104/869(11.97) 24/223(10.76) 0.618 
Location at enrollment   <0.0001 
Antenatal Clinic 200(23.01) 90(40.36)  
Antenatal ward 163(18.76) 37(16.59)  
Labour Ward 1(0.12) 0(0)  
Day Ward 308(35.44) 87(39.01)  
Emergency room  105(12.08) 9(4.04)  
Other 92(10.59) 0(0)  
Highest BP reading recorded in the 48 hours prior to study entry 
Systolic mm Hg, mean (SD) 136.1(18.21), n=855 132.7(17.59), 
n=220 
0.013 






Highest dipstick level of proteinuria in the last 48 hours prior to study entry 0.438 
Trace 122(14.07) 32(14.35)  
1+ 93(10.73) 16(7.17)  
=2 66(7.61) 13(5.83)  
None 550(63.44) 153(68.61)  
Not Done 36(4.15) 9(4.04)  
Suspected Fetal growth restriction prior to enrolment   0.144 
No 250(50.51) 66(43.71)  
Yes 245(49.49) 85(56.29)  
AC <10th centile 135/245(42.45) 41/85(48.24) 0.002 
EFW <10th centile 227/245(92.65) 80/85(94.12) 0.792 
Umb Art PI >95th centile 37/245(15.10) 14/85(16.47) 0.338 






Table 5. 12: Clinical outcome diagnosis 12 weeks post-delivery for women in each arm of the study 
 Control Intervention p-Value 
Final Diagnosis   0.142 
Pre-eclampsia 130(14.96) 29(13)  
Gestational Hypertension 236(27.16) 49(21.97)  
Gestational Proteinuria 16(1.84) 3(1.35)  
Transient Hypertension 112(12.89) 25(11.21)  
Superimposed Pre-eclampsia (background CHT) 6(0.69) 0(0)  
Superimposed Pre-eclampsia (background renal disease) 4(0.46) 1(0.45)  
HELLP 1(0.12) 0(0)  
Suspected SGA only 57(6.56) 21(9.42)  
Chronic Hypertension only 46(5.29) 11(4.93)  
Superimposed pre-eclampsia (background CHT and renal disease) 5(0.58) 0(0)  
Isolated SGA 151(17.38) 51(22.87)  
Chronic Hypertension and SGA 11(1.27) 2(0.90)  




Other 15(1.73) 12(5.38)  
Gestation at diagnosis (weeks, days), median (IQR) 33.5(29, 36), n=832 33(29, 36), n=218 0.773 
Additional Diagnosis   0.004 
No additional diagnosis 809(93.10) 199(89.24)  
Eclampsia 2(0.23) 0(0)  
HELLP 4(0.46) 0(0)  
DIC 0(0) 0(0)  
ELLP 4(0.46) 0(0)  
Placental Abruption 7(0.81) 0(0)  
Transient Hypertension 15(1.73) 7(3.14)  
IUGR at delivery 7(0.81) 9(4.04)  
IUGR undetected antenatally 11(1.27) 5(2.24)  
Cholecystitis 0(0) 1(0.45)  






Table 5. 13: Maternal morbidity composite co-primary outcome 




No 526/862(61.0) 144/219(65.75) 
 
  







Table 5. 14: Neonatal morbidity composite co-primary outcome 




No 460/869(52.9) 131/223(58.7) 
 
  











We set out to examine if the incorporation of PlGF testing into routine care, 
improved maternal outcomes without negatively influencing neonatal 
outcomes. The result of this interim analysis found no significant reduction in 
either maternal or neonatal morbidity with the integration of point of care PlGF 
based testing, in addition to usual clinical care, in women with suspected 
preterm pre-eclampsia and a singleton pregnancy. These results however, are 
based on an interim analysis, performed on only the first half of participants 
recruited to the PARROT Ireland trial and should be interpreted with caution. 
Given the stepped wedge design and the timing of this interim analysis, the 
proportion of participants represented here is unbalanced; with many more 
control than intervention cases.  
Our interim results contrast to those of the UK PARROT trial which published 
earlier this year, reporting PlGF testing to be beneficial (188). These findings 
were based upon an observed reduction in time to diagnose preterm pre-
eclampsia (from 4.1 to 1.9 days) as well as a reduction in maternal adverse 
outcomes in those with revealed PlGF testing.  
Similarly to our trial, the UK PARROT trial used a stepped wedge design, 
recruited women with suspected preterm pre-eclampsia and utilised the 
Triage® Meterpro for PlGF quantification . The UK trial began a year prior to 
the Irish trial and was slightly shorter in duration, finishing eighteen months 
ahead of ours. Subtle differences exist between the two PARROT trials, 




in all participants and the primary outcome employed, which must be 
considered when interpreting and comparing the results (Table 5.15).  
The incidence of pre-eclampsia among the UK trial participants was 
approximately 35%. In comparison, our incidence was much lower at 
approximately 14%, potentially explained by the use of differing definitions for 
pre-eclampsia between the two trials. To harmonise clinical diagnosis across 
all seven maternity units in our trial, we adhered to the 2010 NICE 
Hypertension in pregnancy guidelines which necessitate the presence of 
significant proteinuria for the diagnosis of pre-eclampsia (3).  In contrast, the 
UK trial adopted the newer International Society for the Study of Hypertension 
in Pregnancy (ISSHP) 2014 statement, which advocates that proteinuria is not 
essential for the diagnoses of pre-eclampsia, if either maternal organ 
dysfunction or fetal growth restriction are present (15).  
Importantly, the primary outcome measures of the two trials differ. The UK trial 
measured “time from presentation with suspected pre-eclampsia to 
documented pre-eclampsia in women enrolled in the trial who received a 
diagnosis of pre-eclampsia by their treating clinicians” as the primary outcome 
measure, with maternal and neonatal morbidity analysed as secondary 
outcomes. Given the importance of ensuring clinical benefit and out ruling any 
clinical harm with the intervention, we opted for a co-primary composite of 
maternal and neonatal morbidity as the primary outcome measure for 
PARROT Ireland.   
Our trial has limitations that we acknowledge; the first of these being a lack of 




quantified PlGF in all recruited participants but only revealed the PlGF result 
for those randomised to the intervention (188). This allows for comparison of 
not just participant demographics and clinical parameters but also of the PlGF 
results itself, ensuring the two arms of the study are equal in all aspects (327). 
Given both the financial and technical constraints of PlGF testing, it was not 
feasible for us to perform PlGF testing on all participants in all maternity units 
at the commencement of the trial. Biobanking samples locally to facilitate  later 
analyses was also considered but as the infrastructure at most sites was not 
conducive with the necessary high quality standards required for biobanking, 
practically this was not a realistic option.  
Significantly lower blood pressure was present at the time of enrollment among 
those in the intervention in our interim analysis. Potentially this is a reflection 
of the increased interest and engagement of staff locally in the trial once their 
unit transitioned to the intervention. Unfortunately, this is a challenge when 
using an unblinded randomisation design, where it is not possible to blind the 
clinicians at site as knowledge and education is required for adaption of PlGF 
into clinical practice. A final limitation to consider is potential confounders. 
Aspirin, multiparity and smoking are known to confer a protective effect against 
pre-eclampsia and placental dysfunction (328, 329) and a significantly higher 
incidence of all of these was noted in the intervention group compared to the 
control of our interim analysis. Potentially, the lack of difference in the primary 
outcome of our interim results may have been influenced by this imbalance.   
Our trial has a number of notable strengths. Thanks to the collaborative work 
of many maternity units, universities and the health research board mother 




that a national, multi-site, randomised control trial among the pregnant 
population is possible in Ireland. Additionally, very few eligible women 
approached to take part declined, demonstrating the acceptance of clinical 
research among pregnant women in Ireland. These findings help pave the way 
for future perinatal research studies, critical for the practice of evidence-based 
care.  
A second strength of the trial is its overall timing, with the publication of the UK 
trial results occurring just at the very end of our recruitment in April 2019. This 
enabled equipoise, regarding the potential merits of PlGF testing, to be 
maintained for the duration of our trial and thus did not influence the 
participants’ decision to enrol nor clinicians’ decision to refer their patients. An 
additional strength of our trial is its design. The cluster randomisation allowed 
a change in clinical management to occur at a hospital level rather than at an 
individual patient level, facilitating a pragmatic approach to PlGF use. This 
approach demonstrated the likely day-to-day practice should PlGF be 
introduced into clinical practice in the future. In the intervention cohort, a higher 
incidence of recruitment was observed to occur from antenatal clinic, 
highlighting the utility of point of care PlGF testing as a rule out test for pre-
eclampsia in an outpatient setting. The stepped wedge design also ensured 
that each hospital had an opportunity to experience the intervention and thus 
remained engaged with the trial and committed to not adopting any off protocol 






On foot of the PARROT UK publication, the National Health Service (NHS) in 
the UK has now endorsed PlGF testing to aid diagnosis of preterm pre-
eclampsia in maternity units throughout the UK (187). Our trial has finished 
recruitment, outcome data is collected, and shortly we will analyse the clinical 
outcomes and report the primary endpoints. Despite some limitations, given 
the large number of participants that have completed the study we are 
optimistic we will be able to report adequately powered, high quality data on 
the effect of PlGF testing.  Should our trial demonstrate a positive impact on 
maternal morbidity, without a negative impact on  neonatal morbidity, we would 
advocate the incorporation of PlGF testing into routine clinical investigations 






Table 5. 15: Similarities and Differences in PARROT UK versus PARROT Ireland RCTs 
 UK Ireland 
Date of commencement of Trial June 2016 June 2017 
Date of cessation of Trial October 2017 April 2019 
Number of clusters (Maternity 
Units) 
11 7 
Duration of trial (months) 17 22 
Duration of each block (weeks) 6 12 
Gestational age of participants at 
recruitment 
20-36+6 weeks 20-36+6 weeks 
Inclusion Similarities • new-onset or worsening of existing 
hypertension 
• dipstick proteinuria 
• epigastric or right upper-quadrant 
pain 
• headache with visual disturbances 
• fetal growth restriction 
 
• new-onset or worsening of existing 
hypertension 
• dipstick proteinuria 
• epigastric or right upper-quadrant pain 
• headache with visual disturbances 




Inclusion differences If abnormal maternal blood tests that were 
suggestive of disease (thrombocytopenia or 
hepatic or renal dysfunction) participants 
were still eligible for inclusion 
If abnormal maternal blood tests that were 
suggestive of disease, participants were not 
included 
Number of Participants Enrolled 1035 2313 
Guidelines used for diagnosis of 
Pre-eclampsia  
ISSHP 2014 NICE 2010 
Primary Outcome 
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6.1 An exploration of women’s experience of taking part in a 
randomised controlled trial of a diagnostic test during 
pregnancy; a qualitative study 
 Abstract 
Objective: To explore pregnant women’s views of participation in a clinical 
research trial while pregnant  
Design: Prospective nested qualitative cross sectional study embedded within 
a national, multi-site randomised controlled trial of a diagnostic test for pre-
eclampsia; Placental Growth Factor. One to one in depth semi-structured 
interviews were undertaken with 19 women who had recently participated in 
the trial at a single recruiting site. The interviews were conducted in private, 
recorded digitally and transcribed verbatim.   
Setting: Single tertiary maternity hospital currently recruiting eligible women 
onto an ongoing randomised controlled trial (NCT 02881073) 
Participants: Women who had participated in the PARROT Ireland 
randomised controlled trial during their recent pregnancy 
Methods: Thematic analysis was utilised. Each line of the transcribed 
interviews was coded into a category by two researchers. The resultant 
categories were reviewed and those with similarities were pooled allowing the 




Main Outcome Measures: Women’s opinions and experience of participation 
in a randomised controlled trial of an interventional diagnostic test during their 
pregnancy 
Results: Four major themes were identified: 1) Understanding of pre-
eclampsia, 2) Motivators for clinical trial participation 3) Barriers to decision-
making and 4) Influence of PARROT Ireland on pregnancy experience 
Conclusions: Women are generally interested and positively inclined to 
participate in research during pregnancy.  The potential of risk is an important 
consideration for eligible pregnant woman. Information and support by both 
researchers and clinicians are paramount in aiding women’s understanding of 
a research trial.  
Keywords: Pre-eclampsia, Pregnancy, Research, Randomised Controlled 
Trial, Diagnostic Test, Qualitative 
 
 Introduction 
A randomised controlled trial (RCT) is regarded as the gold standard when 
testing efficacy of any new drug, intervention or diagnostic test (189, 191). The 
use of drugs such as thalidomide and diethylstilbestrol in pregnant women has 
had long lasting repercussions; with women of childbearing age traditionally 
being excluded from clinical trials owing to safety concerns and fear of litigation 
(203, 204). Nevertheless, up to 74% of pregnant women take mediation for 
chronic or acute conditions while the use of prescription medications by 




most of these drugs being used off-label  (201, 218). The paucity of evidence 
available on the use of medications in pregnancy means that some pregnant 
women may not be receiving optimal treatment, as clinicians are often unsure 
regarding correct dosage due to the physiological and metabolic changes that 
occur in pregnancy (208, 330). Further, lack of inclusion of women in clinical 
trials has resulted in a lack of evidence-based care for pregnant women. 
Interventions such as cardiotocography and fetal fibronectin testing were 
integrated into clinical practice prior to robust evidence of their benefit (205). 
Once use of such clinical interventions are established within a system, 
withdrawal becomes challenging (206).  
In the last number of years concerns have arisen over the ethics of actively 
excluding pregnant women from clinical trials (207, 331-333). In 1993 the Food 
and Drug Administration (FDA) lifted its ban on the testing of medicinal 
products in women and the National Institute for Health (NIH) legally endorsed 
the inclusion of pregnant women in trials (334, 335). Since the mid 90’s there 
has been a concerted effort to ensure minorities, such as women and children, 
are represented in research in order to help guide scientific based practice for 
all societal groups (336-338). With the advent of perinatal research centres, 
each year more trials specific to pregnant women are developed, funded and 
conducted globally (339, 340). Literature is sparse in relation to women’s 
willingness to take part in in clinical research while pregnant (341-343). In 
addition, lack of experience in including pregnant women in trials may lead to 
poor trial design and hence recruitment difficulties (211, 344, 345).  It is well 
documented that under-recruitment is often an issue in RCTS, with a third not 




involved in conducting an RCT of an interventional diagnostic test on a 
pregnant population; we determined we had a unique opportunity to explore 
pregnant women’s views of participation in research, within a clinical trial. Our 
aim was to explore women’s experience on being involved in a clinical trial, 
specifically a randomised controlled trial, while pregnant.  
 
 Methods 
This qualitative study was nested within a randomised controlled trial of a point 
of care diagnostic test (NCT 02881073) for preterm pre-eclampsia in Ireland. 
We first describe the PARROT Ireland RCT and then describe the nested 
qualitative study.  
 
PARROT Ireland 
PARROT Ireland was a multi-site, national study recruiting women in the 
seven largest maternity units in Ireland, from 29th June 2017 until 26th April 
2019. The trial aimed to examine if the addition of point of care Placental 
Growth Factor (PlGF) testing to routine clinical care improved both maternal 
and neonatal outcomes for women with a preterm singleton pregnancy, and 
signs or symptoms of pre-eclampsia or placental dysfunction (179). If an 
eligible pregnant woman consented to participate, she was randomised to 
either control (routine care) or intervention (immediate additional PlGF testing) 
based on the current randomisation of her hospital at the timepoint of her 




clinical care team were aware of her allocation and her PlGF result if she was 
randomised to the intervention. 
 
Nested Qualitative Study Design 
Participants at a single study site were invited to participate in the qualitative 
study. We employed a qualitative study design, using semi-structured 
interviews, to explore women’s views, experience and beliefs regarding 
pregnancy research.  A semi-structured topic guide which was developed 
based on existing literature (211-215).  Qualitative research has been utilised 
for many years to provides insight into problems, help develop hypotheses and 
to gain an understanding of underlying reasons, opinions, and motivations 
(347). Interviews rather than surveys were employed as they facilitated a 
relationship of trust to be established between the researcher and participant 
(348). One to one interviews allowed for an environment where each 
participant was able to express themselves more openly than perhaps a focus 
group may have allowed (349).  
Recruitment 
Purposive sampling of women who had recently completed the PARROT RCT 
was employed to ensure each arm of the trial was represented. Due to the 
stepped wedge design of the trial, the interval from recruitment until the 
interview was longer for those recruited in the control than the intervention. 
These women had previously consented to be approached about further trial-




participate by post. Women who agreed to participate attended to the 
maternity hospital in-person (n=16) or were interviewed by telephone (n=3) if 
in-person attendance was not feasible. Informed written consent was 
obtained, and the interview process took approximately 30 minutes. Interviews 
were conducted over a three month period (September 2018-December 2018) 
by DHR until data saturation was reached. At the time of interview, the 
PARROT Ireland trial was ongoing so results were not yet available to 
participants or researchers.  Eighteen of the nineteen interviews were 
recorded digitally, and transcribed verbatim. The one woman that did not wish 
to be digitally recorded, gave consent for note taking by the researcher 
throughout the interview. These notes were used to inform the analysis.  
 
Analysis 
Interview transcripts were thematically analysed by DHR and SM (220, 221). 
In the initial analysis, each line of the transcript was coded into categories. The 
categories were then reviewed and refined, and themes were developed. 
These key themes were then presented and agreed upon by the entire 
research team. 
     
 Results 
Nineteen women were interviewed, ten of whom had been randomised to the 
control arm and nine who had been randomised to the intervention arm of the 




the interview. All women interviewed were Caucasian, age ranged from 24 to 
42 years and 52% were nulliparous prior to their recent pregnancy.  Four 
themes were identified; 1) Understanding of pre-eclampsia, 2) Motivators for 
clinical trial participation 3) Barriers to decision-making and 4) Influence of 
PARROT Ireland on pregnancy experience.  Direct quotations from the 
women, presented in-text, are used to illustrate these themes. 
  
Understanding of pre-eclampsia  
Women were recruited to the PARROT Ireland trial on the basis that they were 
exhibiting signs or symptoms of preterm pre-eclampsia in their pregnancy. 
Some women were diagnosed with pre-eclampsia. They described the 
significant impact this had on their pregnancy, emphasising how it took over 
their lives leaving them with a lack of control and autonomy.  
“…suddenly I was in hospital and I didn't leave for a month. I had loads 
of planning to do and my mat leave was happening the next day and 
just small things that were kind of taken away in a sense, putting the 
nappies in where I wanted to put them and the vests and washing them 
and all those little preparation stuff that I was kind of looking forward to” 
P8 
Most of those interviewed reported only having vaguely heard of the condition 
prior to their pregnancy with friends or social media being the main source of 




beginning of their pregnancies, these women did not feel that pre-eclampsia 
was of concern to them.   
“It didn’t really affect me, it wasn’t anything to do with me” P3 
Most of those interviewed were not aware of risk factors for pre-eclampsia and 
had misconceptions about who might develop pre-eclampsia. Women 
commonly stated that they were shocked when the possibility of pre-eclampsia 
arose later in their pregnancy.  
“Like I thought it was something kind of third world people got” P7 
“I would have heard of it, but I wouldn’t have known much about it” P15 
“Before being pregnant I don’t think… maybe I had heard the word pre-
eclampsia, but I definitely wouldn’t have known any specific 
information” P17 
Those who had been pregnant previously, especially those previously 
investigated for pre-eclampsia, had better knowledge of the risks, symptoms 
and potential consequences of the condition.  
“I definitely thought that you were overweight and unfit and like you'd 
brought it on yourself kind of thing” P9 
“I was definitely more aware of it, because they had mentioned it’s a 
possibility or that it is more probable the second time round. So, I would 
have been aware of at least the symptoms of it and watching out more 




When subsequently informed that they required investigation for pre-
eclampsia, women were eager for simple, clear, concise information about the 
condition from a reliable source.  Some felt they got the necessary information 
from their clinical care team. Others searched for the information themselves, 
usually using online sources, and often felt overwhelmed at the vast amount 
and varied quality of information available.  
 “You don't know where to look regarding wanting to get correct 
information because there's so much now online” P8 
 
Motivators for participation in clinical research  
Despite limited previous experience with participation in research, especially 
medical research, the women had extensive knowledge regarding research. 
All were convinced about the merit and importance of research, especially in 
pregnancy, for increasing knowledge of conditions and improving future 
clinical care.  
“I just think information is power and the numbers don't lie and if you 
have information, you can do something” P9 
“I felt like whatever we could do it would be a benefit, so I was happy to 
participate to be honest” P13 
Almost all of those interviewed reported it was a straightforward decision to 
take part in PARROT Ireland, and that it did not require a lot of time for 




“…as far as I was concerned it was my body and they didn’t really have 
a say” P2 
 “The study was quite easy-going, you know, it's a blood test or no blood 
test and then a questionnaire, so that was no real decision on my part 
in that it was handy enough” P13 
The women reported altruism and the potential to help others in the future as 
a key motivator for participation. Many felt their contribution was essentially 
“paying it forward” for the knowledge that could be garnered from their current 
pregnancies in order to benefit those in the future. A second key motivator to 
participate was a lack of burden associated with participation in the PARROT 
trial. Even though women reported they would be happy to give extra time or 
attend for extra appointments if required for research purposes, one of the 
main factors was how straightforward it was to take part in the PARROT trial.   
“other people being involved in research previously surely helped me 
when I was pregnant” P3 
 “ the fact that it was so simple….you could say yes or no…and then 
you have a blood test or you didn’t and then there was no extra travel 
or filling out huge surveys or anything like that” P17 
The potential of participation facilitating an opportunity of an earlier diagnosis, 
or identification of a problem, also influenced women’s  decision to enrol. 
Women felt that by being part of the study they might know sooner than others 
if they developed a pregnancy complication.  The demeanour of the PARROT 




part. Women discussed the researcher’s style of approaching eligible women 
remarking that the researcher was kind and friendly, made them feel at ease, 
explained the study in clear simple terms, all without rushing or pressurising 
women in any way.  
“she couldn’t have been nicer, she really couldn’t…had she not been 
so sensitive and understanding I possibly wouldn’t have you know” P5 
“It was completely up to me and I didn’t feel at all under pressure. I 
mean I could have just left it. I remember there was a window just next 
to me so I could have just left it on the window sill and you know, nothing 
would have ever come of it” P17 
Women reported being positively influenced to take part if they heard about 
the trial from their treating clinician. Most believed the trial would not have been 
suggested to them unless it was useful and would be beneficial to them. They 
also reported being more likely to take part if they recognised the name of one 
of the Principal Investigators (PI) of the study. The women discussed how 
these PI’s are senior consultants who are well respected clinically and are 
highly sought after for private obstetric antenatal care locally.  
“I think that was less pressure in a sense, because you know when the 
researcher approached me directly, it’s kind of my responsibility “do you 
want to take part?” whereas when it comes from you know your 






Barriers to decision making  
The main deterrent to participation in clinical research identified by the group 
was risk.  The group reported being highly reluctant to take part in any research 
should they perceive it as being potentially harmful to the developing fetus. 
Taking a medication while pregnant, as part of a research trial, was an 
example of what women would consider risky. Most would be very reluctant to 
take part in such a trial and admitted it would require very careful consideration 
and discussion with their partner if they were approached in the future about 
such a research study.  
“I'd be very slow, I'd have to really think about it, purely because it's 
somebody else's life you're putting on the line, not just your own, it’s 
somebody else's future “ P7 
The potential requirement for blood tests from the woman as part of a clinical 
study was not found to be a deterrent among the group, however if blood 
sampling were required from the baby following delivery, this would be 
considered a deterrent. Any test that was invasive, and potentially would cause 
distress or pain to the baby, that was not required outside of a research setting 
would not be well received.  
“You don't want to be the guinea pig and you certainly don't want the 
baby to be the guinea pig either… you're like well can some people in 
some other countries sign up first and see what the outcome is. You 




The clinical situation of the individual woman, at the time point when she is 
approached to participate in a trial, was flagged by those interviewed as 
important to consider.  Many participants reported that if they had recently 
received sensitive or distressing information or were currently experiencing 
serious complications in their pregnancy; they may have been less willing to 
take part in the trial.  The women interviewed mentioned that the language 
used by researchers when approaching eligible pregnant women is important 
to consider. Using complicated words and medical jargon could be frightening 
for some women and many stated it would sway them against participation.  
“Like I do think it is very dependent on you know the news that you have 
been given, like if you have been given very sensitive news, you might 
feel like, why should I be…. the guinea pig to help future cases” P5 
 “I think any pregnant woman would happily take part, I think the only 
time that someone might not want to do it is if they are facing a crisis, 
and they are in a bit of a fog and they can’t really think” P2 
 “I think the only thing that would turn people off is saying its medical 
research –that can be scary. Maybe, say its more for women’s health” 
P4 
 
Influence of PARROT on pregnancy experience  
When approached for further interview, all those who agreed to take part 
reported recalling the trial and their agreement to take part. The name of the 




trial concerning pregnant women and pre-eclampsia had used an acronym 
representing a bird. Some understood this was an abbreviation for a longer 
name. Nobody reported the name to have negative connotations, but some 
did mention that if it had mentioned a baby in the title it may have been more 
inviting.  
“no I remember the name because I have a parrot! So, if it had been 
another name … but I remember this” P6 
“It did cross my mind…”why parrot”? but I didn’t think too much about it 
really. I remembered it straight away so maybe the name was good” 
P14 
All enrolled participants in PARROT Ireland were asked to complete a five 
page paper Quality of Life questionnaire at the time point of their enrolment 
and again prior to their discharge from hospital postnatally. When asked about 
their thoughts on the questionnaire, most respondents had little memory of it 
and did not report it as being off-putting or time-consuming. Some commented 
that they were a welcome distraction while waiting in a busy antenatal clinic 
and allowed them time to reflect on their current self.   
“The researcher … she was dropping the follow-up questionnaire, so 
she could know if I needed to get on to somebody” P13 
“One thing I did like about it was it makes you think, it made me think 
about where I was at in the weeks after having my baby, it gives you 
time to think what level of anxiety am I now, so that was nice, that was 




The majority of participants were aware of the concept of randomisation in a 
research setting and recognised the importance of assigning participants to 
groups in order to be able to examine the outcomes when evaluating a new 
test etc.   
“I guess controls are important I suppose, to some extent you know, 
you need a certain amount of people to take part in order to get a certain 
level of statistics, that you need you know” P10 
 “While I would still like to be part of the group of people that get the 
test, for research to develop and everything they need people on the 
other side of it, so I suppose that I would accept the plan whatever it 
was“ P12 
A distinct difference was expressed between those in the control and those in 
the intervention regarding the overall experience of the trial on their pregnancy. 
Those from the control group had a poorer recollection of what the purpose of 
the trial was and that a blood test was offered to some participants. The women 
recruited to the control arm felt that the trial did not impact on or influence their 
pregnancy in any way but were still happy to have taken part.  
“It was really personable, it actually wasn’t like we were just another 
case number. If anything it brought me on sense of…somethings going 
right. Like there was never anything bad to come out of the trial for me, 
like worst case scenario you got nothing, you were just like you were 
when you started. it was all beneficial in one form or another depending 




 “I suppose, all I was thinking of was if it will help me or help other people 
I will.  But to be honest information probably went a little over my head, 
I actually can’t tell you now what the Parrot Study is, and that ….through 
no fault of anybody, but I personally had so much going on  P16 
Those who were in the intervention arm had a better recollection of the 
purpose of the trial and overwhelmingly felt being enrolled onto the trial was 
beneficial to their pregnancy. They felt that knowledge of the PlGF result, 
whether it was normal or abnormal was useful to the clinicians caring for them 
and positively influenced their pregnancy. They also felt they received extra 
care from their clinicians due to their involvement in the trial and having had 
the extra blood test performed.  
“I just felt that everyone was giving the best care and all of this research 
and all of this information was for my baby’s good so I thought it was a 
very positive thing” P18 
“I thought it was very good, to be honest.  It was hands-on like, you 
know. I don’t remember ever a doctor ringing me like, so….I was happy 
with that. I think it put a rush on me being monitored, if I’m being honest, 
it was definitely beneficial” P18 
 
 Discussion 
This qualitative study brings together insight into women’s decision-making 
regarding participation in an interventional clinical trial during pregnancy. We 




research and are interested in taking part, provided participation does not put 
their unborn baby at any risk. We found there was limited background 
knowledge of pre-eclampsia among the group and women wanted information 
on this condition to be clear, concise and provided by a reliable source.  In our 
study, those randomised to the intervention felt participation in the trial directly 
benefited their pregnancy; with the additional test providing valuable 
information on placental functioning and the perception of increased care from 
clinicians.  On reviewing the literature, we identified limited numbers of 
previous studies examining women’s experience of participation in a RCT 
while pregnant (212-215, 350). These RCTS vary in terms of design and 
methodology, frequently involved administration of a medicinal product or a 
placebo. Given that our RCT employed a diagnostic test as the intervention, 
we identified a novel opportunity to gain insight and add new knowledge to this 
under-examined area.  
Participants of our nested study, reported both altruism and the potential of 
personnel benefit to be key motivators in their enrolment in PARROT Ireland. 
The prospect of an additional blood test, with its potential of earlier 
identification and diagnosis of a clinical complication, was an incentive for our 
study.  Others have similarly reported a sense of civic duty, the opportunity to 
help others and the possibility of an improved outcome for their baby to be 
driving forces behind participation (213, 214). A Brazilian group reported the 
main motivator to comprise access to free medicine and an opportunity to 
engage with healthcare providers (212). This highlights that in countries where 
health care during pregnancy is not publicly available, participation in clinical 




order to access medical care. In such cases, governance of research trials 
must be closely regulated to ensure this vulnerable group are not exploited.  
Respondents in our study reported being more likely to take part in the trial if 
it was mentioned to them by their treating clinician or a member of the medical 
team.  Endorsement of the trial from medical personnel appears to validate a 
study for patients. Similarly a lack of interest or support from local clinical staff 
has been reported as a barrier to participation (211).  Accurate knowledge by 
clinicians of ongoing trials in their unit and the vocalisation of their support is 
crucial in promoting participation of pregnant women in future trials.   
This nested study identified that the main barrier preventing participation of 
pregnant women in clinical research is the potential of causing harm to the 
baby. Others have also found  pregnant women to be risk adverse, with 
apprehension and risk-limitation being common barriers prohibiting 
participation (211, 214). Clincal trials require sponsorship, insurance and 
undergo rigorous review by national ethical committees prior to their 
commencement. Ongoing clinical trials are vigilently monitoried by 
stakeholders, to ensure any trends in adverse events are quickly detected and 
can be acted upon with possible cessation of the trial if neccessary  (331, 340, 
351). Changing a pregnant woman’s perception of risk is key. Education, 
through the information and explanation provided by reseachers is paramount. 
Adequate training of researchers and clinicians, to maximise this skillset, 
should be prioritised for future studies.  
This study revealed that, the decision to take part in the PARROT Ireland trial 




consultation with her partner, friends or family. Similar findings were reported 
in the QUOTE study (215), while in contrast the RIPE study (214) reported 
equal involvement of both the women and her partner in the decision to take 
part in an RCT. Both RCTs involved taking a medication while pregnant, 
however in QUOTE women had pre-eclampsia when enrolled, whereas in 
RIPE healthy pregnant women were recruited. This finding highlights trials that 
involve taking a medication while pregnant, especially if recruiting healthy 
pregnant volunteers, likely require a longer time interval from first approach by 
researchers until signing consent, to facilitate shared decision-making. 
Women reported feeling well informed about the PARROT Ireland trial prior to 
signing the consent and later had a good understanding of the trial when 
interviewed. Respondents reported that the timing and setting of the 
researcher’s approach was appropriate and the language used was 
understandable and unambiguous. In contrast, participants of both the 
MAGPIE (216) and the ORACLE (217) RCTs reported confusion when the trial 
was initially explained to them. They did not fully understand that 
randomisation meant they might not receive the intervention and subsequently 
had limited knowledge and recall about the trials (213, 215). This difference 
may be attributable to the clinical situation of the women at the time of 
recruitment. For PARROT Ireland eligible women were approached in a variety 
of clinical settings; antenatal clinics, wards, assessment units, all while 
undergoing routine assessments. Both the MAGPIE and ORACLE trials 
recruited women in Labour Ward/High Dependency Ward, either in preterm 
labour or close to indicated emergency delivery. Given the complexity of these 




unable to clearly assimilate information provided about a research study. 
Designing future trials with recruitment focused in non-emergent situations 
may provide a solution to this and ensure patient vulnerability is not exploited.  
An alternative could be to employ the use of a delayed consent process for 
labour ward based trials (352). This approach has been employed in trials of 
critically ill patients, is well described and has been found to be acceptable to 
patients (353).  
The women in our study randomised to the control did not report negative 
experiences. Although they felt the trial had no direct impact on their 
pregnancy, they were still happy to have taken part. In contrast to our results, 
others have reported randomisation to the control of an RCT perceived as 
being disadvantageous (214). A loss of equipoise on the subject under 
investigation may be one explanation, or equally a familiarity of the intervention 
among the population. Prior to randomisation in a study, if participants have 
strong favourable personal opinions on the product being investigated, it may 
lead to disappointment and disillusionment if they then are randomised to the 
control. This highlights the need for education of eligible participants by 
researchers on the purpose and importance of both arms of an RCT. It also 
highlights the impact background knowledge of the topic under review in the 
eligible population may have on their willingness to participate and needs to 
be considered by researchers when planning future studies.  
The women we interviewed are likely to be highly motivated and interested in 
research as they not only took part in the trial during their pregnancy, but also 




interviewed those who declined to take part in the trial also, as this would have 
better elicited the barriers to research participation in pregnancy. However, as 
per Good Clinical Practice (GCP) (354) and General Data Protection 
Regulations (GDPR) (355) we did not retain any information on eligible women 
who were approached but declined to participate in the trial, thus contacting 
them for this study was not feasible. Strengths of our study include in-person 
interviews; facilitating a more personal relationship between the researcher 
and participant as well as close proximity of interview to time of participation, 
which greatly aided participants recall. Uniquely, the PARROT Ireland RCT 
was not blinded, hence even though the trial has not yet published, women 
subsequently interviewed were aware of their randomisation and, for those in 
the intervention, knew their PlGF result.  
Our findings correlate well with those from a recent systematic review 
examining the facilitators and barriers to pregnant women’s participation in 
research (350). It reported altruism and the potential to contribute to science 
to rank highly as motivators to women’s participation. The potential for 
personal benefit, through increased surveillance or earlier detection of medical 
conditions, was also a commonly reported  motivator. Similar to our nested 
study, the systematic review reported pregnant women to be risk adverse with 
the potential requirement of taking a medication whilst pregnant a major barrier 
to participation.  Unlike our study, the review reported personnel 
inconvenience as a barrier to participation amongst pregnant women. This 
difference may potentially be explained by the design of our trial; with no 
ongoing assessments or repeat attendance required it was well received by 




distrust of researchers identified by the authors of the systematic review. This 
difference may possibly be explained by the demeanour and approach 
adopted by the research midwife of our study. Her candour and non-




This study highlights that pregnant women are aware of the importance of 
research and are generally interested and positively inclined to participate. It 
identifies that the context, purpose and potential risk of any research are the 
most important considerations to an eligible pregnant woman. The approach 
and explanation adopted by both researchers and clinicians is paramount in 
aiding women’s understanding of a research trial. This information may aid the 

















7.1 Overview  
Worldwide, women who get pregnant are at risk of developing a hypertensive 
disorder of pregnancy, particularly if pregnant with twins or if conception 
occurred through use of assisted reproductive therapy (74, 85, 224). 
Hypertensive disorders arise on a background of placental dysfunction and 
are a global health issue, as they confer increased risk of both maternal and 
neonatal morbidity and mortality. Close vigilance of clinical parameters and 
optimal timing of delivery in women with pre-eclampsia have reduced mortality 
from this condition in the last numbers of decades in developed countries (21, 
27, 356).  
Prompt diagnosis of any form of placental dysfunction, including pre-
eclampsia, is key to facilitating interventions around management and 
delivery. The gestation at onset of placental dysfunction as well as clinical 
symptoms vary between women, necessitating caregivers to be constantly 
vigilant for concerning signs requiring further investigation.  In recent years, 
the concept of using the angiogenic biomarker placental growth factor to aid 
diagnosis of placental dysfunction, such as hypertensive disorders, has shown 
significant promise  (89, 183).  
There were three main objectives to this thesis. Firstly, to explore the potential 
of using PlGF in women at increased risk of placental dysfunction such as twin 
pregnancy. Secondly, to examine the impact of adding PlGF as a diagnostic 
aid in women with a singleton pregnancy presenting with signs/symptoms of 




involved in a clinical trial while pregnant. Five research projects were 
undertaken to investigate these objectives: 
1. The incidence of hypertensive disorders of pregnancy in a twin 
pregnancy cohort and the maternal and perinatal implications when 
present (Chapter 2)  
2. An overview of placental growth factor (PlGF) knowledge and use to 
date, both in pregnancy and outside of pregnancy, and identification of 
areas requiring further research (Chapter 3). 
3. Examination of differing immunoassay platforms for PlGF 
quantification, exploration of the potential for use of PlGF in twin 
pregnancy and development of a reference range for dichorionic twin 
pregnancies (Chapter 4) 
4. The development, conduct and interim results of a national multi-site 
randomised controlled trial of PlGF as an adjunctive aid to diagnosis 
preterm pre-eclampsia in women with a singleton pregnancy and 
signs/symptoms concerning for placental dysfunction (Chapter 5) 
5. The facilitators and barriers to conducting clinical research in a 
pregnant population through a qualitative study of women’s opinions 
and experience of participation in a randomised controlled trial of an 
interventional diagnostic test while pregnant (Chapter 6) 
For the purposes of this discussion, I have chosen to group similar themed 
papers together and to present interpretation of each chapter’s findings in this 
way. Given the different aims, content and methods used in the studies, this 




of my work. It will also allow for greater clarity when discussing the implications 
my work has for future research and clinical practice.  
The papers have been grouped according to three main areas covered by this 
thesis;  
1) Chapters 2 and 4 assess the impact of Hypertensive Disorders of 
Pregnancy (HDP) in the setting of twin pregnancy (Paper 1) and explore 
the potential of using PlGF as a potential biomarker of HDP/placental 
dysfunction in twin pregnancy (Papers 3 & 4).   
2) Chapter 3 and 5 give an overview of PlGF knowledge and use to 
date (Paper 2) and investigate the impact of adding PlGF to routine 
clinical investigations of women with suspected preterm pre-eclampsia 
and a singleton pregnancy (Papers 5 & 6).  
3) Chapter 6 focuses on the facilitators and barriers to conducting 
clinical research in a pregnant population (Paper 7). 
 
7.2 Hypertensive Disorders of Pregnancy in twin pregnancy 
and the potential for using PlGF as a biomarker  
Twin pregnancy is well documented to increase the risk of the development of 
HDP and consequently is associated with an increased incidence of adverse 
maternal and neonatal outcomes (13, 56, 71, 78, 222). In order to examine the 




twin pregnancies over a nine-year consecutive period in our own maternity unit 
in Cork. All women with a twin pregnancy that delivered in the unit from 2009 
to 2018 inclusive were included, maternal and neonatal clinical outcomes 
recorded and compared between those pregnancies that developed HDP and 
those that did not. From this study I produced a paper on the impact of HDP 
on maternal and perinatal outcomes in twin pregnancy (Chapter 2). Most 
research to date on PlGF has been conducted on singleton pregnancies with 
limited information available on twin pregnancy thus I next conducted a 
prospective study over the course of a two-year period in the same maternity 
unit. Women attending with a twin pregnancy underwent plasma PlGF 
sampling across a variety of gestational time points. This study resulted in the 
production of two papers (Chapter 4). The first paper compared the results of 
two different platforms available for PlGF quantification. The second paper 
gives a detailed description of the course of PlGF in a twin pregnancy, provides 
a reference range for PlGF in a dichorionic twin pregnancy and compares the 
PlGF values between uncomplicated twin pregnancies to those complicated 
by HDP. 
  
 Main findings and how they relate to existing research 
Chapter 2: Hypertensive Disorders of Pregnancy in twin pregnancy 
One out of every five women with a twin pregnancy in our unit developed a 
HDP, in keeping with the global reported incidence (74, 77, 223, 224). 
Nulliparity, maternal age over 40 years and conception though use of donor 




previously recognised in literature (75, 77, 224). In this paper we demonstrated 
that  the presence of obstetric cholestasis conferred an almost fourfold 
likelihood of HDP, a more recently recognised risk factor (71, 227). When HDP 
was present in our cohort, it was more likely to result in iatrogenic late 
premature delivery. A composite measure of perinatal morbidity did not show 
any difference between those twin pregnancies complicated by a diagnosis of 
HDP and those that were not,  a similar finding to other research (234).  In our 
cohort, we did note an increased incidence of neonatal hypoglycaemia in the 
infants born to women with a HDP. Potentially this finding may be related to 
the administration of antenatal steroids for fetal lung maturation or influenced 
by the use of beta-blockers to treat maternal hypertension, as both of these 
have been reported to be associated with neonatal hypoglycaemia (237, 238).  
 
Chapter 4; PlGF in twin pregnancy 
The first paper in this chapter indicated that although there is good correlation 
between the laboratory and point of care immunoassays examined, there 
exists a significant difference in the range and in the PlGF values obtained 
between the two assays. This difference in PlGF values may possibly be 
explained by the use of different antibodies in each assay and their cross 
reactivity with different PlGF isoforms (104-106, 121, 153, 276). These results 
highlight that clinical cut-offs developed and validated using one biomarker 
immunoassay are not transferrable to another immunoassay for the same 
biomarker. Comparative studies performed in singleton pregnancies have 




pre-eclampsia (158). A comparative study of three different automated PlGF 
immunoassays (Brahms®, Elecsys® and Delfia®) similarly found that PlGF 
values obtained on automated immunoassay platforms are manufacturer 
specific, not interchangeable and require separate validation (157). 
The second paper in this chapter demonstrated that maternal plasma PlGF in 
a twin pregnancy follows the same gestational pattern as described in 
singletons with a steady rise corresponding with development of the placenta, 
peaking slightly earlier than in singletons at approximately 28 weeks’ 
gestation, and then declining thereafter (126, 159). While research has 
previously demonstrated maternal plasma PlGF is altered in twin pregnancies 
at the time of diagnosis of pre-eclampsia (166, 180), this study demonstrated 
that PlGF levels are significantly lower in twin pregnancies that will later 
develop pre-eclampsia, independent of gestational age at time of sampling. 
This finding highlights the potential of using PlGF as a diagnostic aid for 
evolving placental dysfunction in twin pregnancies.  
Through recruitment of a cohort of twin pregnancies, despite the necessary 
removal of many cases due to subsequent pregnancy complications indicating 
placental dysfunction, I was successful in developing a reference range for 
PlGF in dichorionic twin pregnancy, which has not previously been available.   
 
 Major Limitations 
The main limitations in relation to the HDP in twin pregnancy retrospective 
study (Paper 1) was the lack of certain clinical information in the database. 




medications including aspirin on outcomes. It also prevented much exploration 
of the impact of timing of antenatal steroids and quantity of labetalol on 
neonatal hypoglycaemia (237, 238). Similarly, the effect of gestational age at 
time of diagnosis of HDP and exactly what type of HDP was present was not 
well documented in the cohort. Generally, the earlier the onset of pre-
eclampsia the more severe it is and subsequently the poorer the perinatal 
outcomes (232, 233). Despite the lack of certain data points in this 
retrospective study, the wealth of information provided through its descriptive 
collective of nine years of data from a large tertiary maternity unit, with its 
dedicated twin pregnancy clinic, is immense, highlighted by its successful 
publication. 
In relation to the PlGF twin study, limitations of Paper 4 include the use of a 
customised birthweight centile not specific to twin pregnancy as well as the 
exclusion of cases where only both twins were <3rd customised centile. While 
in relation to Paper 3,  and the lack of inclusion of additional automated PlGF 
immunoassays for comparison of performance as suggested, owing to lack of 
availability of these locally must be acknowledged (141). Given that 
biobanking of plasma samples was employed, there is potential for future 
research of these samples with many different PlGF immunoassays. Serial 
sampling of all participants would have provided a more robust, informative 
account of PlGF distribution, however this was a pragmatic study, recruiting 
women while they attended for antenatal review to facilitate their schedule. 
This flexibility, with no onus for repeat attendances, increased study 
acceptability and participation. Despite the large number of participants 




further analysis of this group was limited. However, we did identify that PlGF 
was lower in monochorionic twin pregnancy, highlighting the need for further 
research in this area and specifically the development of a monochorionic 
specific reference range for PlGF in twin pregnancy.   
 Implications for health policy, clinical practice, and future 
research recommendations 
As healthcare professionals there is a responsibility to appropriately counsel 
women in relation to the potential increased risks of HDP and preterm birth 
when embarking on a pregnancy at an advanced age, especially through use 
of ART and/or donor oocytes. The Irish ART sector needs regulation , with 
protocols aimed at minimising the risk of twin pregnancy needing to be 
introduced nationally (57, 70, 85). In December 2019, plans were  announced 
by the Minister for Health to introduce a publicly funded IVF service in Ireland, 
once human reproduction legislation is passed (357). Introduction of state 
funding for fertility treatment in the Republic of Ireland would reduce the 
numbers of women travelling abroad to seek less expensive fertility treatment 
which is often poorly regulated and frequently results in twin pregnancy due to 
the practice of multiple embryo transfer (60, 61). Research has shown that 
many Irish couples conceiving through use of donor oocytes do not disclose 
this information to their clinical care providers, due to confidentiality concerns, 
hindering the ability of care providers to risk stratify them appropriately 
antenatally (358).  
Women with a twin pregnancy are at increased risk of developing a HDP and 




each appointment for evolving disease (71, 227). Awareness of HDP among 
both pregnant women and their healthcare providers needs to be improved.  
Antenatal education and patient information leaflets could help to increase 
knowledge among women and their partners in relation to symptoms of 
concern. Education of health care professionals needs to be encouraged and 
continuously updated in line with new research developments (230). In 
addition, the introduction of a dedicated twin antenatal clinic, led by a clinician 
experienced in the management of twin pregnancy would likely result in 
harmonisation of care to all twin pregnancies in a maternity unit. This approach 
would likely reduce adverse outcomes and could be considered by 
professional organisations (53, 241). Future research on twin pregnancy 
should explore the relationship between chorionicity and HDP as this is 
unclear and evidence is  conflicting, (224, 226) as well as examine the 
mechanisms responsible for the predisposition to obstetric cholestasis in twin 
pregnancy (228).  
Further research on PlGF in twin pregnancy will be informed by the final trial 
results of the PARROT Ireland in which only singleton pregnancies were 
eligible for inclusion. PlGF has potential for use in twin pregnancy as an 
adjunct to diagnose evolving placental dysfunction (90, 160, 165, 166, 168). 
However, plasma levels of circulating PlGF in twin pregnancy differ from 
singletons and therefore clinical cut-offs developed and validated for use in 
singletons pregnancies cannot simply be applied to a twin pregnancy cohort.  
Further research on PlGF in twin pregnancy is required (359, 360). The volume 
of placental tissue present differs dependent on the underlying chorionicity of 




developed a reference range for PlGF in dichorionic twin pregnancy, one 
specific to monochorionic twins also needs to be developed.  
Once chorionicity specific references ranges for PlGF are available, an 
observational study should be conducted to evaluate these PlGF reference 
ranges and develop and validate clinical cut-offs specific to twin pregnancy for 
PlGF. Future research work on PlGF should also include comparison of other 
commercially available platforms such as the DELFIA Xpress PlGF 1-2-3 test, 
Brahms Kryptor and the Roche Elecsys ratio test, (141). Appropriate cut-offs 
specific to each immunoassay are required if PlGF quantification is to be 
introduced as a diagnostic aid in clinical practice (281-283). It is essential that 
stakeholders, policy makers and clinicians alike are aware that clinical cut-offs 
developed using one platform are not transferrable to another, when deciding 
on which immunoassay to introduce locally and what advice to advocate when 
introducing local and national guidelines (157, 158).  
 
7.3 PlGF use to date and the impact of adding PlGF to 
routine clinical investigations of women with suspected 
preterm pre-eclampsia in a singleton pregnancy  
In order to understand the structure, function and utility of PlGF, I first 
conducted a literature review of PlGF research to date (Chapter 3). I identified 
there was significant potential to improve clinician’s ability to detect pre-




was a lack of information regarding the potential impact on both pregnant 
women and neonates from this additional testing. NICE guidelines on PlGF 
published in 2016 advocated that while PlGF could be used as a rule out test 
for pre-eclampsia, further research was warranted before it should be 
introduced into clinical use to help diagnose pre-eclampsia (141).  
Recognising this gap in current PlGF knowledge and the need for further 
research, I led a national multisite randomised controlled trial of PlGF in 
women with suspected preterm pre-eclampsia in order to adequately examine 
these outcomes (Chapter 5).  
 
 Main findings and how they relate to existing research 
Chapter 3: Placental Growth Factor 
PlGF, a circulating angiogenic factor, plays an integral role in the development 
of  normal pregnancy along with its soluble receptor sFlt-1 (133, 135, 247, 
248). Incorporation of PlGF into screening algorithms in early pregnancy 
improves prediction of those at increased risk of subsequent development of 
pre-eclampsia (177). In order to be beneficial, both clinical and health 
economic benefits of such screening needs to be demonstrated (177, 251). 
Maternal plasma PlGF concentrations are significantly altered in women prior 
to the clinical onset of pre-eclampsia and are associated with adverse 
pregnancy outcomes (87, 88, 128-132, 137, 140, 249, 250, 360, 361). 
Observational studies demonstrated the potential to improve detection of 
preterm pre-eclampsia if PlGF was included in routine clinical investigations 




of PlGF may lower gestational age at delivery and adversely impact on 
neonatal outcomes, thus highlighting the need for appropriately powered 
randomised controlled trials, such as PARROT Ireland, to be conducted (155). 
The therapeutic potential of PlGF is just beginning to be explored. 
Experimental animal studies have suggested administration of plasma PlGF 
in early pregnancy may prevent development of pre-eclampsia while reducing 
its soluble receptor s-Flt1 by plasma  aphesis ameliorates pre-eclampsia 
symptoms (254, 255).  
 
Chapter 5: PARROT Ireland; Placental growth factor in Assessment of 
women with suspected pre-eclampsia to reduce maternal morbidity; a 
Stepped Wedge Cluster Randomised Control Trial 
The result of the interim analysis of PARROT Ireland reported no significant 
reduction in either maternal or neonatal morbidity with integration of point of 
care PlGF based testing, in addition to usual clinical care, in women with 
suspected preterm pre-eclampsia. These results should be interpreted with 
caution as they are based only on an interim analysis, conducted on a larger 
proportion of control rather than interventional participants, and thus the final 
trial results may differ.  
Our interim results contrast to those of the only published RCT on the use of 
PlGF as a diagnostic test in women with suspected pre-eclampsia in 
pregnancy; the UK PARROT trial, which reported PlGF testing to be beneficial 
(188). The integration of PlGF significantly reduced the time required to 




cohort. Revealed PlGF testing also resulted in a significant reduction in 
maternal adverse outcomes, without any detected difference in gestational 
age at delivery or in adverse perinatal outcomes.  
The importance of performing appropriately powered, robust, interventional 
studies before the integration of a new test is well accepted but not always 
adhered to in clinical practice. The contrasting results of the PARROT UK trial 
with the interim analysis of the PARROT Ireland trial demonstrates the 
necessity of multiple studies on a topic, and not to solely rely on the results of 
a single study. Of course, the final PARROT Ireland results may demonstrate 
similar findings to the UK study once complete. Another RCT of PlGF 
integration (EuroPE Study) is currently ongoing in Spain, aiming to recruit in 
excess of 2000 participants (362). Unlike the two PARROT trials, where PlGF 
quantification was performed using the Triage PlGF test, this Spanish study is 
utilising the Elecsys immunoassay sFlt‐1/PlGF ratio test for PlGF assessment. 
The investigators estimate trial completion in February 2021.  
 Major Limitations 
The main limitation of the PARROT Ireland trial has been the deficit in 
participant recruitment. The aim was to recruit in excess of 4,000 women with 
suspected preterm pre-eclampsia, however just over half this figure, 2313, 
were recruited by trial closure. Due to the stepped wedge design utilised, the 
end date of the trial was fixed and could not be extended in order to increase 
sample size (195). This under-recruitment may potentially lead to under 
powering of the final trial results, however it is still a substantial number of 




on clinically important outcomes; information which is eagerly awaited by 
international investigators and health care policy makers (141, 363). A second 
limitation of the trial was the lack of PlGF testing in the control arm which would 
have allowed post hoc comparison of the blinded as well as revealed PlGF 
results, ensuring the two arms of the study were equal in this respect. It would 
appear however from the interim analysis that the demographics between the 
two groups are very similar, suggesting the groups are comparable (327).  
Some might suggest that the incidence of pre-eclampsia subsequently 
diagnosed in participants of the trial was low, at approximately 14%. The use 
of the NICE definition for pre-eclampsia may be contributory, owing to its 
narrow diagnostic criteria compared to the ISSHP definition employed by the 
PARROT UK trial. Units in the NHS utilise NICE criteria routinely, hence our 
Belfast trial site was obliged to use this definition. In order to harmonise all trial 
sites, a decision was made to adopt the NICE definition of pre-eclampsia at all 
recruiting sites. When diagnostic outcomes for those recruited to PARROT 
Ireland were examined, the interim analysis indicated that only 5% of those 
recruited had a final diagnosis of “none of these”, indicating that in 95% of the 
sample some form of placental dysfunction was present and that they were 
appropriately recruited to the trial.   
 
 Implications for health policy, clinical practice, and future 
research recommendations 
It was concluded by the  PARROT UK trial group in their publication that PlGF 




to aid diagnosis of preterm pre-eclampsia in maternity units in the UK (187).  
The steering committee for PARROT Ireland will examine the final Irish trial 
results once available. If results demonstrate a favourable outcome, the 
Institute of Obstetricians & Gynaecologists will likely advocate that PlGF be 
integrated into clinical care pathways in Ireland. The current HSE guideline on 
management of hypertension in pregnancy details appropriate referral for 
investigation and management for symptoms suggestive of evolving pre-
eclampsia and stratifies location and frequency of review dependent on the 
level of hypertension present (1). It would be practical and feasible to add PlGF 
testing as an adjunct in the national guideline, should the results of the 
PARROT Ireland trial support this.  
An individual participant data (IPD) meta-analysis of participants from both the 
UK and Irish PARROT trials should next be conducted. This would increase 
the power of both trials substantially and provide the highest quality evidence 
in relation to the integration of PlGF testing (364). Given that both trials used 
the same online electronic clinical report form templates, collecting the same 
data points, an IPD of the two trials is feasible. An alternative option is to 
conduct a systematic review of PlGF interventional studies to assess the 
impact of PlGF testing on maternal and neonatal outcomes. The review could 
also examine which automated commercial immunoassay platform is best 
utilised. This information will facilitate the updating of guidelines such as the 
NICE guidance on PlGF testing and Irish clinical practice guidelines (1, 326). 
Having an effective diagnostic test for pre-eclampsia should eliminate 
protracted hospitalisations of pregnant women and allow limited resources to 




clinical care, the financial burden of this additional test needs to be assessed 
(147). As part of the PARROT Ireland trial, health economic data on cost 
impact to individual participants, as well as to maternity units, was collected. 
Planned analysis of these data will enable the cost effectiveness of the 
implementation of PlGF in Ireland to be determined, which will be a key factor 
for hospitals in their decision as to whether to finance PlGF testing locally. 
Acquisition of maternal plasma in pregnant women with suspected pre-
eclampsia is an onerous process. Biobanking of participant maternal plasma, 
upon their initial recruitment, was performed in over 200 participants as part of 
the PARROT Ireland trial. This resource is priceless in terms of facilitating 
much quicker evaluation and assessment in future research projects, as the 
task of sample collection will not be necessary. Many research opportunities 
for these samples are possible, with potential for PlGF use yet to be explored.  
Assessment of different commercially available automated PlGF 
immunoassay platforms, such as Brahms®, Elecsys® and Delfia®, to 
compare their efficacy and to validate clinical cut-offs for PlGF and/or sFlt-1 
would be both interesting and a clinically useful study (141, 157, 158). A 
second option worth exploring is the potential of using serial PlGF-based 
testing in order to reduce adverse perinatal outcomes. The recently launched 
PARROT-2 randomised controlled trial aims to examine this in women 
presenting with suspected preterm pre-eclampsia. Recruiting across 19 units 
in the UK from April 2019 to November 2021, by repeating PlGF testing, every 
week/fortnight, it will investigate the natural course of PlGF over time and 
assess if repeat testing is beneficial for neonatal outcomes (365). In PARROT 




that initially had a normal (>100pg/ml) PlGF result. Serial samples from 
consenting participants are biobanked at our research centre in Cork, hence 
a similar retrospective study of our cohort could be conducted. 
The prospect of using PlGF or its receptors as therapeutic agents have begun 
to be considered with animal studies demonstrating that administration of 
VEGF early in pregnancy prevented the development of pre-eclampsia (254). 
Similarly, animal studies inducing a reduction in circulating sFlt-1 levels 
through plasma apheresis reported an alleviation in pre-eclampsia like 
symptoms (255). These studies suggest the potential utility of early pro-
angiogenic therapies in treating pre-eclampsia in the future. 
 
7.4 Facilitators and barriers to conducting clinical research 
in a pregnant population 
Since the mid 90’s there has been a concerted effort to ensure minorities, such 
as women and children, are represented in research in order to help guide 
scientific based practice for all societal groups (336-338). Pregnant women 
are seldomly included in randomised controlled trials and their attitudes and 
experiences of participation rarely investigated. Gathering feedback of their 
experience is paramount for future trial design to facilitate participation. In 
order to examine the factors that influence women in their decision to take part 
in research during pregnancy, I conducted a qualitative study among women 
who had participated in the PARROT Ireland randomised control clinical trial 




interviews facilitated a more personal relationship between the researcher and 
participant, and proximity of interview to the time of participation greatly aided 
women’s overall recall of the trial. 
 
 Main findings and how they relate to existing research 
Chapter 6: Clinical research in a pregnant population 
The main objective of this study was to investigate the barriers and facilitators 
to pregnant women taking part in research. Overall, the study found that 
pregnant women are aware of the importance of research and were generally 
interested and positively inclined to participate. Both altruism and the potential 
of personnel benefit were key motivators behind women’s decision to enrol in 
PARROT Ireland. Similarly a sense of civic duty, the opportunity to help others 
and the possibility of an improved outcome for their baby has been reported 
by other researchers to be driving forces behind participation in research 
during pregnancy (212-214).  
The decision to take part in the PARROT Ireland trial was made independently 
by the pregnant woman herself, a finding which has been reported by others 
previously (214, 215). The timing and setting of the researcher’s approach and 
the language she used were reported as key factors in women’s decision to 
participate in PARROT Ireland, a finding not widely reported previously but 
important for researchers to understand when planning future trials so as to 




Women reported feeling well-informed about the PARROT Ireland trial prior to 
signing the consent and later had a good understanding of the trial when 
interviewed, in contrast to previous studies which reported limited recall by 
participants, potentially relating to the researchers approach or to the clinical 
setting at the time of recruitment. (213, 215-217).  
Women randomised to the control group did not report negative experiences 
and although they felt the trial had no direct impact on their own pregnancy, 
they were still happy to have taken part as they felt it may have benefited 
others. In contrast, some researchers have reported randomisation to the 
control arm in an RCT being perceived as a disadvantage among participants 
(214).  
 
 Major Limitations 
The interviewed women in this study represent only a subgroup of women, 
and potentially a biased group, as these women had not only consented to 
participate in research during their pregnancy, but also agreed to take part in 
this additional qualitative study. Ideally, to fully evaluate the barriers to 
research participation in pregnancy I would also have liked to interview those 
who had declined to take part in the trial. However, as per GCP and GDPR 
(354, 355) no information on eligible women who were approached but 
declined to participate in the trial was retained; thus contacting them for this 





 Implications for health policy, clinical practice, and future 
research recommendations 
In general pregnant women are willing and interested to participate in 
research,  provided it does not confer a risk to their pregnancy (212-215, 350). 
The attitude, approach and information of their clinicians is a key factor in a 
woman’s decision to participate in research (37). If pregnant women feel well 
informed, especially if a trusted clinician provides the information, they are 
much more likely to participate.  Accurate knowledge by clinicians of ongoing 
trials in their unit and the vocalisation of their support is crucial in promoting 
participation of pregnant women in future trials.   
In order to generate evidence based information on the impact of  interventions  
in pregnancy, research is required. Given the stringent pre-initiation 
examination that clincal trials require (sponsorship, insurance and review by 
national ethical committees) as well as the ongoing vigilence and monitoring 
by stakeholders for any trends in adverse events, the safety of any such 
research is a key priority for all involved, including the pregnant woman herself  
(331, 340, 351). The context, purpose and potential risk of any research are 
the most important considerations, thus maximising eligible women’s 
understanding of the research being conducted and allowing shared decision-
making, is key to a trial’s acceptability. The information and explanation 
provided by reseachers is crucial. Adequate training of researchers and 
clinicians, to maximise this skillset, should be prioritised to aid success of 




Designing future trials with recruitment ideally based in non-emergent settings 
would increase the likelihood of participant recall following the event and 
reduce the potential for exploitation of potentially vulnerable patients. 
Alternatively, where the setting of a trial must be emergent, such as a labour 
ward or emergency theatre, a delayed consent process  could be to employed 
(352). This approach has been used previously in trials of critically ill patients 
and has been found to be acceptable (353). Using the information generated 
from my qualitative study on research in pregnancy to design and conduct 
future pregnancy studies will likely increase the trials acceptability, 
participation and chance of successful completion. 
   
7.5 Conclusion  
The purpose of this thesis was to explore the potential for the use of PlGF in 
twin pregnancy and evaluate its impact in singletons with suspected preterm 
pre-eclampsia.  The findings from this thesis, though supportive of the current 
literature in relation to the potential of PlGF, highlight that there is more 
research required.  
The thesis outlines that exact PlGF quantification with the differing commercial 
immunoassays available differs, and hence clinical cut-offs for PlGF are not 
transferrable. Further research should ideally utilise multiple immunoassays to 




PlGF has an important role in healthy placentation in early pregnancy. 
Aberrations in circulating plasma PlGF as pregnancy progresses are strongly 
associated with   placental dysfunction and adverse pregnancy outcomes. It is 
clear from the studies presented that there is potential for the use of PlGF in 
twin pregnancy as a diagnostic aid in conditions of placental dysfunction such 
as pre-eclampsia. PlGF levels in twin pregnancies differ to those in singletons, 
as well as differing by chorionicity. Before PlGF can be utilised clinically in twin 
pregnancy, chorionic specific validated clinical cut-offs need to be established 
and agreed in clinical guidance.  
The research presented in this thesis adds to a growing body of work focusing 
on utilising PlGF as a diagnostic aid for preterm pre-eclampsia in singleton 
pregnancies. The potential for use of PlGF in the prediction of other placental 
dysfunction conditions such as IUGR and stillbirth warrants further 
investigation but evidence to date is promising.  
Pregnancy research is important in order to generate evidence-based 
information. This thesis highlights that pregnant women are aware of the 
importance of research and generally satisfied to participate in clinical trials 
once appropriately informed of the purpose and nature of a study.  
The PARROT Ireland trial examined the clinical impact of point of care PlGF 
based testing in over 2300 women with suspected preterm pre-eclampsia 
across seven maternity units. While the results of the interim analysis reported 
in this thesis showed no significant reduction in either maternal or neonatal 
morbidity with PlGF use, the full trial results are awaited, before making any 




Combining these Irish trial data with those from the UK PARROT trial, and 
possibly those of another ongoing RCT, has the potential to provide large 
scale, high quality results, adequately powered to give a definitive answer in 
relation to PlGF use in clinical practice. This information is eagerly awaited 
and will aid the updating of international clinical practice guidelines as well as 
helping to direct further evidence-based best practice in the diagnosis and 
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Appendix 6: Documentation of enrollment for Participants 








































































































































































Appendix 15: Data Monitoring Committee Charter 
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